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ABSTRACT 
The next generation of regenerative medicine solutions will depend on smart materials that can 
activate “self-healing” mechanisms. Cells respond to changes in pO2 through a hypoxia-sensing 
pathway, the HIF-1 pathway, which activates numerous processes necessary for bone and 
cartilage development and for normal tissue repair. Control of these processes is critical in tissue 
engineering (TE), therefore this thesis aimed to develop novel hypoxia-mimicking materials for 
skeletal TE. 
Resorbable bioactive glasses (BG) were chosen as the delivery system for a hypoxia-stimulating 
ion, Co2+. Two series of melt-derived BGs containing increasing amounts of Co2+ were 
synthesised. Co2+ was equally distributed through both the silicate and orthophosphate phases of 
the BG, and acted as both an intermediate oxide and network modifier in the silicate network. Co2+ 
significantly decreased the ion-release rate and HCA-forming ability of BG, and a controlled 
release of Co2+ was achieved.  
The biological activity of the hypoxia-mimicking BGs on human mesenchymal stromal cells 
(hMSCs) and endothelial cells (ECs) was assessed. In both cell types the Co2+-containing BGs 
activated the HIF-1 pathway. hMSCs exposed to the BG reduced their proliferation rate but 
enhanced glycolytic activity and collagen production, and VEGF expression was up-regulated in a 
concentration-dependent manner. Exposure of ECs to the hypoxia-mimicking BGs reduced cell 
viability. However, in a co-culture system with hMSCs, EC viability and angiogenic potential were 
rescued. These results suggest that the hypoxia-mimicking BGs can activate several processes 
involved in skeletal regeneration, including cell differentiation, ECM production and angiogenesis, 
either by a direct effect on hMSCs or by a paracrine effect of hMSCs.  
Finally, the hypoxia-mimicking BGs were successfully incorporated into collagen freeze-dried 
scaffolds. hMSC viability was not affected by the presence of the Co2+-containing BG. Importantly, 
the BG was still able to activate the HIF-1 pathway when incorporated into collagen scaffolds. The 
results presented in this thesis strongly suggest the potential of the hypoxia-mimicking BGs for 
skeletal TE. 
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Cartilage is an avascular tissue with a very disperse cell population, and has a very limited self-
renewal capacity. By contrast, bone is highly vascularised and remodels rapidly to heal fractures. 
However, if the defects are too large, they do not heal naturally. With an increasingly aging 
population, there is extreme clinical need for bone- and cartilage-generating therapies as, 
presently, the existing ones are only symptomatic. Many approaches are being explored that 
combine varying degrees of synthetic, natural and biomimetic materials and different fabrication 
techniques to construct highly tailored environments for bone and cartilage regeneration.  
Tissue engineering is a multidisciplinary area of research that has the potential to revolutionise the 
treatment of damaged tissues. Currently, the main challenges in this area are the production of 
materials with the ability to direct cellular behaviour, either by delivering stimulatory/inhibitory 
molecules or by activating specific intracellular pathways. 
Local oxygen pressure often drops, during natural tissue development and repair, creating a 
hypoxic environment. All cells respond to these changes in the oxygen pressure through a 
hypoxia-sensing pathway1. Several cellular processes, including new blood vessel formation 
(angiogenesis)2 and recruitment of stem cells3,4, as well as proliferation5,6 and differentiation of 
multiple cell types3,4,7,8 have been shown to be activated by this pathway. Moreover, anti-microbial 
activity and other cell survival mechanisms are enhanced under hypoxia9,10. These processes, 
which are essential for natural tissue development and regeneration, might be critical for many 
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tissue-regeneration strategies. Therefore, the development of materials that regulate the HIF 
pathway might be of great potential for tissue engineering therapies. 
The main goal of the present project was to develop a bioactive material with the ability to 
stimulate the cellular response to low oxygen pressure (hypoxia), a principal skeletal development 
and regeneration mechanism, to restore damaged skeletal tissue to its original functionality. Cobalt 
ions (Co2+) were chosen as the hypoxia-mimicking agent, since their ability to activate the main 
hypoxia-sensing intracellular pathway, the HIF-1 (hypoxia inducible factor-1) pathway, has been 
demonstrated in the literature11. Bioactive glasses (BGs) were chosen as the delivery system. 
Mono- or divalent cations can be easily incorporated in this Si-O-based material and ion release is 
then easily tailored by modifying the BGs composition. Once in contact with body fluids, the 
hypoxia-mimicking BGs degrade, releasing the Co2+ ions. We hypothesised that these ions will 
activate the hypoxia-sensing pathway, even in the presence of O2, and a series of subsequent 
cellular responses critical for tissue regeneration will be then initiated (Fig. 1.1)  
 
Fig. 1.1. Hypoxia-mimicking bioactive glasses: Hypoxia-mimicking BGs allow controlled Co
2+
 release, 
through cation exchange with the surrounding environment, once in contact with body fluids. The ions 
released then activate the hypoxia-sensing pathway (HIF-1 pathway) in the cells, which leads to the initiation 
of a series of subsequent cellular responses critical for normal tissue regeneration. Importantly, the cellular 
responses activated by the HIF-1 pathway are cell-type-specific.  
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Chapter 2 of this thesis provides a comprehensive review of the fields of skeletal tissue 
engineering (TE), hypoxia and the hypoxic cellular response, as well as a summary of the current 
knowledge on BGs and their use in TE. Chapters 3-7 describe and discuss the main experimental 
results of this project and also include specific literature reviews, experimental methodologies, and 
when appropriate suggestions for future work. The final conclusions and general overview are 
presented in Chapter 8.  
The project was divided into three main parts. The first part consists of the development of 
hypoxia-mimicking BG (Chapter 3), the second consists of the assessment the BG biological 
activity (Chapter 4-6) and the third consists of the incorporation of the BG synthesised into three-
dimensional collagen scaffolds (Chapter 7). 
Part 1. Development of hypoxia-mimicking bioactive glass 
BGs that regulate the cellular oxygen-sensing pathway through the controlled release of Co2+ ions 
were developed. Two series of melt-derived BGs containing different amounts of Co2+ were 
synthesised. The BG composition was designed considering Co2+ ion acts in the silicate network 
either as a network former (charge balanced series) or as a network modifier (non-charge 
balanced series). The glasses produced were next characterised to determine the role of the 
hypoxia-mimicking ion on the glass network. Finally, the effect of Co2+ addition on the BGs’ ion 
release profile and hydroxycarbonated apatite-forming ability was assessed. The addition of Mg2+ 
and Zn2+ ions to the hypoxia-mimicking BGs was also assessed, since these ions are known to 
reduce the BGs’ hydroxycarbonated apatite-forming ability, which is recommended for some 
applications as is the case of cartilage TE. 
Part 2. Assessment of hypoxia-mimicking BG biological activity 
The biological activity of the hypoxia-mimicking BGs was assessed in two different cell types, 
human mesenchymal stromal cells (hMSCs) (Chapter 5) and human endothelial cells (ECs) 
(Chapter 6). Firstly, several techniques were used to evaluate the effect of the Co2+-containing 
BGs on cell viability. Next, activation of the hypoxia-sensing pathway was confirmed by assessing 
the activity of the transcription factor responsible for regulating the intracellular pathway, the HIF-1 
dimer. Expression of vascular endothelial growth factor (VEGF) was evaluated as an indicator of 
initiation of subsequent cellular responses. This growth factor is known to be over-expressed under 
hypoxia, via HIF-1, but, more importantly, it is one of the main regulators of blood vessel formation. 
The effect of the Co2+-containing BGs on several other processes regulated by pO2 was also 
assessed. In hMSCs, we evaluated the effect of the BG developed on cell metabolism, proliferation 
and ECM production. In ECs, we studied the effect of the hypoxia-mimicking BG on their 
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angiogenic potential, either directly or through a hMSCs-stimulated paracrine effect. However, 
before these two studies were performed, it was necessary to define experimental conditions and 
parameters. The preliminary studies were performed on SaOs2 cells, an immortalised 
osteosarcoma cell line, and are described in Chapter 4. 
Part 3. Development of collagen-BG composite scaffolds 
To use the hypoxia-mimicking BG developed in vivo, it should be incorporated in a scaffold with 
the appropriate architecture, physical, chemical and mechanical properties. Collagen freeze-dried 
scaffolds were chosen for this purpose as they contain natural constituents of the extracellular cell 
matrix, their degradation rates can be adjusted within a wide range and they are fabricated from a 
number of macromolecular constituents with a variety of pore structures; a number of useful 
qualities for a tissue engineering construct. Part of this study was performed in collaboration with 
Prof. Fergal O’Brien’s group in Dublin. The best manner in which to incorporate the cobalt-
containing BG in the collagen freeze-dried scaffolds was assessed. The integrity of the BG 
properties after the scaffold fabrication was analysed, as well as the ion dissolution rates. Once the 
scaffolds were successfully produced, several seeding methods were tested, to achieve a 
homogeneous 3D distribution of cells on the scaffolds. Finally, hMSCs were cultured on the 
scaffolds to evaluate cytotoxicity and activation of the hypoxia pathway. 
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2.1 TISSUE ENGINEERING 
Living tissues have the remarkable ability to regenerate after injury with no external intervention. 
The liver is the most striking example of such regeneration, as it can regrow to its original size 
even when half of its mass is removed12, but other tissues, such as bone and skin, can also self-
regenerate if the damaged site is below a critical size. However, in tissues with low regenerative 
potential or in aged patients, when the injured site is too big or if the original tissue is completely 
destroyed, therapeutic intervention is required for proper healing to occur. In many cases, the use 
of stem and progenitor cells is seen as a solution, as these cells have the potential, under the 
correct conditions, to differentiate into the required cell type and form new tissue. However, the use 
of such cells does not offer a universal solution. Biomaterials are often required as carriers of 
either the stem/progenitor cells to the site of damage, or of signalling molecules that direct the cell 
function. 
The concept of tissue engineering (TE) comes from the early 1930s when mouse tumour cells 
encased in a polymer membrane were implanted into the abdominal cavity of chicken embryos and 
survived13. In the following few years, whole organ culture was pursued to advance knowledge for 
transplantation surgery14,15. Later, in 1993, Langer and Vacanti defined TE for the first time as “an 
exciting interdisciplinary field which applies the principles of both engineering and life sciences 
towards the development of biological substitutes able to restore, maintain or improve tissue 
function”16. Nowadays, TE seems to have the potential to revolutionise medicine; it aims to develop 
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strategies/materials that closely match the needs of the patient and that can often be transplanted 
into the patient’s body with minimal surgical intervention. TE can not only be used to repair or 
replace tissues and organs but also to design in vitro physiological models to study disease and 
develop new therapeutics8. 
In the last two decades, significant advances have been made towards the development of a 
number of tissues including skin17, cartilage18, bone19, ligaments20, tendons21 and cardiovascular 
tissue22,23. Practically no organ or tissue is currently excluded from this increasing research field13, 
however, the ability to fully direct cellular behaviour remains a challenge. 
Although the initial concept was maintained, during the last decade the philosophy of TE changed 
significantly. The accumulation of knowledge and experience made tissue engineers realise that 
smaller and more easily achievable goals should be defined; for example, instead of trying to build 
entire organs, they should start by regenerating smaller parts of the organ. In addition, the potential 
of the organism to promote regeneration was recognised. Formation of new tissue does not have 
to fully occur ex vivo before implantation; the body can be used as a “bioreactor”, if the correct 
stimuli are applied. This was first shown by Stevens et al., who injected an alginate gel into an 
artificial space between the tibia and the periosteum and were able to promote new bone and 
cartilage formation from the progenitor cells present in the inner layer of the periosteum24. Finally, 
the TE community also became conscious of their need to understand developmental biology. 
Trying to recreate the complexity of organs or tissues at a macroscopic level is not enough; TE 
strategies should aim at stimulating the essential steps of tissue development or natural repair at a 
microscopic and molecular level25,26. 
The most common Tissue Engineering approach is represented in Fig. 2.1. The choice of cell type 
and scaffold material is essential for successful regeneration and depends on the specific 
application. The use of several stem cell sources for therapeutic purposes, is currently under 
extensive study27. Their ability to self-renew, to divide themselves continuously, generating not 
only new stem cells but also progenitor cells, combined with their plasticity, or ability to adopt the 
expression profiles and functional phenotypes of cells from different tissues, are of great use for 
tissue engineering and regenerative medicine therapies. The most studied stem cells are adult 
stem cells (ASCs), embryonic stem cells (ESCs) and, more recently, induced pluripotent stem cells 
(IPSCs). Both ESCs and IPSCs are pluripotent, have the ability to originate any cell type in the 
body. ASCs are multipotent, already partially commited, which means they are only able to 
originate a restricted range of progenitor and terminal cells. 
Although it initially showed great potential, the use of stem cells in human medicine carries several 
risks. The main risk is due to their genetic instability that has been extensively shown to be 
associated with a higher risk of developing cancer. Pluripotent cells carry a higher risk of causing 
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cancer once cells are implanted in the body than ASCs27. Several in vivo studies in rodent models 
and clinical trials using embryonic stem cells have shown high levels of cancer, mainly teratomas 
or teratocarcinomas27. There are still no similar studies with IPS cells, but there is the possibility 
that a similar risk might exist28. ASCs, on the other hand, present a significantly lower risk27-29. 
Such cells have been used in the clinic for several years, as in the case of bone marrow 
transplants, with low cancer related risks27. The cell source used in this particular study was 
mesenchymal stem cells (MSCs), a type of ASCs. Its characteristics and the reason why they were 
chosen will be discussed later in this thesis (Chapter 5).  
 
 
Fig. 2.1 The most common Tissue Engineering (TE) 
approach. (1) Cells are harvested from the patient; 
(2) Cells are expended in vitro; (3) Cells are seeded 
in an appropriate scaffold with specific cues; (4) 
Cells are cultured in the scaffold in vitro; (5) Scaffold 
containing cultured cells is implanted in the patient’s 
body. (figure used with author’s permission
30
) 
 
The current section will focus on the materials and scaffolds; specifically on their role and the most 
recent developments. In the last decades many significant advances have been reported in the 
field of biomaterials and scaffold production in order to achieve materials that are able to provide 
both physical support and biological cues to direct cellular behaviour. The provision of physical 
support until the new tissue is formed is extremely important to maintain tissue function during the 
regeneration process and deposition of the new matrix31-34. The heterogeneous organisation and 
co-existence of mechanically distinct zones within a tissue, such as in cartilage, increases the 
complexity of the materials’ production. The achievement of stable and resistant bonds between 
mechanically dissimilar materials is yet another major challenge in the development of materials 
with biomimetic mechanical properties26. In addition, the degradation rate of the implanted material 
should occur at a similar rate as matrix formation by the implanted cells so that the construct 
maintains its physical integrity while not obstructing cell growth.  
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Cells acquire “information” from each other, but also from their environment, and the extracellular 
matrix (ECM) is known to have a critical role in the regulation of cell fate. Both the ECM’s 
composition and physical and mechanical properties direct stem/progenitor cell differentiation and 
new tissue formation35. The scaffolds/materials used for TE should therefore be able to direct cell 
behaviour by presenting specific cues which help to promote new tissue formation and 
regeneration. Many different strategies for delivering stimulating/inhibitory growth factors have 
been explored26. However, this approach is not always ideal, as it is very difficult to define the 
minimum combination of signals required and to engineer their delivery in an adequate spatial and 
temporal manner. Activation of specific intracellular pathways has therefore been suggested as a 
promising strategy, and many research groups are currently working on this approach36. 
A comprehensive discussion of the ways in which materials can be engineered to direct cellular 
behaviour is beyond the scope of this introduction. However, broadly speaking there are several 
typical routes by which materials can be made bioactive. One major consideration is the 
biomolecular information provided to cells by the ECM. Matrix proteins such as collagen and 
fibronectin contain many recognition sites that can be bound by cell-surface receptors. These 
include integrins, a family of membrane receptors that physically couple cells to their matrix while 
also performing a signalling role. Various non-proteinaceous matrix constituents also have specific 
receptors, such as CD44 and RHAMM, both of which bind hyaluronic acid, a non-sulfated 
glycosaminoglycan present in many tissues37. Therefore, many TE scaffolds are based on purified 
matrix components such as collagen, fibronectin, and/or hyaluronic acid26. This basis can provide 
cells with normal physiological cues and support functions such as attachment and survival 
(preventing anoikis – apoptotic death resulting from a lack of matrix interactions)38,39. However, in 
some instances – where specific binding domains of proteins are known – some of the functions of 
these molecules can be provided by simple synthetic peptides which are easy to functionalise and 
far less costly to manufacture40,41. The best known of these peptides is the adhesion (integrin-
binding) sequence RGD, although many examples exist including YIGSR and IKVAV from laminin, 
and GFOGER from collagen (reviewed in 38,39). In this way, even biologically inert substances such 
as poly(ethylene glycol) (PEG) – a polymer which is widely used to fabricate hydrogels – can be 
modified such that cells can interact with it in a biologically meaningful, but precisely controlled, 
fashion42.  
As mentioned above, many groups have worked on optimising the delivery of growth factors from 
scaffold materials. In the case of materials for promoting angiogenesis, sustained, low-level 
release of the growth factor vascular endothelial growth factor (VEGF) has been found to give rise 
to higher quality blood vessels than a burst release for the same factor43. In bone and cartilage TE, 
meanwhile, much effort has focussed on optimising the presentation and release of bone 
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morphogenetic proteins (BMPs) and transforming growth factor betas (TGF-βs)44-46. Materials 
delivery strategies involving attachment of the growth factors to the scaffold have been shown to 
improve response, at least in part because this retains the growth factor inside the material for 
longer47-51. 
Again, in some cases the function of growth factor proteins may be mimicked by synthetic peptides 
derived from receptor-binding sequences52,53. In fact, there is great interest in 
discovering/developing active compounds with growth factor-like or pharmacological activity for 
therapeutic use; some of these may be suitable for incorporation into TE scaffolds to promote 
regeneration. The scaffold therefore becomes a vehicle for the delivery of drugs as well as 
(usually) cells. To pick one example of many, a variety of ions are known to have various biological 
effects. Strontium, complexed and marketed as strontium ranelate, is approved as an osteoporosis 
therapy (in the EU) due to its unique ability to both increase bone formation by osteoblasts and 
inhibit bone resorption by osteoclasts54,55.  
Even simple materials chemistry may be utilised to direct cell behaviour, it seems. In one recent 
study, Benoit and colleagues demonstrated that PEG functionalised with different chemical groups 
caused a preference in mesenchymal stem cell (MSC) differentiation towards adipocytes or 
osteoblasts56. Intriguingly, the t-butyl groups that stimulated PPARγ production (an adipocytic 
transcription factor) were hydrophobic (as are lipids) while osteoblast differentiation (indicated by 
up-regulation of RUNX2) was favoured by the inclusion of phosphate groups, which are abundant 
in bone matrix56.  
As well as being sensitive to biochemical features of their environments, cells also respond to 
physical features such as grooves and ridges, two- versus three-dimensionality, and matrix 
stiffness57,58. These observations have led to attempts to develop materials that incorporate, for 
example, nanoscale features such as the fine meshwork of nanofibres that can be achieved by the 
electrospinning technique. Work from the Discher laboratory over the past several years has 
underlined the importance of matrix stiffness in cell function, with clear implications for TE scaffold 
design. In one famous example they showed that MSCs grown on polyacrylamide gels with 
stiffnesses close to those of bone, muscle and brain preferentially differentiated towards 
osteoblasts, muscle cells, and neurons, respectively59. Elsewhere they showed that muscle cell 
and cardiomyocyte striation and beating were best supported on substrates with the stiffness of 
normal tissue, and inhibited on stiffer substrates that mimicked fibrotic tissue60. Therefore, many 
researchers now actively try to mimick normal tissue stiffness when constructing scaffolds.  
Despite the advances in the field of tissue engineering there still remain a few challenges. 
Currently, one of the major obstacles is the induction of a proper nutrient supply and waste 
removal to and from the constructs13. Some tissues recruit their nutrients by diffusion, however, the 
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majority of tissues and organs depend on a microvascular system and the creation of such a 
system remains an unsolved challenge13. As mentioned above, the delivery of single growth or 
differentiation factors seems to be insufficient in many cases, for example, the administration of 
VEGF (a potent angiogenic factor) has been shown to promote the formation of leaky and 
immature blood vessels61. 
Most authors suggest that only an increased symbiosis of engineered materials and cell biology 
may result in materials that contain the necessary cues to recapitulate developmental processes in 
tissue- and organ-specific differentiation and morphogenesis62. In order to do so, a better 
knowledge of the developmental biology and stem cell science is still necessary and an enhanced 
understanding and control of the immunological response is also essential. In this regard, the 
development of molecular biology and systems biology tools will be of great help. This knowledge 
will be highly important to the development of materials/scaffolds systems which deliver combined 
stimuli to the cells in a spatially and temporally regulated manner63. 
2.1.1 Skeletal TE 
Bone is a highly vascularised tissue that rapidly remodels to heal traumatic features64. Large bone 
defects, however, do not heal naturally. With the increasingly aging population, osteoporosis and 
bone fractures have become more frequent and the therapies currently used to repair bone defects 
cannot tackle this problem completely65. Cartilage, however, is an avascular tissue with a disperse 
cell population66,67 and a very limited capacity for self-renewal when damaged67-70. The prevalence 
of osteoarthristis71, a cartilage degenerative disease that results in the erosion of joint surfaces and 
loss of mobility, underscores the importance of developing functional articular cartilage 
replacement. The ability to generate new bone and cartilage graft substitutes for skeletal use is 
then a major clinical need. Recent research has focused on TE as a promising approach for 
skeletal regeneration and repair; its aim is to develop versatile implantable biocompatible materials 
that can direct tissue regeneration, while providing structural support and maintaining the tissues in 
a functional state. 
In the last decades there have been significant developments in skeletal TE. There are already 
several products on the market or in clinical trials for use in skeletal regeneration (Table 2.1). Many 
different materials as well as cell types and sources, including primary osteoblasts, adult 
mesenchymal stromal cells and embryonic stem cells72, to be used in bone tissue engineering 
have been investigated73. Different strategies have been developed in order to produce scaffolds 
that closely mimic the structure and strength of bone73 and which present growth and 
differentiation stimuli61. Cartilage tissue engineering is critically dependent on the selection of the 
correct cell type68, fabrication and use of biocompatible and mechanically suitable scaffolds for cell 
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delivery67,74, stimulation of chondrogenic bioactive materials75 and the application of a dynamic, 
mechanical stimulus76.  
However, unlike organ transplants, in a synthetic bone constructs there is no pre-existing 
vasculature, which very often causes cell death in the centre of the construct. Researchers are 
currently trying to address this problem by developing pre-vascularised scaffolds in vitro77,78 and 
using scaffolds that release a combination of angiogenic factors that promote angiogenesis in 
situ65 (this will be discussed in depth in Chapter 6). Recent studies have demonstrated that the 
combination of angiogenic and osteogenic factors can stimulate bone healing and regeneration65. 
Gene therapy, stem cells and intelligent scaffolds that can release growth factors with controlled 
kinetics are all currently being used to enhance bone fracture repair and regeneration65. The 
development of bioengineered bone remains an exciting promising alternative approach to skeletal 
repair with the potential to impact on daily clinical practice. 
In the case of cartilage, since it is an avascular tissue, the absence of nutrients and oxygen can 
also be a problem for creating scaffolds of functional size70. Another issue in cartilage TE is the 
fact that some chondrogenesis protocols induce only transient cartilage since, through a process 
similar to endochondral bone formation (Fig. 2.8), cartilage cells can then become hyperthrophic 
and originate bone tissue formation68. Currently, cell selection, scaffold design and biological 
stimulation remain the big challenges in cartilage tissue engineering67. 
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Table 2.1. Products on the market and in clinical trials for use in skeletal regeneration (adapted from 
26
). 
Tissue Product Description Material Cells Use Form 
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Graft, 
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Bovine type I collagen sponges 
soaked in rhBMP-2 in LT-
CAGE Lumbar Tapered Fusion 
Device 
x x x   x   Spinal fusion Solid 
OP-1, Stryker  Bovine  type I collagen with 
rhBMP-7 
 x x   x   Bone injury Paste 
Pura Matrix, 
3DM 
Synthetic 16-amino-acid 
peptide, forming nanofibers 
x x       Dental bone 
defects 
Gel 
Vitoss Scaffold 
FOAM, 
Orthovita 
Porous scaffold comprising β-
TCP and bovine type I 
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Rat-tail type I collagen matrix 
seeded with chondrocytes 
 x x     x Articular cartilage 
injury 
3D disc 
Bioseed-C, 
Biotissue 
Technologies 
Polyglycolic acid and 
polydioxane scaffold 
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2.2 HYPOXIA 
Oxygen is the main electron acceptor in various intracellular biochemical reactions. During aerobic 
metabolism, it is essential for ATP generation in mitochondria through oxidative phosphorylation. 
For this reason, its presence is critical for the survival of many organisms, from bacteria to 
mammals. However, although oxygen was initially considered essential uniquely for energy 
production in the cell, it was later found to be critical for regulation of cell fate as well.  
Oxygen tension modulates embryonic development (reviewed in79). Various processes, including 
branching of tracheal development, mammalian cardiovascular development and bone 
morphogenesis, are regulated by O2 tension gradients
79-82. Changes in pO2 regulate embryonic 
stem cell quiescence, proliferation and differentiation79. The O2 level strongly affects stem cell 
niches and it can either promote or inhibit differentiation of these cells in a cell-type-specific 
manner79. The cells’ response is controlled through several signalling pathways; O2 has been 
shown to regulate Notch and Wnt signalling pathways, as well as Oct4 expression79.  
In the body, oxygen tension varies significantly from tissue to tissue, but in most mammalian 
tissues, pO2 is usually between 2 and 9%
79  (significantly lower than the pO2 value to which cells 
are usually exposed to in in vitro culture, 21%). However, due to either alteration of the external 
pO2 value, damage or enhancement of the metabolic activity in specific tissues, local pO2 values 
can change significantly. Hypoxia is a state that refers to pO2 being significantly reduced when 
compared to the normal levels for that tissue or organ. Under hypoxia, the organism must respond 
rapidly to avoid cell death, either by promoting adaptation of the tissues to O2 deprivation or by 
enhancing O2 delivery. The response can occur at a cellular level, by altering the energy 
production mechanism from oxidative phosphorylation to glycolysis or limiting energy-dependent 
processes such as cell division, ribosome biogenesis and mRNA translation83. Alterations can also 
occur at a local or systemic level. Response to hypoxia may include formation or remodelling of the 
local vascular network or enhancement of erythropoiesis, ventilation or cardiac output83. Several 
molecular pathways, including the hypoxia inducible factor (HIF), the mammalian target of 
rapamycin (mTOR), the unfolded protein response (UPR), the cyclic guanosine monophosphate 
(cGMP), the NF-κB and p53 pathways, have been reported to be involved in the response to 
hypoxia84 (Fig. 2.2).  
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Fig. 2.2 Molecular pathways are involved in the cellular response to hypoxia. The main intracellular pathways 
activated in response to low pO2 are represented in this figure (HIF - hypoxia inducible factor, mTOR - 
mammalian target of rapamycin, UPR - unfolded protein response, cGMP - cyclic guanosine 
monophosphate), as well as the responses regulated by each of them. (Figure adapted from 
79
) 
The HIF pathway is, however, the main O2-sensing pathway
1. The hypoxia inducible factor-1 (HIF-
1) was first described in 1992, by Semenza et al., when they were studying erythropoietin 
expression under low pO2
85. The protein was later purified and discovered to be a heterodimer86,87. 
HIF-1 is composed of two subunits; an O2-regulated subunit, hypoxia inducible factor-1α (HIF-1α), 
and another constitutively expressed subunit, hypoxia inducible factor-1β (HIF-1β)86,87. The HIF-1α 
subunit is a 120 kDa protein, formed by 826 amino acids and the HIF-1β subunit exists in two 
isoforms of 91-94 kDa, composed of 774 or 789 amino acids, respectively88 (Fig. 2.3). The HIF-1α 
protein had never been described before, and it is not known to be involved in any other process88. 
The HIF-1β subunit, however, has been previously described as ARNT (aryl hydrocarbon receptor 
transporter)88. This subunit is now known to dimerise with both HIF-1α and AHR (aryl hydrocarbon 
receptor) when exposed to either hypoxia or aryl hydrocarbons, respectively80,88. Two HIF-1α 
paralogues have been described, HIF-2α and HIF-3α89,90. HIF-2α is also O2-regulated and 
dimerises with HIF-1β, however, it is not a redundant factor to HIF-1α. HIF-2α activates 
transcription of an overlapping but still different set of genes1,91-93. HIF-3α, however, is thought to 
inhibit HIF-1α activity94. 
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All subunits belong to the basic helix-loop-helix (bHLH) transcription factors superfamily and share 
common motifs88,95 (Fig. 2.3). The bHLH motif, present on the N-terminal of both proteins, together 
with the PAS domain, mediates dimerisation of the two HIF subunits95-97 (Fig. 2.4). The Per-Arnt-
Sim (PAS) domain is formed of two internal units of approximately 50 residues (the A and B 
repeats), which contain an HXXD motif each. In the C-terminal, both subunits contain the 
transactivation domains (TAD), responsible for the protein DNA-binding and transcriptional 
activation abilities (Fig. 2.3, Fig. 2.4). The HIF-1α subunit has two transactivation domains, in the 
531-575 and 786-826 residues, which are separated by inhibitory domains88,95,98. 
 
 
Fig. 2.3. Hypoxia inducible factors: sequence of the different subunits. Each of the HIF subunits (HIF-1α, 
HIF-2 α and HIF-1β) belongs to the basic helix-loop-helix (bHLH) superfamily. They contain a bHLH domain 
in their N-terminal region of the protein followed by a PAS domain. The PAS domain is constituted of two 
internal units, PAS-A and PAS-B, which, together with the bHLH domain, are responsible for the HIF 
dimerisation. On the C-terminus of all subunits a transactivational domain (TAD) is found. Both HIF-α 
subunits (HIF-1α and HIF-2α) have an O2-dependent degradation domain (ODD). Specific proline residues of 
these domains (Pro402 and Pro564 in HIF-1α and Pro405 in HIF-2α) are critical for targeting of the HIF-α for 
degradation via proteosome. The asparagine residues on the TAD domain of the HIF-α subunits (Asn803 in 
HIF-1α and Asn847 in HIF-2α) are also critical for O2-regulation of HIF activity. The regulatory mechanism 
will be discussed later in this section. (Figure adapted from
79
) 
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Fig. 2.4 The hypoxia inducible factor-1 (HIF-1) dimer. Dimerisation of the two subunits (HIF-1α and HIF-1β) 
occurs through the PAS domains. The HIF-1 dimers then bind to hypoxia-responsive elements (HRE) – that 
contain the 5’-CGTG-3’ sequence - on the promoters, introns or 3’-enhancers of O2-regulated genes. The 
HRE sequences are recognised by the bHLH domains. Finally, the transactivation domain (TAD) of the HIF-
1α subunit recruits co-activator proteins, as the P300/CBP complex, to initiate O2-regulated transcription. 
The residues involved in the O2-regulation of HIF-1α activity are marked in the figure. (Figure adapted 
from
79
) 
Since HIF-1 was first described in 1992, its response to hypoxia has been extensively studied. 
Expression of both HIF-1α and HIF-1β subunits, as well as the dimer DNA-binding activity, was for 
the first time shown to be enhanced by decreasing the pO2 in HeLa cells
99. An inflection point in 
the HIF-1 expression/activity vs. pO2 curve was observed at 4 - 5% O2 and the half-maximum and 
maximum were seen at 1.5 - 2% and 0.5% O2, respectively
99. Since then, both subunits have been 
shown to be expressed in all human tissues assessed. The level of expression and enhancement 
under hypoxia are, however, organ-specific91,100-102.  
The critical role of both HIF-1α and HIF-1β subunits for normal development and response to 
hypoxia was demonstrated by numerous inactivation studies. HIF1a-/- embryos die in utero103; 
developmental arrest, lack of cephalic vascularisation and abnormal neural formation were 
observed104. Defective vascularisation, however, is thought to be due to mesenchymal stem cell 
death and not to vascular endothelial growth factor (VEGF) deficiency105. HIF-1a+/- mice developed 
normally but their response to hypoxia was impaired106,107. Inactivation of HIF-1α in specific organs, 
such as cartilage, leads to defective development (reviewed in 82). In vitro, inactivation of HIF-1α in 
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embryonic stem cells reduced expression of glucose transporters and glycolytic enzymes, as well 
as VEGF expression103. HIF-1β inactivation also leads to embryonic death due to abnormal 
angiogenesis and impaired responses to glucose and O2 deprivation
108.  
The mechanism of O2-sensing and activation of the hypoxia response through the HIF-1 pathway 
has been extensively studied. The HIF-1β subunit is consistently expressed and it localises in the 
nucleus. The O2-regulated subunit, however, although it is also continuously synthesised, under 
normoxia is degraded via proteosome1; its half-life in the cytoplasm is approximately 5 minutes109. 
At low pO2, however, HIF-1α degradation is inhibited and the protein accumulates in the 
cytoplasm. It then translocates to the nucleus, where it dimerises with the HIF-1β subunit (Fig. 2.5). 
The HIF-1 dimer binds to hypoxia responsive elements (HRE) present in the promoters, introns or 
3’-enhancers of hypoxia-regulated genes, which contain the 5’-CGTG-3’ sequence. Co-activator 
proteins, as CBP/p300, SRC-1 and TIF-2, are recruited and transactivation of the genes is initiated 
(Fig. 2.5)1.  
 
Fig. 2.5 The hypoxia pathway: its inhibition in normoxic conditions (A) and its activation under hypoxic 
conditions (B). At a normal O2 tension (A), HIF-1α is constitutively expressed in the cytoplasm but 
hydroxylated at two proline residues (Pro402 and Pro564 - *) by prolyl hydroxylase 2 (PDH) (II). The von 
Hippel-Lindau tumour-suppressor protein (VHL) then binds to the hydroxylated HIF protein (III) and targets it 
to degradation via 26S proteasome (IV). Under low O2 tension (B), the HIF-1α protein present in the 
cytoplasm (I) is not hydroxylated by PHD (II), since this enzyme is inactivated in the absence of O2. So, HIF-
1α translocates into the nucleus where it dimerises with HIF-1β (III) and activates the transcription of a 
number of hypoxia-regulated genes, via binding to the hypoxia responsive elements (HRE) present in the 
promoters, introns or 3’-enhancers of those genes (IV). 
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Under normoxia, the O2-regulated HIF-1α degradation is triggered by binding of the von Hippel 
Lindau (VHL) tumour-suppressor protein to the transcription factor subunit (HIF-1α)110. VHL then 
interacts with protein Elongin C, which recruits the E3 ubiquitin ligase complex, which is able to 
ubiquitinate HIF-1α protein. Ubiquitination finally targets HIF-1α for degradation via 26S 
proteosome1. VHL, however, only binds to HIF-1α if two proline residues (Pro 402 and Pro 564) in 
the oxygen-dependent degradation (ODD) domain are hydroxylated111-113 (Fig. 2.6). This is the O2-
regulated step of the process. Hydroxylation of the two proline residues is catalysed by prolyl 
hydroxylase 2 (PHD2), a dioxygenase enzyme, which requires O2 and α-ketoglutarate as co-
substrates. As it transfers one oxygen atom to the proline residue, the second oxygen atom reacts 
with the α-ketoglutarate to generate CO2 and succinate
114,115. PHD2 activity is also dependent on 
the presence of one iron atom in the active core of the protein liganded by two histidine and one 
aspartic acid residue. The iron atom binds the O2 molecule, and for this it should be kept in its 
ferrous state. The maintenance of iron in its ferrous state is dependent on ascorbic acid (vitamin 
C), as generation of reactive oxygen species (ROS) in the complex III of the mitochondrial 
respiratory chain oxidises the iron atom, which leads to HIF-1α stabilisation by inhibition of PHD2 
activity1,116-119. Other prolyl hydroxylases capable of hydroxylating HIF-1α have since been 
identified; PHD1 and PHD3 (reviewed in 116). 
Although this post-translational modification mechanism was the first to be described, O2-
regulation of HIF-1α also occurs at the activity level (Fig. 2.6). Factor-inhibiting HIF-1 (FIH-1) is 
another dioxygenase that hydroxylates an asparagine residue on the transactivation domain of 
HIF-1α (Asn 803), consequently blocking its interaction with the CBP/p300 co-activator complex 
and inhibiting transactivation of the O2-regulated genes
82,115,116.  
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Fig. 2.6 O2-regulation of HIF-1α occurs at both post-transcriptional and functional levels. In the presence of 
O2, prolyl hydroxylase 2 (PHD2) adds hydroxyl groups to two proline residues (Pro402 and Pro564). This 
promotes binding of the VHL/ubiquitin ligase complex and targets the HIF subunit to degradation via 26S 
proteosome. In addition, the HIF asparaginyl hydroxylase (FIH) hydroxylates one asparagine residue (Asn 
803) on the HIF-1α transactivational domain (TAD), which blocks interaction of this subunit with the 
P300/CBP co-activator complex, inhibiting HIF-1 transcriptional activity. (Figure adapted from
79
) 
HIF-1 activity is also regulated in an O2-independent manner (see Table 2.2). Synthesis of the HIF-
1α subunit can be stimulated in an O2-independent way by various growth factors and cytokines, 
via the mTOR, PI3K and AKT pathways (reviewed in116). Plus, other molecules, including nitric 
oxide, have been shown to stabilise HIF-1α (reviewed in116). The involvement of HSP 90 (heat 
shock protein 90) and RACK1 proteins in HIF-1α half-life regulation has also been reported120. 
Competitive binding of these proteins plays a critical role as HSP90 stabilises HIF-1α and RACK1 
interacts with Elongin C, which promotes ubiquitination and subsequent degradation of HIF-1α120. 
Besides, HIF-1α nuclear localisation is also crucial for the activation of the HIF pathway. Its 
translocation, however, seems to be autonomous due to the presence of a nuclear translocator 
signal in the HIF-1α subunit (reviewed in116). Finally, HIF DNA-binding and assembly of the 
transcriptional complex are the last steps of the signalling cascade and are also regulated. As 
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described earlier, recruitment and binding of transcriptional co-factors can be inhibited by post-
translational modifications on the transactivation domain82. In addition, methylation of the CpG 
islands on the HRE sequence of the promoters also inhibits HIF DNA-binding ability82,116. 
Regulation of HIF-1 activity is then an extremely complex process, in which various levels of 
regulation are involved and can act in combination. 
Table 2.2 O2-dependent and –independent regulatory mechanisms of HIF-1α activity
82,116
. 
Mechanism Enzyme Result 
O
2
-d
e
p
e
n
d
e
n
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 Prolyl hydroxylation (Pro 402; Pro 564) PHD2 signals for ubiquitination 
Lysine acetylation (Lys 532) ARD1 facilitates pVHL binding 
Poliubiquitination pVHL signals for degradation  
Asparagine hydroxylation (Asn 803; Asn 851)  FIH-1 prevents CBP/p300 binding 
Phosphorylation of HIF-1α MAPK enhances transactivation 
 O
2
-i
n
d
e
p
e
n
d
e
n
t 
 
Activation of HIF-1α synthesis Cytokines  
GFs 
NO 
enhanced HIF-1α levels  
Competitive binding HSP90/RACK1 HIF-1α stabilisation/ 
degradation 
Methylation of CpG islands on HRE sequences  inhibition of HIF-1 DNA-binding 
 
Although the hypoxia-sensing pathway is very well conserved6, the response under hypoxic 
conditions is cell-type-specific1,102,121. As discussed earlier in this section, HIF-1 mediates 
developmental and physiological pathways that either promote O2 delivery to cells or allow cells to 
survive in O2 deprivation
1. In an organism a wide range of responses is then triggered by hypoxia 
at both systemic and cellular levels. HIF-1-mediated adaptation is regulated through control of 
gene expression. At low pO2, the HIF-1 pathway has been shown to regulate the expression of four 
main groups of genes, each of them associated with a specific adaptation mechanism (Fig. 2.7). At 
a cellular level, the HIF-1 pathway regulates metabolism alterations, as well as cell proliferation 
and survival mechanisms. Under hypoxia, expression of a series of glycolytic enzymes including 
lactate dehydrogenase A (LDHA), aldolase A (ALDA), enolase 1 (ENO1), liver phosphofrutokinase 
(PFKL) and phosphoglycerate kinase 1 (PGK1) is enhanced by the HIF-1 pathway122-125, which 
promotes the switch from oxidative phosphorylation to glycolysis as the main energy-production 
mechanism. Also under low pO2, the HIF-1 pathway has been shown to regulate the expression of 
several growth factors, including Insulin Growth Factor-2 (IGF-2) and Tumour Growth Factor-β 
(TGF-β), as well as kinase signalling pathways involved in cell-survival mechanisms (MAPK, PI3K) 
and apoptotic proteins (caspase 9)5,82,121,126. Another group of genes up-regulated by HIF-1 is 
associated with vascular remodelling and formation of new blood vessels. Molecules involved in 
vascular biology, such as VEGF, nitric oxide (NO) and endothelin-1, are over-produced under 
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hypoxia, in a HIF-1-dependent manner127-130. Finally, at the systemic level, hypoxia significantly 
enhances the levels of transportation of O2 to the hypoxic tissues and/or organs. For this 
enhancement, HIF-1 pathway regulates expression of erythropoietin (EPO)96,121, which determines 
the O2-carrying capacity, as well as the expression of hemeoxygenase-1 (HO-1) and inducible 
nitric oxide synthase (iNOS), which is responsible for the synthesis of vasoactive molecules131,132. 
 
Fig. 2.7 Adaptation mechanisms regulated by hypoxia via HIF-1 pathway and the genes involved in each of 
them. 
Since the O2 homeostasis regulates all these processes critical for cellular and systemic viability 
and survival through the HIF-1 pathway, disruption of the pO2 delicate balance is extremely 
dangerous and known to be involved in various serious diseases. Ischemic heart disease, cancer, 
hypoxic pulmonary hypertension and pregnancy disorders, as pre-eclampsia and intrauterine 
growth retardation, are examples of disorders caused by disruption of the local pO2 balance. The 
HIF-1 pathway has been reported to be involved in all these disorders; its role, however, can be 
protective or pathological. Involvement of HIF-1 in human disease has been extensively reviewed 
elsewhere133,134. Complete understanding and control of the pathway, however, would be of great 
potential for clinical use. 
2.2.1 Hypoxia in Tissue Engineering and Regenerative Medicine 
As mentioned in the previous section, hypoxia is involved in numerous fundamental processes, 
some of which are vital for tissue regeneration. In regenerating as in developing tissues, blood 
supply is often reduced, due to the damage or absence of blood vessels; this causes reduced O2 
and nutrient diffusion to the tissues. Simultaneously, the tissues’ metabolic activity and O2 
consumption is enhanced. This imbalance can only be solved by formation of new blood vessels. 
Formation of new blood vessels (angiogenesis) is known to be modulated by O2 tension gradients 
and HIF-1α has been shown to be essential in developmental, adaptative and neoplastic 
HIF-1 
(under hypoxia) 
Metabolic alterations: 
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- ENO1 
- LDHA 
- PFKL 
- PGK1 
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angiogenesis130; this is also the case in lymphangiogenesis, the formation of new lymphatic 
vessels. Lymphangiogenesis has been shown to be regulated by VEGF-C (vascular endothelial 
growth factor-C), a protein from the VEGF family that is known to be active during angiogenesis 
and endothelial cell growth135; its expression is also regulated by hypoxia via HIF-1α. 
In addition, hypoxia is known to be involved not only in the recruitment of progenitor and 
endothelial cells to the site of injury (a hypoxic region)136 but also in the regulation of the 
differentiation of various different cell types, such as embryonic stem cells7,8,79, adult stem and 
progenitor cells3,4, neurons137 and chondrocytes3,138. The effect of hypoxia in both embryonic and 
adult progenitor cells is currently under extensive investigation. In vitro culture of both embryonic 
and adult progenitor cell types at lower pO2 has been shown to be beneficial for expansion and 
maintenance of their pluri- or multipotency (reviewed in139). However, manipulation of the O2 levels 
seems to also be a promising strategy to regulate differentiation. Directing progenitor cell 
differentiation towards a specific phenotype by manipulating pO2 levels has been shown for various 
cell types, including chondrocytes140 and cardiomyocytes141. Cell proliferation and survival are 
other processes that have been demonstrated to be modulated by the HIF-1 pathway5,6. Finally, 
enhancement of the bactericidal9 and cytoprotective properties of phagocytes, through recruitment 
of macrophages into hypoxic areas10, are two other processes extremely pertinent during 
regeneration, which have been shown to be stimulated by low pO2. 
Some of the biggest challenges in regenerative therapies, nowadays, are the supply of nutrients 
and oxygen into the regenerating tissue, as well as the control of cell differentiation. Hence, a 
material able to mimic a hypoxic environment could be of great importance by stimulating 
angiogenesis and directing cell differentiation. However, directing cell differentiation with O2 levels 
is not straightforward. Prolonged hypoxia could lead to situations in which the intrinsic healing 
capacity of the tissues stalls136. Therefore, a delicate balance must be reached between the 
hypoxia stimulatory and inhibitory effects. Moreover, as specific tissues have specific 
requirements, the development of biospecific materials with appropriate architecture, physical and 
mechanical properties, as well as delivering the right cues is essential. 
2.2.2 Hypoxia and Skeletal Development and Regeneration 
As discussed in the previous section, O2 tension has a crucial role in directing development and 
cell fate (reviewed in 79). Skeletal development is not an exception; several critical steps of skeletal 
development are regulated by O2 gradients which activate a cellular response
4,142-144. 
Long bones are formed through a process called endochondral bone formation (Fig. 2.8). During 
endochondral ossification, mesenchymal cells differentiate into chondrocytes (Fig. 2.8 b), which 
then proliferate and produce cartilage models of the future bones (Fig. 2.8 c). As development 
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proceeds, chondrocytes in the centre of each of the cartilage templates cease to proliferate and 
the post-mitotic cells differentiate to hypertrophy (Fig. 2.8 d). The differentiation of chondrocytes to 
hypertrophy is followed by the invasion of blood vessels (Fig. 2.8 e), osteoclasts and other 
mesenchymal cells from the perichondrium into the cartilage (Fig. 2.8 f). Hypertrophic 
chondrocytes die progressively through apoptosis and are replaced by bone marrow and 
trabecular bone in the so-called primary ossification centres (Fig. 2.8 h)145. 
 
 
Fig. 2.8 Endochondral bone formation. (adapted from 
145
) Mesenchymal cells condense (b) and differentiate 
into chondrocytes (c). A cartilage model of the future bone is formed (c). Chondrocytes in the centre of the 
cartilage templates become hypertrophic and stop proliferating (d). Blood vessels invade the hypertrophic 
region and the chondrocytes die via apoptosis (e). Osteoblasts and other mesenchymal cells are transported 
into that region forming the primary spongiosa (f). The bone is lengthened through chondrocyte proliferation 
on both extremities (g). Finally, secondary ossification centres are formed, ordered columns of proliferating 
chondrocytes originate the growth plate and stromal cells invade the marrow space originating the bone 
marrow (h). MSCs – mesenchymal stromal cells; BV – blood vessel; Ob. – osteoblast; SOC – secondary 
ossification centre. 
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Hypoxia is essential for the process of endochondral bone formation. Low pO2 is the main force 
promoting coupling of angiogenesis and osteogenesis146, which is essential for endochondral bone 
formation to proceed146. It has been shown that bone formation does not occur if angiogenesis is 
inhibited147,148. Initial condensation of mesenchymal cells occurs at low pO2 and HIF-1α has been 
shown to be up-regulated (at both mRNA and protein levels) in the chondrogenic phase of 
endochondral bone formation142,149. Hypoxia also regulates chondrocyte growth arrest and survival 
in the cartilaginous growth plate4,142-144; hypertrophic differentiation of chondrocytes is affected in 
conditional HIF-1α knock-out mice149. In addition, low pO2 promotes VEGF release by hypertrophic 
chondrocytes148. Enhanced activity of this pro-angiogenic factor has been shown to be essential for 
coupling of angiogenesis and osteogenesis65,146,147,150,151; it mediates capillary invasion of the 
growth plate150,151. Together these data suggest that hypoxic chondrocytes in the centre of the 
growth plate activate the HIF-1 pathway, which then enhances synthesis of VEGF and other 
angiogenic mediators by the chondrocytes. The angiogenic molecules then stimulate invasion of 
cartilage by the newly formed capillaries, which transport osteoblast progenitor cells and signalling 
molecules to promote differentiation of pre-osteoblastic cells and bone formation and maturation148. 
In addition, the HIF-1 pathway has also been reported to affect intramembranous bone 
formation148. In this case, however, it has been suggested to promote bone formation by acting 
directly on the bone progenitor cells. More recently, however, Saito et al. proposed regulation of 
endochondral bone formation to be controlled essentially by HIF-2α152. Expression of the main 
markers of endochondral bone formation, including collagen 10 (COL10A1), matrix 
metalloproteinase 13 (MMP13) and VEGFA, was significantly enhanced by HIF-2α and hardly 
affected by HIF-1α152. The role of HIF-2α was confirmed by an independent study of osteoarthritic 
cartilage destruction, which showed enhancement of catabolic factors, including matrix 
metalloproteinases (MMPs) and aggrecanase-1, by HIF-2α expression, in a process similar to 
endochondral bone formation153.  
During cartilage development, O2 and vascular gradients are also of great importance
70,154. 
Cartilage formation is known to be modulated by hypoxia. HIF-1α has been shown to regulate 
DEC1 and DEC270, as well as SOX9, three of the main chondrogenesis regulators, in 
chondrocytes cultured under hypoxia155. Various other studies suggest hypoxia directs 
chondrogenic differentiation. Early chondrogenesis is delayed in conditioned HIF-1α knock-out 
mice149 and massive cell death in the hypoxic centre of the cartilage anlage, but also at the 
chondrosternal junction of ribs (where chondrocytes normally do not undergo hypertrophy and 
death and cartilage is not replaced by bone) was also observed121. Furthermore, chondrocyte 
metabolism is known to operate normally at low O2 tension within the matrix due to the absence of 
vascular supply in cartilage69,70. The hypoxia pathway has been demonstrated to be activated in 
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chondrocytes156,157 and to be essential for their survival promoting metabolism adaptation70,144. 
Extracellular matrix formation and accumulation by chondrocytes has also been demonstrated to 
be stimulated by hypoxia. HIF-1α stabilises a group of procollagen hydroxylases essential for 
collagen formation and an increased accumulation of collagen type II and aggrecan has been 
observed if chondrocytes are cultured under hypoxic conditions121,158,159.  
Unsurprisingly, O2 tension and the HIF-1 pathway also play a key role in skeletal regeneration. In 
the case of bone, activation of the HIF-1 pathway has been reported during bone repair due to 
inflammation160 and increased vascularisation161. Interestingly, induced activation of the HIF-1 
pathway by selective inactivation of VHL in mice osteoblasts or administration of DFO (a PHD2 
inhibitor), resulted in accelerated bone regeneration and enhanced angiogenesis161. Plus, 
enhanced VEGF levels have been shown to enhance bone regeneration, via activation of the HIF-
1 pathway136. 
Differentiation of progenitor cells into osteoblasts under hypoxia has also been reported162 but is, 
however, controversial, as several studies have shown inhibition of the osteogenic potential at low 
pO2
136,163-165. The difference in the results obtained in the different studies could probably be due to 
the levels of hypoxia used and to the cell sources tested. In addition, some researchers claim that 
hypoxia stimulates osteoclast activity and bone resorption3,166.  
One of the major current problems in bone regeneration is the absence of a microvascular system 
to transport the O2 and nutrients required
8,65. Angiogenesis is well established to be essential for 
bone healing73. Hypoxia is known to be one of the main stimuli of blood vessel formation and/or 
remodelling, through activation of the HIF-1 pathway and expression of VEGF and other pro-
angiogenic factors2. Under low O2 tension, activation of the HIF-1 pathway stimulates production of 
angiogenic factors by the hypoxic cells, which then stimulates migration of endothelial and pericyte 
cell precursors to the hypoxic site. Activation of the endothelial cells (ECs) then leads to blood 
vessel formation (reviewed in 2). Hypoxia has been shown to stabilise HIF-1α and increase VEGF 
expression in osteoblasts161,167. In addition, hypoxia has been shown to stimulate the production of 
various angiogenic factors in mesenchymal stromal cells (MSCs)136,168. Further, under hypoxia, 
MSCs promote EC proliferation and migration168, as well as enhance their in vitro angiogenic 
ability169. 
Primary chondrocytes have a significant limitation when used for TE purposes in that they 
dedifferentiate when expanded ex vivo. However, hypoxia has been shown to delay the aging 
process in chondrocytes70,159, probably avoiding dedifferentiation in culture. Moreover, primary 
chondrocytes kept in culture for a longer period have been shown to re-acquire a chondrogenic 
phenotype if encapsulated in alginate gels and cultured at a low O2 tension
159. Interestingly, 
various chondrocyte progenitor cells, including mesenchymal stromal cells and adipocyte-derived 
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stromal cells, have been shown to differentiate into chondrocytes if exposed to low O2 tension, in 
both monolayer culture70,136,170,171 and 3D constructs70.  
Not all literature agrees with the significant role of hypoxia in chondrogenesis. A few studies of 
cells in 3D constructs show no effect or inhibitory effects of low O2 tension in chondrogenesis
70. 
However the vast majority of studies show that hypoxia promotes chondrogenesis136. In addition, a 
recent study showed cartilage formation in pig knee grafts using periosteal cells in which HIF-1α 
was activated using BMP-2 and IGF-1172. We hypothesize that the development of a hypoxia-
mimicking material could significantly improve skeletal regeneration. Such a material could be 
used to assist the differentiation of progenitor cells into either chondrocytes or osteoblasts, as well 
as stimulate blood vessel formation or remodelling, which are essential for bone healing and 
regeneration. 
2.2.3 Targetting the Hypoxia Response in Cells 
To target the hypoxia response under normoxic conditions, HIF-1α degradation should be inhibited 
such that the O2-regulated HIF-1α subunit can translocate into the nucleus and activate gene 
transcription (Fig. 2.5). So far, several different strategies have been used to mimic hypoxia under 
normal O2 tension conditions. Some researchers have used prolyl hydroxylases or proteosome 
inhibitors161,173,174. Others have transfected cells with a gene encoding a stabilised form of HIF-1α 
which lacked the oxygen-sensitive degradation domain173,175. Ion-chelators and nitric oxide have 
also been used176,177 and many growth factors, such as TNF-α, IGF and TGF have been shown to 
promote HIF-1α accumulation6. However, exposure of cells in culture to transition metals such as 
copper, iron176, nickel178 and cobalt100,167,178-180 is one of the most common ways to activate the 
HIF-1 pathway. Cobalt in particular has been extensively studied in vitro and has also been 
previously used in vivo for different applications. 
Several authors have demonstrated that Co2+ ions activate the HIF-1 pathway in vitro. Exposure to 
CoCl2 solutions (25 – 500 µM) enhanced HIF-1α accumulation, as well as HIF-1 activity, in several 
cell types, including endothelial cells181-183, mesenchymal stromal cells184,185, and various 
carcinoma cell types100,167,178,186. In addition, activation of subsequent cellular response, such as 
enhancement of VEGF expression, has also been reported167,181,183,187. Several authors, however, 
claim that the Co2+-induced response may differ from the hypoxia-induced one. For example, a 
proteomic study with human leukaemic monocytes (U937 cells) has shown different protein 
expression profiles under the two conditions188. A separate study using human ECs has shown 
inhibition of their in vitro angiogenic ability under exposure to various CoCl2 solutions (10 - 700 
μM), contrary to the effect observed under exposure to hypoxia (0% to 3% O2)
181. Interestingly, the 
same study demonstrated enhancement of both HIF-1α and VEGF levels under exposure to both 
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hypoxia and CoCl2. This result suggests that the mechanisms for hypoxia-induced and CoCl2-
induced HIF-1α stabilisation are distinct. Evidence to support this was added by a study by Kim et 
al.; they showed that the use of ROS scavengers has no effect on hypoxia-induced HIF-1α 
response, but it inhibits the CoCl2-induced HIF-1α response
167. 
In vivo studies, however, have shown very promising results regarding the use of cobalt as a 
hypoxia mimic. Administration of CoCl2 solutions in rats can enhance angiogenesis and bladder 
growth, through the activation of the hypoxia pathway189. Additionally, an independent study 
reported reduction of apoptosis and enhancement of proliferating endothelial cells in rat 
tubulointestinal injuries, which then ameliorated the healing process190.  
Different mechanisms have been suggested to explain the hypoxia-mimicking role of cobalt. The 
most widely accepted theory indicates that cobalt inhibits HIF-1α degradation by inactivation of 
PHD2191. As discussed previously in this chapter, PHD2 activity is highly dependent on three 
factors besides O2, and a small alteration in any of them can affect the enzyme’s activity. The three 
factors are iron (Fe2+), α-ketoglutarate and ascorbic acid, which act as the activating metal, a co-
substrate and a cofactor, respectively. If cells are exposed to cobalt, the intracellular iron content is 
maintained constant but ascorbate levels decrease192. Since ascorbate is essential to keep iron in 
its active (ferrous) state (Fe2+), in the presence of cobalt, the PHD2 activity can be reduced if not 
totally inhibited192. So, HIF-1α is not targeted to degradation by VHL and the hypoxia pathway is 
activated even in normoxic conditions. 
A different theory suggests that cobalt ions are able to inhibit PHD2 activity by actually replacing 
the iron ion in the active site of the dioxygenase (PHD2), instead of altering its ferrous state 
through action on ascorbic acid. Other theories, in addition, suggest cobalt can interfere in the next 
step of the HIF-1α degradation process, the bonding of VHL, or directly on HIF-α expression193. 
Moreover, cobalt has been shown to bind directly to the ODD domain of HIF-α subunits, even after 
hydroxylation of the two proline residues by PHD2194. The transition ion has then been suggested 
to occupy the VHL binding site, inhibiting proteosome degradation of the HIF-1α subunit under 
normal pO2
194,195. Finally, cobalt is known to affect the PI3K signalling pathway through the 
production of ROS193. Activation of the kinase signalling pathway is then thought to enhance HIF-
1α expression, and subsequently activate the HIF-1 pathway193,196. 
Cobalt is essential for the human organism in the form of vitamin B12 (hydroxocobalamin)197. It 
functions as a co-factor in enzyme-catalysed reactions and is involved in the production of 
erythropoietin197. The transition metal is present in the body in very low concentrations; its mean 
concentration in serum varies from 0.1 to 0.3 mg/kg198. Cobalt deficiency causes reduction of 
vitamin B12 in the serum and liver199, but excess of cobalt is also toxic. Severely impaired lung 
function, cardiovascular dysfunction and asthma, as well as goitre and reduced thyroid activity, 
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have been reported after prolonged exposure to high cobalt concentrations in humans199. Cobalt 
toxicity is thought to be caused by ROS formation, which then leads to DNA breakage and 
inhibition of the DNA repair mechanisms200, as well as apoptosis201. 
The transition metal has, however, already been used in the past as a therapy for anaemia202 and 
also in prosthetic implants, for more than 30 years203. In addition, in vitro, CoCl2 concentrations up 
to 200 µM have been shown to maintain cell viability in various cell types204-207. In vivo, sub-chronic 
administration of CoCl2 in rats up to 12.5 mg/kg was shown to be non-toxic
208. In addition, studies 
in humans who underwent total hip replacement have shown enhanced levels of cobalt in the 
serum (up to 4.3 µg/L), but no toxic effects two years after the surgery209. These studies indicate 
that cobalt ions might be of great potential for use in regenerative therapies and tissue 
engineering, but controlled release of the transition metal ion is essential. Bioactive glasses will be 
used for this purpose in this thesis. 
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2.3 BIOACTIVE GLASSES 
Inert materials were initially thought to be the best materials for use in the human body as they 
would generate a minimal tissue response. However, due to increasing life expectancy, people 
now often out-live the implanted materials. Therefore, nowadays, biomaterials are expected to 
form a strong connection with the surrounding tissues and, in many cases, to activate an 
appropriate cellular response and tissue repair/regeneration. 
The first bioactive glass (BG) was developed by Larry Hench in 1969210. While working for the US 
army, developing a glass-ceramic material that could resist high energy radiation, he was asked 
whether he would also be able develop a material that could survive exposure to the human body. 
Bioglass® was the result of that quest. For a material to resist exposure to the human body it 
should be able to form a living bond with the host tissue instead of an interfacial layer of scar 
tissue. A SiO2-Na2O-CaO glass of composition 45% SiO2 – 24.5% Na2O – 24.5% CaO – 6% P2O5 
(wt%) was chosen to provide a large amount of CaO and some P2O5 within the SiO2-Na2O 
matrix210. The glass was melted and small implants were tested in a rat femoral model. Six weeks 
after implantation, it was impossible to remove the glass implants from the bone, while the controls 
would easily slide out210. In vitro tests were later performed and the glass was shown to be able to 
form a hydroxyapatite (HA) layer in solution210. The strong bond formed between the bone and the 
ceramic implants was found to be created by the chemical bonding between the HA crystals and 
the collagen layers produced by osteoblasts in the interface210,211. 
Since then many researchers have been trying to understand the mechanisms behind Bioglass® 
bioactivity and, also, to develop new bioactive glass compositions with enhanced properties or that 
can be used for different purposes. The results of the most relevant studies in the area will be 
summarised in this section. 
2.3.1 BG structure 
In order to enhance the properties of bioactive glasses and to tailor them to different purposes, the 
chemical structure and the way it influences the chemical and physical properties should be well 
understood. The bioactive glass structure is based on a SiO4 tetrahedral network where the 3D 
continuous network is formed by SiO4 tetrahedra connected to each other by the oxygen atoms in 
the corners212 (Fig. 2.9). The addition of alkali and alkali earth oxides (e.g. CaO, Na2O) modifies 
the structure by reducing the degree of connectivity in the network, replacing bridging oxygens 
(BOs) with non-bridging oxygens (NBOs)213 (see Fig. 2.10). According to Zachariensen214, silicon 
atoms are network formers, as they form the network with BOs and NBOs. The alkali and alkali 
earth metals act as network modifiers. These ions are in the free spaces in between the SiO4 
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network and their role is very important since they open up the glass network, lower its glass 
transition temperature (Tg) and enhance the glass degradability, which increases its bioactivity
214. 
 
 
Fig. 2.9 The structure of bioactive glasses is based on a SiO4 tetrahedral network (a) where the 3D 
continuous network is formed by SiO4 tetrahedra (b) connected to each other by the oxygen atoms in the 
corners. 
 
Fig. 2.10 The addition of alkali and alkali earth oxides (eg. CaO, Na2O) reduces the degree of connectivity in 
the network (a) and replaces bridging oxygens (BO) (c) with non-bridging oxygens (NBO) (b). 
The network modifiers can diffuse through the network, that is to say they are mobile. Many of the 
glasses’ properties, such as the glass transition temperature (Tg), the crystallisation temperature 
(Tc), the dissolution rate and the ability to form HA, are dependent on the alkali metal content of the 
glass and also on the contribution of these cations to the glass network213,215. Moreover, it has 
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been shown that when an additional alkali metal is added to form a binary alkali metal oxide glass, 
the glass dynamic and transport properties are significantly altered213. In addition, mixed alkali 
oxide compositions are known to enable glass formation at lower temperatures213. Mixing different 
alkali metal oxides in a glass can therefore be used to produce glasses with a superior 
combination of properties than can be obtained with the incorporation of a single alkali metal oxide. 
Alkali or alkali earth metals commonly incorporated in BGs are calcium, sodium, strontium216, 
magnesium217, zinc218-220 and silver221,222. Furthermore, some of these elements are known to have 
therapeutic effects (as is the case of calcium and strontium in bone regeneration223-225). Controlled 
release of the active ions at desirable dosages, however, is essential to enhance their beneficial 
effects. 
The concept of the inorganic polymer model and network connectivity (NC) to BGs, introduced by 
Hill, describes highly disrupted glasses as inorganic polymer chains of oxygen and silicon atoms 
cross-linked in places and charge-balanced by network modifiers226. The model is quantitative; 
network connectivity can be obtained by calculating the concentration of BOs and NBOs per silicon 
oxygen tetrahedron as a function of the alkali oxide concentration (Eq. 2.1)226-229 The term Qn 
expresses NC; it gives an indication of the number of BOs per silicon tetrahedron and the value of 
n is the number of BOs230. A tetrahedron in which the four oxygen atoms are BOs is denoted as a 
Q4 unit, while a tetrahedron in which all oxygen atoms are NBOs is denoted as a Q0 unit (Fig. 
2.11). Increasing the network formers content of a glass has been shown to increase its NC, due to 
a reduction of NBOs213. Inverted glasses, which are glasses where NC<2 (meaning the average Q 
distribution is lower than Q2), are considered to be the most bioactive glasses. For instance, the 
NC of 45S5 Bioglass® is 1.9, which is lower than 2 and indicates a distribution of 90% Q2 and 10% 
Q1. Glasses with a Si content higher than 60 molar% have NC>2 and are usually non-bioactive231. 
 
            NF
NBOBO
NC

                                                                                                    (Eq. 2.1) 
 
NC – network connectivity 
BO – bridging oxygens 
NBO – non-bridging oxygens 
NF – network formers 
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Fig. 2.11 Network connectivity: the Q
n
 notation, where n indicates the number of BOs. (a) a silicon atom 
surrounded by four BOs is a Q
4
; (b) a silicon atom surrounded by 4 NBOs is a Q
0
. 
The inorganic polymer model can therefore be used to determine the bioactivity of glasses in the 
ternary SiO2-CaO-Na2O system. However, if P2O5 were to act as a network former, this model 
would no longer apply. There is now enough evidence which indicates that instead of entering the 
silicate network, the phosphorus phase separates into orthophosphate species213,226,229. 31P NMR 
data clearly showed that phosphorus is present in an orthophosphate environment with Ca2+ and 
Na+ associated213,226. Thus, the phosphate-rich phase removes both Na+ from a network modifying 
role in the silicate network, increasing the NC of the silicate phase (Fig. 2.12). A sodium 
phosphate-rich phase will be extremely soluble and when exposed to water will dissolve more 
rapidly than the silicate phase, effectively increasing the local level of phosphorus supersaturation 
of the external physiological environment and increasing the hydroxycarbonated apatite (HCA) 
formation rate232. 
 
 
Fig. 2.12 The possible roles of phosphorus in a bioactive glass structure: (a) phosphorus as a network 
former, entering the silicate network; (b) phosphorus phase-separating in an orthophosphate environment.  
In summary, SiO2-Na2O-CaO-P2O5 bioactive glasses phase separate into a silicate and a 
phosphate phase. The silicate phase is based on a non-mobile Si-O network that is modified by 
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the addition of alkali or alkali earth oxides. The phosphate phase consists of an orthophosphate 
environment and it can associate network-modifying cations, removing them from their role in the 
silicate network. The phosphate phase is more mobile. 
2.3.2 BG bioactivity 
After the initial in vivo study by Hench described earlier in this section233, many questions were 
raised concerning the nature, strength and stability of the Bioglass®-bone bond as well as the 
mechanisms involved in its formation. Various experiments have therefore been performed in 
different animal models in order to better comprehend the strong Bioglass®-bone bond and hence 
the bioactivity of bioactive glasses (reviewed in 234). 
Surprisingly, early studies in rat and monkey models showed the bond between Bioglass® and 
bone could be stronger than that of the host bone235,236. Such a strong bond was later shown to be 
the result of a series of chemical reactions that occur on the surface of the material in contact with 
the living tissue237. This process is initiated by the formation of the HCA layer and is thought to 
continue with protein adsorption to the BG surface, cellular adhesion and extracellular matrix 
(ECM) formation. HCA formation begins with cation exchange between the glass and the solution 
and silanol bonds (Si-OH) are formed as a result. Condensation and repolymerisation of the SiO2-
rich layer occurs on the surface (Si-OH + Si-OH → Si-O-Si + H2O), to where Ca
2+ and PO4
3- 
groups migrate, forming a CaO-P2O5-rich film on top of the SiOH-rich layer. Crystallisation of the 
amorphous film and incorporation of OH- and CO3
2- from the solution to form HCA (Ca10(PO4)6-
x(CO3)x(OH)2) follows. Hench proposed that this process would continue with protein adsorption at 
the surface of the material during HCA formation and this would be enhanced by the several 
reaction layers. Attachment, proliferation and differentiation of both macrophages and osteoblasts 
would then prepare the implant for tissue regeneration. Mineralisation of the matrix would follow 
soon thereafter, which would lead to the formation of mature osteocytes in a collagen-HCA 
matrix237-241. 
Later on, HCA formation was found to be useful but not the critical step for the Bioglass® 
interaction with bone238,240-242. Controlled release rates of ionic dissolution products at specific 
doses were shown to be the key factor231. The boundaries for the BG-bone bond were then found 
to be kinetic240,241. The bioactivity of glasses can be represented by a diagram such as the one in 
Fig. 2.13 (adapted from 231). In the middle of the diagram the glasses with the highest level of 
bioactivity (region E) are represented; these glasses contain similar amounts of SiO2, CaO and 
Na2O. The glasses with a slower rate of bonding contain between 52-60% weight of SiO2 and, 
finally, glasses with a composition of more than 60% SiO2 (region B) are considered to be bio-
inert231. However, BG bioactivity does not only depend on the glass composition, it is also highly 
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regulated by surface area. By increasing the surface area it is possible to produce bioactive 
glasses with SiO2 content greater than 60%
243. 
 
Fig. 2.13 Tissue-bonding as a function of the glass 
composition: compositional diagram for bone-
bonding. Region A: bone bonding compositions; 
region B: non-bonding compositions, with too low 
reactivity; region C: non-bonding compositions, 
with too high reactivity; region D: non glass 
forming compositions; region S: soft tissue 
bonding compositions; region E: Bioglass® 
composition (taken from 
231
). 
 
Bioactive glasses have been shown to be able to direct cellular behaviour in vitro. Three different 
mechanisms are thought to be involved: surface chemistry, topography and the rate and type of 
dissolution ions (Fig. 2.14) (reviewed in 244). These external signals can activate different cellular 
pathways and promote transcription of specific genes. The resultant proteins determine the cell 
phenotype and thereby the response to the initial stimuli. Some of the processes known to be 
regulated by the BG are proliferation, differentiation and cell death244,245. 
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Fig. 2.14 Bioactivity of bioactive glasses. Regulation of cellular behaviour by bioactive glasses occurs 
through three different mechanisms: ions dissolution, surface chemistry and topography. These external 
signals activate specific intracellular signalling pathways, leading to transcription of target genes. The 
resultant proteins determine the cellular response to the initial stimuli. (adapted from 
244,246
)  
The study of the interaction between bioactive glasses and cells/tissues has focused 
predominantly on bone and osteogenic cells. In these studies, Bioglass® as well as several other 
glass compositions were used in several different forms, such as powder, scaffolds, coated 
surfaces and dissolution ions, either alone or incorporated in other materials, as will be described 
later in this chapter. Different cell sources have been used for in vitro investigations, including pre-
osteoblastic cell lines247,248, primary osteoblasts249-253, foetal osteoblasts254 and bone marrow 
stromal cells255 from mice, rats and humans (reviewed in 244,245). All studies have shown that BGs 
enhance cell proliferation and stimulate differentiation towards a more mature osteogenic state, 
promoting ECM formation and mineralisation. Interestingly, mineralisation and bone nodule 
formation has been observed in the absence of osteogenic supplements250. Furthermore, for the 
first time in 2007, enhanced alkaline phosphatase (ALP) activity, as well as enhanced production 
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of collagen type I and bone nodule formation, was observed when primary human osteoblasts 
(pHOBs) were cultured on sol-gel bioactive glass scaffolds containing no phosphorus253. Alkaline 
phosphatase activity, expression of osteogenic genes (as ALP, Runx2, Osteocalcin, Col I) and 
bone nodule formation were the assays used by most authors to assess osteogenic differentiation. 
More interestingly, Xynos et al. analysed the effect of the dissolution ions from 45S5 bioactive 
glass – Bioglass® - in the gene expression of pHOBs. After exposure of the cells to Bioglass® 
dissolution ions for 48 h seven different gene families were shown to be up regulated251. These 
genes include those involved in several critical cellular processes such as proliferation, cell cycle 
regulation, apoptosis control and different growth factors implicated in bone formation251. 
Although bone repair has been the main focus of the BG-tissue interaction studies, the effect of 
bioactive glasses on different tissues as well as in different processes has also been assessed. 
45S5 Bioglass® has been shown to support chondrocyte growth and enhance expression of some 
chondrogenic markers such as Indian hedgehog and collagen type X256, which indicates that BGs 
can also be used for soft tissue therapy. Human macrophages and monocytes have been cultured 
on 45S5-coated surfaces and Bioglass® was shown to be able to control cytokine secretion in 
response to an inflammatory stimulus219. In addition, a co-culture system of intestinal epithelial cell 
layers with sub-epithelial myoblasts seeded on 45S5-coated surfaces suggested that Bioglass® 
can increase intestinal epithelial restitution257. 
An additional process in which the BG effect has been extensively studied is angiogenesis. As 
previously described on section 2.1, angiogenesis is essential for the regeneration of most tissues 
and the inability to form new blood vessels in most tissue engineering constructs is still one of their 
main limitations. Both in vitro and in vivo studies have been performed that suggest Bioglass® can 
promote new blood vessel formation. Human fibroblasts were extensively used; the cells were 
seeded either in Bioglass®-coated surfaces, Bioglass®-containing scaffolds or encapsulated in 
Bioglass®-containing alginate beads146,258-260. In all cases expression of the vascular endothelial 
growth factor (VEGF) and basic fibroblast growth factor (bFGF) was increased. Additionally, 
fibroblast-conditioned media was used to treat endothelial cells (ECs)258,259 and both their 
proliferation and tubule-forming ability were enhanced with Bioglass®. A different study seeded 
ECs into Bioglass®-containing collagen sponges and compared the effect of high and low BG 
concentrations (BG.46). This study showed that while higher Bioglass® concentrations promote 
osteogenic differentiation on MC3T3-E1 (mouse pre-osteoblastic cells), lower Bioglass® 
concentrations enhance ECs proliferation, VEGF production and ability to form tubules261. 
Furthermore, different Bioglass®-containing scaffolds have been subcutaneously implanted in rats 
and mice for up to six weeks and the number of blood vessels formed increased when compared 
to the controls260,262. Therefore, Bioglass® has been shown to promote angiogenesis both in vitro 
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and in vivo. However, it is now important to elucidate whether other BGs exhibit a similar effect and 
whether the effect can be enhanced. 
Finally, bioactive glasses are considered to be non-toxic materials. However, the effect of 
submicron particles generated by wear or degradation of the BGs was only recently considered. 
Labbaf et al. exposed human bone marrow derived stromal cells (hMSCs) to submicron sol-gel-
derived BG particles and assessed their effect on cell viability and metabolic activity263. Cell 
viability was not significantly affected however, when these cells were exposed to high particle 
doses for seven days, their metabolic activity was significantly reduced. In addition, confocal 
microscopy confirmed cellular uptake of the particles and their localisation on the cytoskeleton. 
2.3.3 BG composite scaffolds 
BGs have limited mechanical strength as well as low toughness, which in many cases prevents 
their use as load-bearing devices. For this reason several authors decided to incorporate or 
combine BGs with polymers or metals. Bioglass® has been incorporated in poly-DL-lactide acid 
(PDLLA) and poly(lactic-co-glycolic acid) (PLGA) porous scaffolds264 and BG particles of different 
compositions have been added to poly-L-lactide acid (PLLA) constructs. In addition, using the sol-
gel process, BG units have been cross-linked with gelatine to form a silica-gelatin hybrid265. In all 
cases, the incorporation of BGs in other materials intended to develop new materials with highly 
tailorable properties, maintaining their ability to control the ion release rates as well as to form HA 
when in contact with the body fluid. 
2.3.4 Commercial products 
Bioglass® has been used in clinical products since the mid 1980s. In 1985, MEP, a Bioglass® 
ossicular reconstruction prosthesis used to treat conductive hearing loss by replacing bones in the 
middle ear, was the first Bioglass® product to be commercialised. The second was ERMI 
(endosseous ridge maintenance implant), in 1988, an implant to support lingual and labial plates in 
natural tooth roots and to provide a more stable ridge for dental construction following tooth 
extraction231. The third generation of Bioglass® clinical products consists of products proven to 
stimulate in situ bone regeneration. They appeared in 1995 with Perioglass® from NovaBone®. 
Currently medical and dental products containing Bioglass® are sold in 35 different countries under 
the name of brands as NovaBone® and NovaMin®. 
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(The data reported in this chapter has been previously published in: M. M. Azevedo, G. Jell, M. D. 
O’Donnell, R. V. Law, R. G. Hill and M. M. Stevens, Synthesis and characterization of hypoxia-
mimicking bioactive glasses for skeletal regeneration, J. Mater. Chem. 20, 8854–8864, 2010266) 
3.1 INTRODUCTION 
As previously discussed in Chapter 2, a major challenge in skeletal tissue engineering is the 
development of constructs that can both promote skeletal tissue formation and in some cases, eg. 
bone, stimulate the formation of new blood vessels (angiogenesis)8,65. In vivo, low oxygen pressure 
(hypoxia) plays a pivotal role in coupling angiogenesis with osteogenesis65,146,151, a vital process for 
the development and regeneration of skeletal tissue. Moreover, chondrogenesis is known to be 
modulated by hypoxia70. Hypoxia activates a series of pro-regenerative processes mediated by the 
Hypoxia Inducing Factor-1α (HIF-1α) transcription factor1. As previously described in Chapter 2, 
under normoxic conditions, HIF-1α is constitutively expressed but immediately degraded via 
proteasome. However, under hypoxic conditions, HIF-1α degradation is inhibited, and the 
stabilised transcription factor is translocated into the nucleus where it dimerizes with HIF-1β and 
initiates the expression of numerous genes associated with tissue regeneration. The importance of 
the HIF-1α pathway in skeletal tissue development and regeneration is emerging, the HIF-1α 
pathway is essential for long-bone development4,142 and artificial HIF-1α stabilisation has been 
shown to enhance fracture repair161. The HIF-1α pathway is also important for mesenchymal stem 
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cell differentiation (MSC), regulating osteogenesis and osteoclastogenesis and importantly 
promoting angiogenesis161,167. Mimicking hypoxia by artificially stabilizing HIF-1α has been 
suggested as a promising strategy to promote the expression of a large number of pro- and anti-
angiogenic genes36. Without a functional vasculature, tissue constructs are limited to the limits of 
oxygen diffusion (approximately 200 μm). The HIF-1α pathway is also vital for cartilage 
development, homeostasis and regeneration69,267. The HIF-1α pathway is essential in enabling 
chondrocytes to adapt their metabolism to a low oxygen pressure environment70, maintain their 
phenotype121,158,159 and in promoting cartilage extracellular matrix formation121,158,159. Materials 
capable of regulating the cellular hypoxia pathway therefore offer a great deal of potential in 
skeletal tissue regeneration. 
Cobalt ions have been used extensively to mimic a hypoxic environment in vitro, due to a well-
established stabilising effect on HIF-1α167,180,181,268. However, exposure to high and/or prolonged 
concentrations of these ions has been shown to cause cell toxicity in vitro and pathologies in 
vivo208,269 (most likely via activation of redox pathways). A controlled ion release system is 
therefore vital for any tissue engineering strategy involving delivery of cobalt. One possible vehicle 
is that of cobalt-doped bioactive glasses (Co2+ BG). The 45S5 Bioglass®, a specific BG 
composition, is a soda-lime-phosphosilicate that does not become surrounded by fibrous tissue 
when implanted; instead it forms an intimate bond to bone270. Several commercially available 
products based on Bioglass® have Food and Drug Administration (FDA) approval, including 
products such as NovaBone®, NovaMin®, Perioglas® and Vitoss-BA® for hard tissue restoration231. 
Several modified versions of 45S5 have been reported and different ions, such as strontium, 
magnesium or zinc, have been added to the initial composition with the aim of improving bone 
bonding and regeneration216,218,271. In the study presented here cobalt ions were incorporated into 
two series of bioactive glasses and the role of cobalt within the BG network investigated. Due to 
cobalt’s charge to size ratio, it can enter the silicate network as a network intermediate, e.g. as 
[CoO4]
2- species, but it can also act as a higher coordination-number (CN) network modifier272. The 
role of cobalt in the glass network will determine the network connectivity (NC) and BG properties, 
such as ion release rates and hydroxycarbonated apatite (HCA) formation, will be affected. 
Since one of the proposed applications for the hypoxia stimulating BG developed here is in 
cartilage tissue engineering, zinc and magnesium ions were added to one of the BG compositions 
in order to decrease HCA formation273-275, which would be undesirable for this application. These 
two ions have previously been used in tissue engineering for a number of different purposes, 
including as dopants in the production of hydroxycarbonated apatite ceramics275, incorporation into 
polymeric microspheres276 and also doping in bioactive glasses218-220. Magnesium can increase 
chondrocyte proliferation and redifferentiation277,278 and zinc is involved in bone metabolism279. 
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Moreover, both magnesium and zinc can improve osteoblast adhesion to scaffolds280,281 and 
promote osteogenic differentiation220,279,282,283. 
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3.2 MATERIALS AND METHODS 
3.2.1 Preparation of bioactive glasses 
Two series of cobalt BGs were prepared by the melt-quench route as previously described284. The 
BG compositions were prepared according to Table 3.1 and then transferred to a platinum–
rhodium crucible and placed into the pre-heated furnace (1400 °C) for 90 min and the molten 
contents of the crucible were then quenched into deionised water. The granular glass frit was 
collected and dried in an oven at 100 °C. Finally, the glass frit was ground into a powder and 
sieved to obtain particles smaller than 38 μm. Glass powders were stored in a desiccator until 
used. 
3.2.2 Differential scanning calorimetry (DSC) 
Differential Scanning Calorimetry (DSC) was performed in order to determine the glass transition 
temperature (Tg) of the glasses synthesised. This thermoanalytical technique measures the 
amount of heat necessary to increase the temperature of a sample and a reference as a function 
of temperature. DSC was carried out on 50 mg samples of BG (<38 μm particles) between 50 and 
1050 °C at a ramp rate of 10 °C min-1. A Polymer Laboratories Thermal Sciences DSC was used 
and Al2O3 was used as the reference. 
3.2.3 Magic-angle-spinning nuclear magnetic resonance (MAS-NMR) spectroscopy 
29Si and 31P MAS-NMR were used to analyze the BG samples using a Bruker DSX-200 NMR 
spectrometer operating at Larmor frequencies of 39.77 and 81.9 MHz, respectively. Samples were 
packed into a 4 mm zirconia rotor and spun at the magic angle (54.74°) to remove anisotropy 
effects. The 29Si and 31P MAS-NMR spectra of the glasses were recorded at spinning frequencies 
from 3 to 12 kHz using a Bloch decay pulse sequence for both silicon and phosphorus. The 29Si 
and 31P MAS-NMR samples were spun with a recycle delay time set to 2 s (although this was 
increased to 60 s if the glass species were not thought to be completely relaxed). All spectra were 
recorded at an ambient probe temperature with 29Si referenced relative to polydimethylsilane 
(PDMS) and 85% H3PO4 for 
31P. (MAS-NMR was performed by Dr. O’Donnell). 
3.2.4 Evaluation of ion release profiles from bioactive glasses 
The prepared BG samples (<38 μm particles) were incubated in Tris buffer (45 mg of glass per 50 
cm3 Tris buffer) at 37 °C, in an orbital shaker at 120 rpm. At intervals, 5 cm3 samples were 
collected, centrifuged and filtered. Inductively coupled plasma optical emission spectrometry (ICP-
OES) was performed on the resulting solutions and the concentrations of ions (silicon, calcium, 
sodium, phosphorus, cobalt, magnesium and zinc) were calculated, based on standard solutions. 
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ICP is a highly sensitive type of spectrometry capable of determining the concentration of several 
elements in a wide concentration range. This technique is based on coupling together inductively-
coupled plasma as a method of exciting atoms with optical emission spectrometry. ICP was 
performed using a Thermo Scientific iCAP 6000 Series ICP Spectrometer and each sample read in 
triplicate. 
3.2.5 Evaluation of hydroxycarbonated apatite (HCA) formation on bioactive 
glasses 
To assess HCA formation, 75 mg of BG powder (particles<38 μm) were added to 50 cm3 of 
simulated body fluid (SBF), prepared according to the method proposed by Kokubo285 in conical 
flasks. The samples were placed in an incubator at 37 °C for 7, 14, 21 and 28 days. At these time 
points, the powder was collected by filtering, sprayed with acetone and then air dried. The 
formation of apatite was characterized using both FTIR and XRD. FTIR is an analytical technique 
that provides information on the infrared spectrum of absorption and emission of solid materials. It 
then allows identification of some of the different molecules present in a sample, through 
identification of specific covalent bonds. A Genesis II Fourier transform infrared spectrometer, 
within a range of 600 to 1600 cm-1 and a resolution of 8 cm-1 was used for FTIR. XRD is a non-
destructive analytical technique which provides information about the crystallographic structure, 
crystallite size and preferred orientation in polycrystalline powered solid materials. For XRD, a 
Phillips powder diffractometer with copper (CuKa) X-ray source (Phillips PW 1700 series 
diffractometer, Phillips, Eindhoven, NL) was used. The powered samples were recorded between 5 
and 80° 2θ. 
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3.3 RESULTS AND DISCUSSION 
3.3.1 BG synthesis 
To develop a BG with the ability to activate the cellular hypoxia response in cells, cobalt oxide was 
added to the BG compositions in various mole% (mole% will be referred to as % from now on) 
concentrations (Table 3.1). Due to cobalt’s charge to size ratio, it can act as a network 
intermediate, entering the silicate network, e.g. as [CoO4]2- species, but it can also act as a higher 
coordination-number (CN) network modifier272. According to the Zachariasen’s rules286,287 and 
Dietzel’s criterion288, cobalt may enter the silicate network, as a network intermediate, because of 
its relatively high charge to size ratio. We have considered an intermediate oxide to be a cation 
that can enter the silicate network as Si4+ but is not capable of forming a glass by itself, i. e. the 
presence of a network former, such as Si4+, is still necessary. In Co(II), CN = 4 which is equivalent 
to [CoO4]
2- species, the cobalt has a charge to size ratio of 0.49 (value calculated according to the 
formula z/a2, z being charge and a the ionic radius289). This radius is similar to magnesium (0.45 if 
CN = 6 and 0.52 if CN = 4), which has been shown to have a dual role in the silicate network218. 
Co(II) with a CN = 8, however, has a charge to size ratio of 0.35289 which could be considered 
isostructural to calcium and have network modifier characteristics. Cobalt can therefore also act as 
a network modifier, replacing bridging oxygens (BOs) for non-bridging oxygens (NBOs) in a similar 
fashion to calcium. 
In order to understand the role of cobalt in the silicate network, two series of cobalt BGs were 
prepared as previously described284. The network connectivity was maintained constant at 2.13 to 
ensure the maintenance of the BG’s bioactivity. NC was calculated according to equations 3.2 and 
3.3, assuming Co2+ is either entering the silicate network as an intermediate oxide or acting as a 
network modifier, respectively (Table 3.1). The BG compositions were designed using the 
inorganic polymer model of soda-lime–phosphosilicate glasses with the general formula of 
3SiO2·0.07P2O5·(1.4-X)CaO·1.6Na2O·XAO (A = Co, Mg or Zn)
284. Cobalt oxide was added to the 
glass composition in different concentrations to produce the two different glass series: a charge 
balanced (CB) series and a non-charge balanced (NonCB) series. These series were based on the 
assumption of Co2+ entering the glass network as an intermediate oxide or acting as a network 
modifying oxide, respectively (Table 3.1). For the CB series, the BG composition was designed in 
order to maintain a fixed network connectivity, assuming Co2+ substituted for Si4+ in the glass 
network. Thus, each mole of SiO2 content was replaced by one mole of CoO and one mole of 
CaO. BGs with Co2+ contents of 0, 1, 2, and 4 mole% were prepared. In the NonCB series CoO 
was substituted for CaO, to give Co2+ contents of 0, 0.5, 1, 2, and 4 mole%. All other BG 
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components were kept constant. MgO and ZnO were added to a 2% Co2+ BG from the NonCB 
series to achieve 2 and 4 mole%. 
Table 3.1 Designed compositions of the BG used in this study in mole percentages. The two columns on the 
right indicate the network connectivity (NC) of each glass calculated according to the method described by 
Hill
226-229
. Network connectivity 1 (NC1) was calculated assuming Co
2+
 to be a network modifier (Eq. 3.2) and 
network connectivity 2 (NC2) was calculated assuming Co
2+
 enters the silicate network as a network 
intermediate (Eq. 3.3).  
Series BGs SiO2 P2O5 CaO Na2O CoO ZnO MgO NC1 NC2 
 0Co 49.46 1.07 23.08 26.38    2.13 2.13 
N
o
n
C
B
 
NonCB0.5Co 49.46 1.07 22.58 26.38 0.50   2.13  2.192.1  2.19   2.19 
NonCB1Co 49.46 1.07 22.08 26.38 1.00   2.13 2.25 
NonCB2Co 49.46 1.07 21.08 26.38 2.00   2.13 2.36 
NonCB4Co 49.46 1.07 19.08 26.38 4.00   2.13 2.57 
NonCB2Co4Mg 49.46 1.07 17.08 26.38 2.00  4.00 1.97 2.62 
NonCB2CoMgZn 49.46 1.07 17.08 26.38 2.00 2.00 2.00 1.97 2.62 
NonCB2Co4Zn 49.46 1.07 17.08 26.38 2.00 4.00  1.97 2.62 
C
B
 
CB1Co 47.98 1.06 23.85 26.12 0.99   2.01 2.13 
CB2Co 46.53 1.05 24.59 25.86 1.96   1.88 2.13 
CB4Co 43.72 1.03 26.04 25.37 3.85   1.61 2.13 
 
NF
nonBOBO
NC

                                                                                                    (Eq. 3.1) 
OnSi
OnPnZnOnMgOnCoOOnNanCaOOnSi
NC
2
5222 .6)(2.41

                    (Eq. 3.2) 
nZnOnMgOnCoOOnSi
OnPOnNanCaOnZnOnMgOnCoOOnSi
NC



2
5222 .6)(2)(6.42               (Eq. 3.3) 
NC – network connectivity 
BO – bridging oxygens 
nonBO – non-bridging oxygens 
NF – network formers 
NC1 – network connectivity considering Co
2+
, Mg
2+
 and Zn
2+
 network modifiers 
NC2 – network connectivity considering Co
2+
, Mg
2+
 and Zn
2+
 enter the network as intermediate oxides 
n – number of moles in the composition 
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3.3.2 BG Characterization 
X-Ray diffraction (XRD) analysis verified that the BGs were amorphous and not crystalline, as 
evidenced by a lack of sharp crystalline peaks in the spectra (data not shown).  
3.3.2.1 Effect of Co2+ addition on glass transition temperature 
Differential scanning calorimetry (DSC) was performed to determine the glass transition 
temperature (Tg) of the BGs. This is the transition from a glass to a supercooled liquid on heating 
and is seen in the DSC spectra as a negative deviation (endothermic) from baseline. The effect of 
Co2+ addition on Tg was compared for both the charge balanced (CB) and non-charge balanced 
(NonCB) BG series (Fig. 3.1). In the CB series, Tg remained constant until 2% Co
2+ addition and 
then increased slightly. In the NonCB series, however, Tg decreased with Co
2+ addition in a 
concentration-dependent manner ≤2% Co2+ and then increased with 4% Co2+. A lower Tg generally 
infers weaker bonds within the BG and therefore a more readily degradable BG in a physiological 
environment285. The network connectivity of the CB BGs is constant (Table 3.1) as enough modifier 
(Na+ and Ca2+) is added to charge balance any [CoO4]
2- species formed. The viscous flow of the 
silicate part of the BG network, which is of constant polymerisation across the CB series, will 
dominate the signal in the DSC spectra, therefore it follows that Tg should not change significantly 
on addition of Co2+. Two additional processes could also be occurring that result in no significant 
change in Tg, namely: firstly the creation of a weakly bonded cobalt complex species and secondly 
the enhanced polymerisation of the silicate network. In contrast, as Co2+ is added to the NonCB 
series the BG structure initially becomes weaker and more easily disrupted. However at a Co2+ 
content of 4% the opposite seems to happen and Tg increases. Since in the NonCB series Tg 
decreases abruptly with the incorporation of a small percentage of Co2+ in the BG composition and 
Si–O bonds are expected to be stronger than the Co–O bonds, the DSC data suggests Co2+ is 
entering the silicate network as an intermediate oxide. If Co2+ enters the network, Co–O–Si bonds 
would replace the stronger Si–O–Si bonds and thus the BG structure would become weaker and 
more easily disrupted. However, when more than 2% Co2+ is added to the BG composition, the 
effect of replacing a network modifier (Ca2+) with Co2+ seems to predominate. At higher 
concentrations, replacing Ca2+ with Co2+ increases the degree of polymerization of the silicate 
network as more Co2+ enters the silicate network and Tg increases. The BG structure becomes 
stronger and less easily disrupted. In the CB series the data in Fig. 3.1 showed Tg is constant until 
2% Co2+ is reached, whereupon it slightly increases. This suggests that Co2+ is entering the silicate 
network as the excess Ca2+ and Na+ ions added to the BG are charge balancing the cobalt 
complexes and not depolymerising the silicate network. The DSC data discussed herein suggest 
that Co2+ may be both taking part in the silicate network and acting as a modifying oxide in the BG 
structure. This behaviour would mirror the behaviour of other divalent cations with similar ionic 
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sizes, such as Mg2+ and Zn2+, that have also been previously reported to act as both intermediate 
and modifying oxides in the BGs218. 
 
Fig. 3.1 Glass transition temperature (Tg) as 
determined by DSC of NonCB and CB BG series 
as a function of mole percentage (mole%) of Co
2+
 
ions in the BG (n=3). 
 
 
3.3.2.2 Effect of Co2+ addition on BG Qn structure  
If Co2+ is entering the silicate network in the NonCB series, this should induce a change in the 
silicate Q2 structure towards a Q3 structure. On formation of the [CoO4]
2- species additional network 
modifying cations would be required to charge balance the 2- charge in this complex, hence the 
degree of polymerization of the silicate network would increase. This change in the network 
connectivity could influence the chemical shift in 29Si MAS-NMR spectroscopy. In addition, it is also 
possible that Co2+ may charge balance the Q0 orthophosphate (PO4)
3- units in the glass. 31P 
chemical shifts could also be influenced by the presence of Co2+ in the phosphate phase of the 
BG. Therefore, in order to further understand the role(s) of Co2+ in the glass structure, 29Si and 31P 
MAS-NMR were performed (Fig. 3.2 and Fig. 3.3, respectively). 
The 29Si MAS-NMR spectra of the NonCB (Fig. 3.2 a) and CB (Fig. 3.2 b) series showed that the 
resonance did not move ca. -80 ppm across the series and linewidth increased with the addition of 
Co2+ (Fig. 3.2 c). The increase in linewidth is due to the paramagnetic effect of the unpaired 
electrons in the partially filled d-orbitals of the Co2+ ion. The Q3 shoulder characteristic of the 
silicate structure did not increase with addition of Co2+ to the BG. However, a correlation was found 
between the 29Si MAS NMR peak position (Fig. 3.2 d) and the network connectivity, NC1 
parameter (Table 3.1). A shift downfield of the 29Si MAS-NMR peak was observed in the CB series 
with the addition of Co2+ (Fig. 3.2 d). This may be either due to Co2+ entering the network as an 
intermediate oxide or acting as a network modifier depolymerising the network. In the NonCB 
series, however, the position of the 29Si MAS-NMR peak remained constant throughout the series. 
The same happens with the NC1 parameter, which was constant in the NonCB series and 
decreases in the CB BGs. As this correlation is usually used to determine any structural changes 
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and NC1 was calculated assuming Co2+ is a network modifier, these data are consistent with a 
network modifier role for Co2+. 
 
Fig. 3.2 
29
Si NMRspectra of the Co
2+
-containing BGs. (a) 
29
Si NMR spectra of the NonCB BG series. (b) 
29
Si 
NMRspectra of the CB BG series. Spectra for NonCB BG series: (A) 0Co; (B) NonCB0.5Co; (C) NonCB1Co; 
(D) NonCB2Co; (E) NonCB4Co. Spectra for CB BG series: (F) 0Co; (G) CB1Co; (H) CB2Co; (I) CB4Co). (c) 
Linewidth of the 
29
Si peaks as a function of Co
2+
 concentration in the BG for both NonCB and CB BG series. 
(d) Position of the 
29
Si peaks as a function of Co
2+
 concentration in the BG for both NonCB and CB BG 
series. 
The 31P MAS-NMR spectra reveal that orthophosphate is present in the BG. The position of the 31P 
peak does not significantly change with Co2+ addition. Both 29Si and 31P MAS-NMR spectra (Fig. 
3.2 and Fig. 3.3), however, broaden out with the addition of Co2+, which suggests that the Co2+ 
may be evenly distributed over the network units. The effect of paramagnetic cations is difficult to 
analyse using the same approach as for alkali earth or alkali cations. Paramagnetic cations have 
many unpaired electrons that can interact with the nuclei and produce a number of different effects 
on the NMR spectrum290,291, including a reduction in spin–lattice relaxation, T1, times and 
broadening of the resonance line. Whereas some reduction in spin–lattice relaxation T1 time is 
beneficial, for obtaining improved signal-to-noise ratios, line broadening is detrimental, especially 
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in MAS-NMR spectra of BGs where the peaks are already broad due to the variation in bond 
angles and distances in a disordered glass structure. In our 29Si and 31P MAS-NMR spectra both 
effects were observed (Fig. 3.2 and Fig. 3.3), but only for the CB series and not for the NonCB 
series. This difference, however, is associated with the compositional design rather than the role of 
the Co2+ cation. From the DSC, 29Si and 31P MAS-NMR data, Co2+ therefore appears to play a dual 
role in the silicate network depending on its concentration. This is also known to be the case for 
other divalent cations such as Mg2+ and Zn2+ (218) of similar ionic size. 
 
Fig. 3.3 
31
P NMR spectra of the Co
2+
-containing BGs. (a) 
31
P NMR spectra of the NonCB BG series. (b) 
31
P 
NMR spectra of the CB BG series. Spectra for NonCB BG series: (A) 0Co; (B) NonCB0.5Co; (C) 
NonCB1Co; (D) NonCB2Co; (E) NonCB4Co. Spectra for CB BG series: (F) 0Co; (G) CB1Co; (H) CB2Co; (I) 
CB4Co). (c) Linewidth of the 
31
P peaks as a function of Co
2+
 concentration in the BG for both NonCB and CB 
BG series. (d) Position of the 
31
P peaks as a function of Co
2+
 concentration in the BG for both NonCB and 
CB BG series. 
3.3.2.3 Effect of Co2+ addition on BG ion release profiles 
Ion release profiles of the BGs in Tris buffer were analysed by ICP-OES (Fig. 3.4 and Fig. 3.5). 
The ion release profiles of the BGs from the NonCB series (Fig. 3.4 a–d and Fig. 3.5 a-d) were 
more significantly affected by the addition of Co2+ than those of the CB series (Fig. 3.4 e–h and 
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Fig. 3.5 e-h). In the CB series the amount of Si4+, Ca2+ and Na+ released was similar across all 
compositions. However, in the NonCB series the addition of Co2+ to the BG decreased the release 
of soluble silica species and Ca2+ and Na+ ions. The initial release of soluble silica species is faster 
in BGs with a low to zero Co2+ content (Fig. 3.4 a and Fig. 3.5 a), indicating that Co2+ is taking part 
on the silicate network, decreasing dissolution. Ca2+ and Na+ release significantly decreases with 
addition of Co2+ to the BG in a concentration-dependent manner (Fig. 3.4 b and c and Fig. 3.5 b 
and c). The decrease in Ca2+ release might be partly explained by the <20% lower Ca2+ content of 
the Co2+ BGs (although this cannot fully account for the 50% difference), whilst Na+ concentration 
is kept constant throughout the NonCB series. Fig. 3.5, however, clearly shows the lower Ca2+ and 
Na+ concentrations in Tris after dissolution of the higher Co2+ content BGs are not only due to 
lower content of these ions in the BG compositions but to Co2+ addition to the BGs since the 
percentage of both Na+ and Ca2+ released significantly decreases with Co2+ addition especially in 
the nonCB series. If Co2+ was entering the silicate network as an intermediate oxide, the decrease 
of the ion release profiles could be simply explained. In the NonCB series the decreased ion 
release profiles would be due to the replacement of a network modifier (Ca2+) by a cation that 
enters the silicate network (Co2+), which would increase the degree of polymerization of the silicate 
network. In the CB series, a network former (Si4+) would be replaced by another ion with the same 
role (Co2+), so causing little effect on ion release. The ion release profiles are therefore in 
agreement with DSC data and suggest Co2+ enters the silicate network, acting as Si4+.  
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Fig. 3.4 Concentration of the different cations in Tris buffer as determined by ICP-OES as a function of time 
after incubation of BGs from both NonCB and CB BG series for up to 4 h. (a–d) NonCB BG series; (e–h) CB 
BG series; (a and e) Si
4+
 concentration; (b and f) Ca
2+
 concentration; (c and g) Na
+ 
concentration; (d and h) 
Co
2+
 concentration. 
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Fig. 3.5 Percentage of the different cations in Tris buffer as determined by ICP-OES as a function of time 
after incubation of BGs from both NonCB and CB BG series for up to 4 h. The percentage of ions released 
was calculated assuming that a 100% value corresponds to the complete dissolution of the BGs in Tris. (a–
d) NonCB BG series; (e–h) CB BG series; (a and e) % of Si
4+
 released; (b and f) % of Ca
2+
 released; (c and 
g) % of Na
+ 
released; (d and h) % of Co
2+
 released. 
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Longer term (4 week) ion release studies were also completed (here only phosphate release is 
reported). In both the NonCB and the CB BG series (Fig. 3.6 a and b, respectively), phosphate 
ions stay in solution for a longer time period with increasing concentrations of Co2+ in the BG. For 
example, in the case of 0Co BG of the NonCB series, the phosphate concentration in the buffer fell 
to zero after 24 h. However, with increasing concentrations of Co2+ in the BG, phosphate ions 
remained in solution for up to 15 days. This could be due to slower precipitation of the 
orthophosphate ions as HCA or amorphous calcium phosphates in the Co2+-containing BGs. The 
solubility limit for silica in solution was reached in all glasses at approximate times thereby 
indicating similar degradation in all BGs. The more persistent solubility of the phosphate ions (i.e. 
longer induction time for apatite formation) could then be explained by the formation of more stable 
complexes between Co2+ and phosphate than those formed between Ca2+ and phosphate. The fact 
that cobalt has more valence electrons and is more electronegative than calcium could explain the 
higher stability of the cobalt phosphate complexes. It is also possible that Co2+ affects the 
nucleation of HCA crystals as Mg2+ does292,293, since these two ions have similar charge to size 
ratios. The decrease in nucleation rate would then explain the persistence of phosphate ions in 
solution with Co2+ addition to the BGs.  
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Fig. 3.6 Phosphate concentration in Tris buffer as 
determined by ICP-OES as a function of time after 
incubation of BGs from both NonCB and CB BG 
series for up to 28 days. (a) NonCB BG series; (b) 
CB BG series; (c) Mg
2+
- and Zn
2+
-containing BGs 
from the NonCB series. 
 
3.3.2.4 Controlled Co2+ release achieved 
In both BG series controllable Co2+ release was achieved with the novel BGs through modification 
of their Co2+ content (Fig. 3.7). Furthermore, Co2+ is released within a biologically active 
concentration range. In vitro294,295 and in vivo296 studies indicate that the physiologically active 
concentration range is between 50 and 250 μM (3–15 ppm). Additionally, the Co2+-containing BGs 
were tested and shown to activate the hypoxia response in several cell types (described in 
Chapters 4, 5, 6). 
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Fig. 3.7 Cobalt concentration in Tris buffer as 
determined by ICP-OES as a function of mole 
percentage (M%) of Co
2+
 after incubation of BGs 
from both NonCB and CB BG series for 4 h. 
 
3.3.2.5 Effect of Mg2+ and Zn2+ addition on BG structure and dissolution properties 
Substitution of Mg2+ and Zn2+ for Ca2+ in the Co2+-containing BGs resulted in a decrease in Tg (Fig. 
3.8). Mg2+ and Zn2+ can have a dual role in the BG network218, both entering the silicate network 
and acting as modifying oxides. If they enter the silicate network as intermediate oxides, the 
presence of Si–O–M bonds (M being Mg2+ or Zn2+) weakens the BG network because the newly 
created bonds are significantly weaker than Si–O–Si bonds. This explains the observed drop in Tg. 
However, if Mg2+ and Zn2+ act as network modifiers, we would expect Tg to increase because their 
ionic radii are smaller than that of Ca2+, which results in a more compact strongly bonded glass 
network. These results suggest that these two ions can play a role in the silicate network and are 
in agreement with data previously reported218,289,297,298. 
 
Fig. 3.8 Glass transition temperature (Tg) as 
determined by DSC of Mg2+- and Zn2+-
containing BGs from the NonCB BG series as 
a function of the mole percentage (M%) of both 
Mg2+ and Zn2+ ions in the BG. 
 
29Si and 31P MAS-NMR were performed on the Mg2+- and Zn2+-containing BGs. A shift upfield of 
the silicon resonance was observed with the addition of both Mg2+ and Zn2+ to the BG. However, 
the addition of each Mg2+ and Zn2+ separately did not result in any significant shift of the silicon 
peak (Fig. 3.9 a). 31P MAS-NMR spectra suggested that the phosphate phase of the BG was not 
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affected by the addition of Zn2+. In contrast, the phosphate peak shifted to a more positive region of 
the spectra upon Mg2+ addition to the BG (Fig. 3.9 b). This indicates that Na+ increasingly 
associates with orthophosphate groups (Na3PO4 chemical shift is 10–16 ppm
291) as Ca2+ is 
substituted for Mg2+, suggesting Mg2+ is entering the silicate network. The same effect has been 
previously reported to occur in a concentration dependent manner over a range of Ca2+ 
substitutions in BG from 25–100 mole%218,298.  
 
 
Fig. 3.9 
29
Si and 
31
P NMR spectra of the Mg
2+
- and 
Zn
2+
-containing BGs from the NonCB BG series. (a) 
29
Si NMR spectra, (b) 
31
P NMR spectra. Spectra: 
(A) 0Co; (B) NonCB2Co; (C) NonCB2Co4Zn; (D) 
NonCB2CoMgZn; (E) NonCB2Co4Mg. 
 
In agreement with published data273,292,299-301, the dissolution study performed here demonstrated 
decreased Si4+, Ca2+, Na+ and Co2+ release with the addition of both Mg2+ and Zn2+ to the BGs (Fig. 
3.10). This was clearly seen for Ca2+ and Na+ release (Fig. 3.10 b and c), and the effect was more 
pronounced with Zn2+ than with Mg2+ (Fig. 3.10 a and d). These results indicate that these ions 
may also act as network modifiers. Since both Mg2+ and Zn2+ have smaller ionic radii than Ca2+, 
replacing Ca2+ with either of these ions should result in a denser network, causing the BGs to be 
less reactive. Furthermore, Mg–O and Zn–O interactions are stronger than Na–O and Ca–O 
interactions. Conversely, if Mg2+ and Zn2+ take part in the silicate network as intermediate oxides, 
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the BG would become weaker due to the formation of Si–O–M and M–O–M interactions and this 
would increase ion release rates. However, in this instance, a further consideration is that in this 
scenario Ca2+ - a network modifier – is replaced by a cation that enters the silicate network, which 
could decrease the BGs dissolution rates due to a greater degree of polymerization of their 
network. If Mg2+ and Zn2+ replace Ca2+ as network modifiers, the glass structure will also be 
strengthened since the ionic radii of Mg2+ and Zn2+ are smaller than that of Ca2+. In this case, the 
BG network will be tighter and ion release profiles will decrease. These findings corroborate 
previous work218 and suggest Mg2+ and Zn2+, as well as Co2+, can play a dual role acting to take 
part in the silicate network and acting to disrupt it. 
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Fig. 3.10 Concentration of the different 
cations in Tris buffer as determined by 
ICP-OES as a function of time after 
incubation of the Mg2+- and Zn2+-
containing BGs from NonCB BG series for 
up to 4 h. (a) Si4+ concentration; (b) Ca2+ 
concentration; (c) Na+ concentration; (d) 
Co2+ concentration. 
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3.3.2.6 The effect of Co2+ in HCA formation on the BG  
HCA formation is an important property of BGs for bone regeneration applications. HCA formation 
may, however, be undesirable for some other applications of BGs (i.e. cartilage tissue engineering 
or wound healing). The effect of Co2+, Mg2+ and Zn2+ addition on the HCA forming ability of our 
hypoxia-regulating BGs was therefore assessed using the SBF test285, although the limits of the 
SBF test in definitively predicting HCA formation and in vivo behaviour should be considered302. 
The FTIR spectra of the different BGs from the NonCB series after incubation in SBF for 1, 2, 3 
and 4 weeks, revealed bands associated with apatite formation (the 580 cm-1 band is indicative of 
the formation of an amorphous calcium phosphate layer303 and where this peak splits into two 
bands 613 cm-1 and 574 cm-1, this indicates the formation of an apatite crystalline phase303,304). 
The presence of Co2+, Mg2+ and Zn2+ in the BG significantly delays the formation of a HCA layer 
and this delaying effect is strongest with Mg2+ and Zn2+. After 1 week in SBF only the 0Co BG 
revealed the presence of crystalline HCA (Fig. 3.11 a). After 2 weeks (Fig. 3.11 b), however, all 
Co2+-containing NonCB BGs spectra contained peaks around 613 cm-1 and 574 cm-1, indicating the 
formation of the HCA crystalline layer on these BGs. The spectra of the Mg2+-containing BGs and 
the NonCB2Co4Zn BG spectra only revealed crystalline HCA peaks after 3 and 4 weeks 
incubation in SBF, respectively (Fig. 3.11 c and d, respectively). XRD was performed on the same 
samples after incubation in SBF for 2 weeks (Fig. 3.12). A broad peak around 2θ = 32° 
corresponds to hydroxyapatite (hkl = 211, JCDPS card 9-0432)305. The intensity of the calcium 
carbonate peak at 2θ = 29° (hkl = 104, JCDPS card 81-2027)305 decreases with Co2+ addition to 
the BG (Fig. 3.12). As calcium carbonate only forms once all the phosphate available is used to 
form apatite, these data confirm the FTIR data and indicate that addition of Co2+ to the BGs delays 
apatite formation in a Co2+ concentration-dependent manner. In agreement with FTIR data, XRD 
spectra also showed that Mg2+ and Zn2+ addition further delays apatite formation. This result is in 
agreement with the dissolution data discussed above, since Co2+, as well as Mg2+ and Zn2+, 
addition to the BGs was shown to decrease ion release (including calcium and phosphate release), 
an essential step for HCA formation.  
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Fig. 3.11 FTIR spectra of the BGs from the NonCB 
series after incubation in simulated body fluid (SBF) 
for up to 28 days. The 580 cm
-1
 band is indicative of 
the formation of an amorphous calcium phosphate 
layer and where this band splits into two bands at 
613 and 574 cm
-1
, this indicates the formation of 
apatite crystalline phase. (a) FTIR spectra of the 
BGs after 7 days in SBF; (b) FTIR spectra of the 
BGs after 14 days in SBF; (c) FTIR spectra of the 
BGs after 21 days in SBF; (d) FTIR spectra of the 
BGs after 28 days in SBF. Spectra for NonCB BG 
series: (A) 0Co; (B) NonCB1Co; (C) NonCB2Co; (D) 
NonCB4Co; (E) NonCB2Co4Mg; (F) 
NonCB2CoMgZn; (G) NonCB2Co4Zn.  
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Fig. 3.12 XRD spectra of the BGs 
from the NonCB series after 
incubation in simulated body fluid 
(SBF) for 14 days. The broad peak 
around 2θ = 32° corresponds to 
hydroxyapatite and the peak at 2θ = 
29° is the calcium carbonate peak. 
Spectra for NonCB BG series: (A) 
0Co; (B) NonCB1Co;  C) 
NonCB2Co; (D) NonCB4Co; (E) 
NonCB2Co4Mg; (F) 
NonCB2CoMgZn; (G)  
NonCB2Co4Zn. 
 
The reduced HCA formation with Mg2+ and Zn2+ was anticipated as these two ions have been 
previously shown to delay HCA formation218,306. Different mechanisms have been proposed to 
explain this effect. Some authors suggest Zn2+ can adopt a tetrahedral coordination and 
copolymerize with [SiO4] tetrahedra, inducing complexation of the silicate network, which will 
decrease ion dissolution and delay HCA formation299,301. Other authors propose that the Mg2+ and 
Zn2+ ions can reduce the nucleation rate of apatite in solution and then bind to the surface of 
apatite crystals and delay the crystallization of amorphous calcium phosphate292. The fact that Zn2+ 
has a stronger effect than Mg2+ on reduction of glass bioactivity has been previously reported by Li 
et al. and is in agreement with our data293. Since Co2+ has similar properties and seems to behave 
in a similar manner to Mg2+ and Zn2+ in the silicate network, it is possible that it has the same effect 
on HCA crystallization. Moreover, Co2+ has previously been reported to inhibit phase 
transformation during HCA crystal formation, from amorphous calcium phosphate to HCA307. 
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3.4 CONCLUSION 
Novel hypoxia-mimicking BGs were successfully developed introducing different amounts of Co2+ 
ions in the BG network. Co2+ was shown to be present in both silicate and phosphate phases of the 
synthesized BGs. In the orthophosphate phase of the BGs, Co2+ appears to charge balance the 
orthophosphate groups. In the silicate phase of the BGs, however, Co2+ seems to play a dual role, 
both entering the silicate network as an intermediate oxide and disrupting it as a network modifier, 
depending upon concentration. As expected, addition of Co2+ to the BG was also shown to alter 
the BG properties. BG dissolution, ion release and HCA formation are delayed by inclusion of Co2+ 
in the BG in a concentration-dependent manner. 
As previously reported, Mg2+ and Zn2+ also have a dual role in the silicate network as they are able 
to both enter the silicate network and act as network modifiers. A delay in HCA formation was 
achieved upon the addition of these two cations. The addition of either Co2+, Mg2+, and Zn2+ or a 
combination of all three delays HCA formation, which is desirable for the use of these BGs in 
tissue engineering of soft tissues (e.g. cartilage). 
More importantly, the BGs presented here allow a tailorable and controlled release of Co2+ ions 
within a biologically active concentration range indicating that the materials hold great promise as 
new hypoxia-mimicking materials for regenerative medicine. 
For the studies presented in the following chapters (Chapters 4 to 7), the glasses of the non-
charge balanced (NonCB) series were used, as this is the more complete series, containing one 
extra Co2+ glass (NonCB0.5Co) and the Mg2+- and Zn2+-containing glasses. 
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4.1 INTRODUCTION 
A major challenge in designing materials for tissue engineering is to provide suitable cues that can 
direct cellular behaviour and promote tissue regeneration. The development of novel materials 
which activate a natural a “self-healing” response shows great potential. 
During natural tissue development and repair, due either to increased metabolic demand on 
developing tissues or to damaged vasculature, local oxygen pressure often drops, creating a 
hypoxic environment. Cells respond to these changes in the oxygen pressure through a hypoxia-
sensing pathway1. Several cellular processes, including new blood vessel formation 
(angiogenesis)2 and recruitment of stem cells3,4, as well as proliferation5,6 and differentiation of 
multiple cell types3,4,7,8 have been shown to be activated by this pathway. Moreover, anti-microbial 
activity and other cell survival mechanisms have also been shown to be enhanced by hypoxia9,10. 
These processes, essential for natural tissue development and regeneration, might be critical for 
many tissue-regeneration strategies. Therefore, the development of materials that regulate the HIF 
pathway might be of great potential for tissue engineering therapies. 
The hypoxia-sensing pathway was extensively described in Chapter 2. The main steps will, 
however, be repeated here for better comprehension. HIF-1α (hypoxia inducible factor-1α) is the 
transcription factor responsible for the pathway activation. Under normoxia conditions, HIF-1α is 
degraded in the cytoplasm. However, under hypoxia, the transcription factor is stabilised and 
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accumulates in the cytoplasm. Stabilised HIF-1α translocates into the nucleus, where it dimerises 
with the HIF-1β subunit. Ultimately, the HIF dimer activates the expression of specific target genes 
by binding to hypoxia-responsive elements (HRE) in their promoters1. 
Several approaches to regulating the hypoxia pathway, including recombinant proteins or gene 
target technology, have been used. Exposure to transition metals such as copper, iron, nickel and 
cobalt is one of such approach and it has been shown to inhibit HIF-1α degradation. In this study 
we focused our attention on Co2+, since it has been extensively studied in vitro and in 
vivo167,176,178,180,308. Since bioactive glass (BG) composition can be targeted to specific tissues, and 
more interestingly BGs allow controllable ion release, novel resorbable BGs were chosen as the 
Co2+ ion delivery system. 
In the present chapter, the effect of different Co2+ concentrations (in the form of CoCl2) as well as 
different BG concentrations (in the conditioned media) on cell viability and the hypoxia response of 
SaOs2 cells is discussed. A range of hypoxia-mimicking Co2+ concentrations plus a range of non-
toxic BG concentrations are defined. Finally, the effect of the BG characterised in the previous 
chapter on SaOs2 cell viability and hypoxia pathway activation is described. 
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4.2 MATERIALS AND METHODS 
4.2.1 Cell culture 
SaOs2 cells (an osteosarcoma-derived cell line) were expanded in RPMI 1640 (GIBCO®) with 10% 
(v/v) fetal bovine serum (FBS), 1% (v/v) L-glutamine and 1% (v/v) penicillin/streptomycin. Initial 
culture was performed in 75-cm2 flasks at 37 °C in a humidified atmosphere of 95% air with 5% 
CO2 and supplied with fresh medium every 2–3 days. At 90% confluence, cells were detached 
using trypsin-EDTA (GIBCO®), and cell count was determined in a haemocytometer. Cells were 
resuspended to give the appropriate concentration for seeding in complete medium. 
SaOs2 cells were then seeded in 96-well plates at a density of 5x104 cells/cm2 and treated for 
different time periods with RPMI 1640 (GIBCO®) containing either CoCl2 or BG-conditioned media 
at different concentrations (Fig. 4.1). Cell-culture medium was replaced every 2–3 days. 
4.2.2 Preparation of BG-conditioned medium 
BG-conditioned medium was prepared by incubation of BG (<38 µm particles) in RPMI 1640 
(GIBCO®), rolling for 4 h at 37 °C, prior to filtration (0.2 µm pore filters). Initially, a series of BG 
concentrations in media were tested (0.75; 1.5; 3 and 9 mg/mL). Following determination of the 
optimal BG concentration, subsequent studies were performed using BG-conditioned media 
prepared by the incubation of 1.5 mg of BG per mL of media. To stabilise its pH, conditioned media 
was incubated (37 °C, 5% CO2) in a vented flask for 2 h prior to use. Only BGs from the non-
charge-balanced series (NonCB) were used for this study (see Table 4.1). The concentration of the 
different ions released from the BGs to the medium was assessed by using inductively coupled 
plasma-optical emission spectrometry (ICP-OES) (see Table B.2).  
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Fig. 4.1 Schematic representation of the procedure followed in the cell-culture studies performed to assess 
BG biological activity. BG-conditioned media was prepared using the different BGs characterised in chapter 
3. The media with the dissolution ions was then used to treat SaOs2 cells and after different incubation 
periods, samples were collected to assess the Co
2+
 BGs’ effect on cell viability and activation of the hypoxia 
response. 
 
Table 4.1 Composition of the BGs used in this study (in molar %); table adapted from Chapter 3 for case of 
comprehension.  
Series BGs SiO2 P2O5 CaO Na2O CoO ZnO MgO 
 0Co 49.46 1.07 23.08 26.38    
N
o
n
C
B
 
NonCB0.5Co 49.46 1.07 22.58 26.38 0.50   
NonCB1Co 49.46 1.07 22.08 26.38 1.00   
NonCB2Co 49.46 1.07 21.08 26.38 2.00   
NonCB4Co 49.46 1.07 19.08 26.38 4.00   
NonCB2Co4Mg 49.46 1.07 17.08 26.38 2.00  4.00 
NonCB2CoMgZn 49.46 1.07 17.08 26.38 2.00 2.00 2.00 
NonCB2Co4Zn 49.46 1.07 17.08 26.38 2.00 4.00  
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Table 4.2 Ion concentration (Si, Ca, Na, P, Co, Mg and Zn) in BG-conditioned RPMI (in ppm) measured by 
ICP-OES. The Co concentrations presented in the shadowed column were converted to µM. The values 
presented here are the average of all batches used for the experiments presented in this chapter. 
 Conc. Si Ca Na P Co Co (µM) Mg Zn 
RPMI  0.01 12.55 2569 182.7 0.03 0.50 9.81 0.02 
CoCl2 25 µM 0.01 11.88 2376 175.0 1.77 30.02 9.38 0.00 
CoCl2 50 µM 0.01 12.00 2327 174.7 3.49 59.19 9.38 0.00 
CoCl2 100 µM 0.01 11.86 2293 174.2 6.85 116.18 9.23 0.00 
CoCl2 150 µM 0.01 11.44 2284 170.7 9.84 166.88 9.16 0.00 
CoCl2 200 µM 0.01 11.18 2269 169.6 14.60 247.62 9.01 0.00 
CoCl2 300 µM 0.01 10.83 2243 168.9 21.34 361.93 9.01 0.00 
CoCl2 600 µM 0.01 10.01 2124 162.9 41.62 705.88 8.57 0.00 
0Co 
0.75 mg/mL  21.44 32.83 2346 137.0 0.02 0.34 - - 
1.5 mg/mL  37.94 17.76 2343 120.4 0.01 0.17 - - 
3 mg/mL  101.9 17.93 2561 78.0 0.00 0.00 - - 
9 mg/mL  360.6 61.63 2621 11.7 0.00 0.00 - - 
NonCB2Co 
0.75 mg/mL  32.77 37.23 2288 141.8 3.74 63.43 - - 
1.5 mg/mL  40.64 30.10 2243 130.3 4.29 72.76 - - 
3 mg/mL  119.1 17.72 2354 85.6 7.15 121.26 - - 
9 mg/mL  268.1 38.87 2497 29.9 4.02 68.18 - - 
0Co 1.5 mg/mL  31.48 63.34 2446 121.5 0.01 0.17 4.96 0.00 
NonCB0.5Co 1.5 mg/mL  65.81 25.22 2354 102.8 1.69 28.66 3.35 0.00 
NonCB1Co 1.5 mg/mL  66.91 25.17 2354 106.1 3.33 56.48 3.46 0.00 
NonCB2Co 1.5 mg/mL  51.88 22.99 2215 108.9 4.95 83.95 4.11 0.00 
NonCB4Co 1.5 mg/mL  58.02 36.56 2208 111.3 9.17 155.52 4.41 0.00 
NonCB2Co4Mg 1.5 mg/mL  45.11 18.49 2286 117.6 5.51 93.45 8.48 0.00 
NonCB2CoMgZn 1.5 mg/mL  64.28 22.65 2300 115.9 6.25 106.00 7.03 0.31 
NonCB2Co4Zn 1.5 mg/mL  58.38 28.74 2215 112.6 3.89 65.97 4.26 0.33 
4.2.3 Total DNA Assay 
After 1, 2, 4 and 7 days, the standard protocol for a commercially available fluorescent assay to 
measure DNA concentration was used to assess cell viability (Hoescht dye, Sigma®). DNA 
quantification is based on the enhanced fluorescence and shift in the emission wavelength of the 
fluorochrome Benzamide 33258 (Hoescht) when bound to DNA. Briefly, cell-culture medium was 
removed and 100 μL of distilled H2O was added per well after washing the cells with PBS. Cells 
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were lysed by freeze-thaw cycles and 50 µL of the lysates were added to 50 µL of Hoescht dye 
diluted to the working concentration (20 µg/mL). Fluorescence was measured using an excitation 
wavelength of 360 nm and an emission wavelength of 460 nm in a microplate reader (SpectraMax 
M5, Molecular Devices). DNA concentrations were calculated using a standard curve prepared 
with calf thymus DNA (Sigma®) at concentrations between 0-100 µg/mL. 
4.2.4 MTT Assay 
MTT assay was performed to assess the effect of Co2+ BG on SaOs2 proliferation, as previously 
reported. Briefly, MTT salt solution (thiazolyl blue tetrazolium bromide, Sigma®) (5 mg/mL) was 
added to cell culture 4 h prior to the end of the experiment to allow cellular tetrazolium metabolism. 
After removal of cell-culture media, 200 µL of DMSO was added to solubilise formazan crystals. 
Absorbance was measured using a microplate reader (SpectraMax M5, Molecular Devices) at a 
wavelength of 570 nm with a reference wavelength of 620 nm. 
4.2.5 LDH Assay 
A colorimetric assay (CytoTox 96® Non-Radioactive Cytotoxicity Assay, Promega®) was used to 
evaluate the effect of Co2+ BG on cell metabolism. This assay quantitatively measures lactate 
dehydrogenase (LDH), a stable cytosolic enzyme that is released upon cell lysis. Released LDH in 
culture supernatants is measured with a coupled enzymatic assay, which results in the conversion 
of tetrazolium salt in a red formazan product. The amount of colour formed is proportional to the 
number of lysed cells. In brief, adherent cells (live cells) were lysed. 50 µL of reconstituted 
substrate mix were added to both 50 µL of live and dead cell lysates and incubated for 30 min. The 
reaction was stopped with 50 µL of stop solution and absorbance was read at 490 nm using a 
microplate reader (SpectraMax M5, Molecular Devices). 
4.2.6 HIF-1α activity assay  
To determine whether Co2+-containing BGs were able to stabilise HIF-1α, SaOs2 cells were 
seeded (5x104 cells/cm2) in T25 flasks and cultured until they were approximately 90% confluent. 
Cells were then incubated for 8 h with BG-conditioned media. The TransAMTM HIF-1 assay kit 
(Active Motif®) was used to assess HIF-1α activity according to the manufacturer’s instructions. 
Briefly, nuclear extracts were prepared and 10 µg of protein were added to a 96-well plate pre-
coated with HIF-1α specific oligonucleotides. A primary antibody specific for the bound and active 
form of the transcription factor was then added to the plate, followed by subsequent incubation with 
secondary antibody conjugated to horseradish peroxidase and a substrate solution. The 
absorbance was measured using a microplate reader (SpectraMax M5, Molecular Devices) at a 
wavelength of 450 nm and using a reference wavelength of 655 nm. 
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4.2.7 Analysis of VEGF expression 
The cell-culture medium collected from the well plates at specific time points was used to assess 
VEGF A165 production by ELISA (enzyme-linked immunosorbent assay) (Quantikine: Human VEGF 
immunoassay, R&D Systems®). In short, cell-culture supernatant samples or standards together 
with assay diluent were added to the provided 96-well plate (pre-coated with a monoclonal 
antibody specific for VEGF A165). Any VEGF A165 present was bound by the immobilized antibody. 
After washing away any unbound substances, an enzyme-linked polyclonal antibody specific for 
VEGF A165 was added to the wells. Following a wash step to remove any unbound antibody-
enzyme reagent, a substrate solution was added to the wells and colour developed in proportion to 
the amount of VEGF A165 bound in the initial step. Colour development was then stopped and the 
intensity of the colour was measured in a microplate reader (SpectraMax M5, Molecular Devices) 
at 450 nm with a reference wavelength of 540 nm. 
4.2.8 Statistical analysis 
All experimental data shown are expressed as mean±SD and were obtained from experiments 
performed twice and in sets of at least four. All data analysis was performed in Excel. Statistical 
analysis was by one-way analysis of variance (ANOVA) using multiple comparisons (Bonferroni 
test) and p values of less than 0.05 were considered significant. Statistical analysis was performed 
using SPSS® (from IBM®). 
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4.3 RESULTS AND DISCUSSION 
The previous chapter describes the incorporation of Co2+ ions in BGs plus the effect of these ions 
on the glass properties. The BGs produced were shown to release Co2+ within a biologically active 
concentration range. In other words, Co2+ concentrations, shown to activate the hypoxia pathway 
in studies using CoCl2 solutions
167,309, were achieved by dissolution of the hypoxia-mimicking BGs. 
Nevertheless, the biological activity of the BG produced should still be studied. The effect of Co2+-
containing BGs on cell viability as well as on the hypoxia response requires assessment. The 
SaOs2 cell line, an osteosarcoma cell line, was chosen since it is an osteoblast cell line previously 
shown to up-regulate VEGF expression through HIF-1α stabilisation, both under hypoxic conditions 
and with CoCl2 
167 and it is commonly used in our laboratory. 
This chapter is divided into three main sections. Initially, the effect of CoCl2 concentration on cell 
viability and activation of the hypoxia pathway was assessed. Secondly, a similar study was 
performed but focussing on how cell viability is affected by BG concentration of BG-conditioned 
media. Finally, the effect of the BGs produced and described in the previous chapter on SaOs2 
cells’ viability and activation of the hypoxia pathway was investigated. 
4.3.1 Determining the effect of CoCl2 on SaOs2 cells  
As previously discussed, cobalt has been shown to activate the hypoxia pathway through the 
stabilisation of the HIF-1α factor181-183. In most studies, it has been used in the form of CoCl2 
solutions167,188,204,206. To confirm the effect of Co2+ in SaOs2 cells, these were treated with various 
concentrations of CoCl2 (0, 25, 50, 100 and 200 µM) up to 2 days before total DNA, MTT activity, 
hypoxia inducible factor-1α (HIF-1α) activity and vascular endothelial growth factor (VEGF) 
expression were measured. 
Total DNA assay is commonly used to assess cell number or cell viability, while MTT assay is used 
to evaluate proliferation. The various CoCl2 concentrations tested in the present study did not 
significantly affect SaOs2 cells viability, as total DNA content did not significantly change with 
CoCl2 concentration over the time period assessed (Fig. 4.2). MTT assay, however, shows a 
significant decrease in proliferation after 2 days when cells were treated with 200 µM CoCl2 media 
(Fig. 4.3). The decrease as early as 2 days clearly demonstrates the toxicity of high CoCl2 
concentrations, even over short periods of time. Toxicity of high CoCl2 concentrations has been 
previously described204-206 and the toxicity threshold has been shown to vary between cell types. 
Depending on the cell type, CoCl2 concentrations as low as 100μM have been shown to decrease 
cell viability204-206. Studies in osteoblast cells have been performed in various different cell lines 
including SaOs2, U2OS, MC3T3-E1 and MG-63 cells167,207,294. The CoCl2 concentrations that 
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reduced SaOs2 cell viability in our study are within the range of CoCl2 concentrations reported to 
be toxic to osteoblasts207 and other cell types204,205 in the literature (≥100μM). 
 
Fig. 4.2 Effect of CoCl2 on SaOs2 cell viability: Total DNA assay. DNA concentration was measured using 
Hoescht reagent after SaOs2 cells were incubated for 1 or 2 days with RPMI containing different CoCl2 
concentrations (0; 25; 50; 100 and 200 μM). (*) indicates the difference between the marked bar and the 
control (cells cultured with standard cell culture media, 0 μM CoCl2) for the same time period is statistically 
significant (p<0.05). 
 
Fig. 4.3 Effect of CoCl2 on SaOs2 cell proliferation: MTT assay. MTT assay was performed after SaOs2 cells 
were incubated with RPMI containing different CoCl2 concentrations (0; 25; 50; 100 and 200 μM) for 1 or 2 
days. (*) indicates the difference between the marked bar and the control (cells cultured with standard cell-
culture media, 0 μM CoCl2) for the same time period is statistically significant (p<0.05). 
HIF-1α is the transcription factor responsible for the activation of the hypoxia pathway1. VEGF is a 
growth factor involved in angiogenesis and it has been previously shown to be over-expressed in 
hypoxia, via HIF-1α1. Consequently, comparison of the levels of HIF-1α activity and VEGF 
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expression between the different conditions (different CoCl2 concentrations tested) must clearly 
demonstrate the effect of CoCl2 on the hypoxia pathway and the subsequent cellular response. 
SaOs2 cells were treated with RPMI containing increasing concentrations of CoCl2 (0; 75; 150; 300 
and 600 μM) for 8 h and an immunoassay was used to then assess HIF-1α activity (Fig. 4.4). 
Increasing CoCl2 concentrations significantly enhanced HIF-1α activity in a concentration-
dependent manner, with up to a seven-fold increase in activity. Only the highest CoCl2 
concentration tested did not follow the trend observed and that is most probably due to the toxic 
effects of CoCl2 discussed before. VEGF expression was also evaluated using an immunoassay 
after treating the cells with a series of CoCl2 concentrations for 1 or 2 days. As well as HIF-1α 
activity, VEGF expression was enhanced with exposure to CoCl2 in a concentration-dependent 
manner (Fig. 4.5). Both the absolute VEGF levels (Fig. 4.5 A) and the VEGF expression, 
normalised to total DNA content (Fig. 4.5 B), were significantly increased over those of the 
standard culture media (0 µM CoCl2). 
 
Fig. 4.4 Effect of CoCl2 on the hypoxia pathway: HIF-1α activity. HIF-1α activity was determined using an 
immunoassay after SaOs2 cells were incubated with RPMI containing different CoCl2 concentrations (0; 75; 
150; 300 and 600 μM) for 8h. (*) indicates the difference between the marked bar and the control (cells 
cultured with standard cell-culture media, 0 μM CoCl2) for the same time period is statistically significant 
(p<0.05). 
Chapter 4. Preliminary Assessment of Biological Activity of Bioactive Glasses with SaOs2 Cells 
 
Hypoxia-mimicking bioactive materials for skeletal tissue engineering 
 
100 
 
Fig. 4.5 Effect of CoCl2 on the hypoxia response: VEGF expression. VEGF concentration was determined 
using a VEGF immunoassay after incubating SaOs2 cells with RPMI containing different CoCl2 
concentrations (0; 25; 50; 100 and 200 μM) for 1 or 2 days (A). VEGF concentration was also normalised to 
DNA concentration and the normalised results are presented in (B). (*) indicates the difference between the 
marked bar and the control (cells cultured with standard cell culture media, 0 μM CoCl2) for the same time 
period is statistically significant (p<0.05). 
The enhanced HIF-1α activity clearly confirms activation of the hypoxia pathway in SaOs2 cells by 
exposure to CoCl2. Enhancement of HIF-1α activity by exposure to CoCl2 has been extensively 
documented in the literature in various cell types and tissues, as was described in Chapter 2. That 
is also the case for SaOs2 cells. A study by Kim et al. has shown HIF-1α stabilisation and 
accumulation with exposure of SaOs2 cells to CoCl2, as early as 2 h after exposure, as well as 
increased VEGF expression after 6 h167. In the same study, the involvement of reactive oxygen 
species (ROS) in the regulation of HIF-1 by CoCl2 is suggested. N-acetylcysteine (NAC), a ROS 
scavenger, was shown to block HIF-1α protein stabilisation, activation of HREs and VEGF gene 
expression167.  
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Enhanced HIF-1α activity, as well as increased VEGF expression, confirms the activation of the 
hypoxia pathway and subsequent response in SaOs2 cells by exposure to CoCl2. High CoCl2 
concentrations, however, were shown to be toxic for SaOs2 cells. This study then suggests CoCl2 
should be used within a 50 to 100 µM concentration range to activate the HIF-1 pathway and 
subsequent cellular responses on SaOs2 cells without reducing their cell viability. 
Several studies have suggested that the mechanisms for hypoxia-induced and CoCl2-induced HIF-
1α stabilisation are distinct from each other167,181. For example, the use of ROS scavengers was 
shown to have no effect on hypoxia-induced HIF-1α response, however, this was not observed 
with CoCl2-induced HIF-1α response
167. Moreover, a separate study has shown different cellular 
responses to exposure of endothelial cells to hypoxia and CoCl2, although HIF-1α protein levels 
were increased in both conditions181. In this study, human endothelial cells were exposed to 0% 
and 3% O2, as well as various CoCl2 concentrations (10 - 700 μM). Independently of the treatment, 
HIF-1α activity was enhanced. However, exposure of these cells to even low CoCl2 concentrations 
(as low as 10 μM) was shown to inhibit in vitro-angiogenesis, while hypoxia was shown to promote 
it. For this reason, an extensive study of the CoCl2-induced responses is necessary. 
4.3.2 Determining the effect of BG concentration on SaOs2 cells  
BG dissolution not only releases Co2+ ions but also the other BG constituents (Si, Ca, Na, P) to the 
conditioned media. The amount of ions released, especially Co2+ and Si4+, might significantly affect 
cell viability. The following study was performed in order to define a BG concentration range that 
would maintain cell viability while releasing a sufficient amount of Co2+ to activate the hypoxia 
pathway. 
A series of BG-conditioned media was prepared with increasing concentrations of BG. 0.75; 1.5; 3 
and 9 mg of BG were added per mL of RPMI before incubating the media in a roller, for 4 h at 37 
°C. For the experiments described in this section, an older batch of 0% and 2% Co2+ BG was used. 
Their composition is the composition described on Table 4.1 for 0Co and NonCB2Co BGs, 
respectively. However, these glasses were stored for over a year in slightly different conditions, 
which might have affected their release profiles due to the formation of a hydroxyapatite layer on 
the BG surface. Despite the fact that the differences in the BG release profiles could explain small 
differences between the results obtained with these and the newer glasses, the BG from the older 
batch was considered suitable for testing the effect of BG concentration on SaOs2 cell viability. 
After filtration, the conditioned media prepared was used to treat SaOs2 cells for up to 8 days. As 
in the previous section, the effect of BG concentration on cell viability and proliferation was 
evaluated using total DNA and MTT assays. Cell viability was clearly affected by exposure of cells 
to Co2+-containing BG-conditioned media (Fig. 4.6). After 4 days in culture, total DNA content was 
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significantly decreased from that of the standard culture media (control), independent of the BG 
concentration used. The BG with 0% Co2+, however, did not affect cell viability when at low 
concentration (Fig. 4.6). Only the highest BG concentration tested (9 mg/mL) significantly 
decreased cell viability. The MTT assay results clearly confirmed the effect observed in the total 
DNA assay. The presence of Co2+ in the conditioned media, especially with high BG 
concentrations, significantly decreases cell proliferation (Fig. 4.7). If 0.75 or 1.5 mg/mL of BG were 
used to prepare the conditioned media, SaOs2 proliferation rate only decreased after 8 days in 
culture. However, if 3 mg/mL of BG was used, the Co2+ negative effect on cells’ metabolic activity 
was observed after 2 days of exposure. Although BG with 0% Co2+ did not show such a strong 
effect, if SaOs2 cells were exposed to 9 mg/mL BG-conditioned media (with or without Co2+), their 
proliferation rate was reduced to nearly zero (Fig. 4.7). This result clearly demonstrates BG toxicity 
when used at high concentrations. The toxic effect observed may be due to a significant increase 
in pH value or to the high Si4+ concentration (Table 4.2). BG toxicity could also be caused by 
formation of submicron particles during BG degradation. Recently, cellular uptake of BG submicron 
particles has been confirmed. These particles seem to localise on the cytoskeleton and 
significantly decrease cell viability at high concentrations263. The in vitro results however cannot be 
directly translated to in vivo conditions without further consideration. Indeed in the body BG toxicity 
might be significantly decreased due to flow of the body fluids, which will significantly reduce pH 
variations and ions concentrations. Several in vivo studies have been performed with BG and 
toxicity was never considered an issue310-312. 
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Fig. 4.6 Effect of BG concentration on SaOs2 cell viability: Total DNA assay. DNA concentration was 
measured using Hoescht reagent after SaOs2 cells were treated with conditioned media prepared using 
different concentrations of 0% and 2% Co
2+
-containing BGs (0Co and NonCB2Co, respectively; 0.75; 1.5; 3; 
9 mg of BG per mL of RPMI) for 1, 2, 4 and 8 days. (*) indicates the difference between the marked bar and 
the control (cells cultured with standard cell-culture media, with no BG) for the same time period is 
statistically significant (p<0.05). 
 
Fig. 4.7 Effect of BG concentration on SaOs2 cell proliferation: MTT assay. MTT assay was performed after 
SaOs2 cells were treated with conditioned media prepared using different concentrations of 0% and 2% 
Co
2+
-containing BGs (0Co and NonCB2Co, respectively; 0.75; 1.5; 3; 9 mg of BG per mL of RPMI) for 1, 2, 4 
and 8 days. (*) indicates the difference between the marked bar and the control (cells cultured with standard 
cell culture media, with no BG) for the same time period is statistically significant (p<0.05). 
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VEGF expression was used as an indicator of the activation of the hypoxia pathway, as it has been 
previously shown to be over-expressed under hypoxia, via HIF-1α1,128,130. Exposure of SaOs2 cells 
to conditioned media prepared with 9 mg/mL BG reduces VEGF expression to zero (Fig. 4.8), 
which is due simply to BG toxicity and consequent cell death. Conditioned media prepared with low 
0% Co2+ BG concentrations have no significant effect on VEGF production (Fig. 4.8). If total VEGF 
concentration is considered (Fig. 4.8 A), Co2+ addition to the BG seems to decrease VEGF 
production after 8 days in culture. However, if VEGF production is normalised to total DNA content 
(Fig. 4.8 B), Co2+ addition to BG significantly enhances VEGF expression at low BG concentrations 
(0.75 and 1.5 mg/mL). After the analysis of the results just described, 1.5 mg/mL was the BG 
concentration chosen for the preparation of BG-conditioned media used in the following 
experiments. This concentration was shown to maintain cell viability and proliferation rate of 
SaOs2 cells while still releasing sufficient Co2+ to activate the hypoxia pathway. The BG 
concentration chosen to prepare BG-conditioned media for the future studies is similar to 
concentrations used in studies previously published271. 
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Fig. 4.8 Effect of BG concentration on SaOs2 cell hypoxia response: VEGF expression. VEGF concentration 
was determined using a VEGF immunoassay after SaOs2 cells were treated with conditioned media 
prepared using different concentrations of 0% and 2% Co
2+
-containing BGs (0Co and NonCB2Co, 
respectively; 0.75; 1.5; 3; 9 mg of BG per mL of RPMI) for 1, 2, 4 and 8 days (A). VEGF concentration was 
also normalised to DNA concentration and the normalised results are presented in (B). (*) indicates the 
difference between the marked bar and the control (cells cultured with standard cell culture media, with no 
BG) for the same time period is statistically significant (p<0.05). 
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4.3.3 Determining the effect of Co2+-containing BGs on SaOs2 cells 
The effect of Co2+ BG on cell viability and the hypoxia pathway should still be evaluated although 
the amount of Co2+ released from the BG was within the biologically active Co2+ concentration 
range described in studies performed with CoCl2 (Table 4.2). In this section, conditioned media 
were prepared using the BGs characterised in the previous chapter (see Table 4.1) before treating 
SaOs2 cells. The effect of BG dissolution ions was then assessed. 
4.3.3.1 Cell viability and BG cytotoxicity 
Total DNA content was measured to evaluate cell viability as SaOs2 cells were cultured with the 
different BG-conditioned media, as well as evaluating the potential toxicity caused by Co2+ BG 
dissolution products. During the first 2 days in culture, DNA concentrations did not alter 
significantly with the different BG-conditioned media, which indicates no loss of cell viability during 
this culture period (Fig. 4.9). However, after 4 and 7 days, cells incubated with the BG dissolution 
products of the NonCB4Co BG showed a considerable decrease in DNA concentration (Fig. 4.9) 
and cell death was observed (Fig. 4.10). Cell viability seemed to decrease with addition of Co2+ 
BG-conditioned media (Fig. 4.10 H); small vesicles are formed on the cell surface and cell debris is 
observed when SaOs2 cells are incubated with the dissolution products of the NonCB4Co BG for 7 
days. Although in our study this has not been confirmed, in the literature, CoCl2-induced cell death 
has been reported to occur via apoptosis. Co2+ ion-induced toxicity has been extensively studied in 
various tissues and cell types, including macrophages, hepatocytes, fibroblats, neuronal and glial 
cells as well as leukemic cell lines204,205,313-315. In all cases cell death was shown to be induced via 
apoptosis204,205,314,315. DNA fragmentation and depletion, as well as chromatin condensation and 
activation of apoptotic proteins (caspases), have been observed after exposure of these different 
cell types to CoCl2 (at concentrations ≥ 100µM)
205,315. Mitochondria seem to be the main target of 
CoCl2 toxicity
315. Release of mitochondrial apoptotic factors and loss of mitochondrial membrane 
potential have been previously reported315. Formation of reactive oxygen species (ROS) has been 
suggested as the main mechanism of CoCl2-induced apoptosis, as accumulation of hydroperoxyl 
radical and superoxide have been reported205,315,316. However, the use of antioxidants did not 
always protect cells from the Co2+ effects. Chromatin condensation and ATP loss were not 
prevented by antioxidants after exposure of mouse astrocytes, human macrophages or mouse 
embryonic fibroblasts to Co2+ ions315. This clearly indicates ROS formation is not the only Co2+-
induced apoptosis mechanism and that the mechanism may differ between cell types. Other 
processes vital for cell viability, as Ca2+ signalling, have also been altered by exposure to CoCl2 
and could be inducing programmed cell death as well315. 
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Fig. 4.9 Effect of hypoxia-mimicking BG on SaOs2 cell viability: Total DNA assay. DNA concentration was 
measured using Hoescht reagent after SaOs2 cells were treated with BG-conditioned media (1.5 mg/mL) for 
2, 4 and 7 days. A solution of 200 μM CoCl2 in RPMI was used as a positive control. (*) indicates the 
difference between the marked bar and the control (cells cultured with standard cell culture media, with no 
BG) for the same time period is statistically significant. (¥) indicates that the difference between the marked 
bar and the sample treated with the dissolution products of 0Co BG for the same time period is statistically 
significant (p<0.05). 
Total DNA results suggest a synergistic trend with the addition of Zn2+ ions to the glass. Cells 
treated with the conditioned media of BG containing 2 and 4% Zn2+ (NonCB2CoMgZn and 
NonCB2Co4Zn, respectively) showed an increase in DNA concentration over that of the cells 
incubated with the dissolution products of the BG containing 4% Mg2+ and no Zn2+ 
(NonCB2Co4Mg) (Fig. 4.9). The mechanism behind this effect is not completely understood but 
the trend observed could be due to higher proliferation rates in the presence of zinc. Zinc has been 
previously reported to promote osteoblast proliferation279. The proliferation rate of MC3T3-E1 cells 
was shown to increase after exposure to Zn2+-doped β-tricalcium phosphate (0.6 – 1.2 wt%) in 
comparison to β-tricalcium phosphate with no Zn2+ ions. This effect, however, was concentration-
dependent, the highest Zn2+ concentrations were shown to be toxic279. Zinc toxicity has also been 
reported by other authors, which showed that Zn2+-containing 45S5 BG significantly enhanced 
LDH release in MG-63 cells if Zn2+ concentration in the media exceeded 2 ppm. In our study, Zn2+ 
concentration in RPMI was determined and shown to be approximately 0.33 ppm (Table 4.2), 
which is still considerably lower than the Zn2+ concentrations reported as toxic. The increase in 
DNA content observed in our study after exposure of SaOs2 cells to the Zn2+-containing BG-
conditioned media is probably due to enhanced proliferation. 
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Fig. 4.10 Images of SaOs2 cells treated with BG-conditioned media for 2 (A, C, E, G) and 7 days (B, D, F, 
H). A and B were treated with standard cell-culture media; C and D were treated with the dissolution 
products of 0Co BG; E and F were treated with dissolution products of NonCB0.5Co BG; and G and H were 
treated with dissolution products of NonCB4Co BG. These images were taken using an optical microscope; 
scale bars correspond to 250 μm and 500 μm, in images A, C, E, G and H and in images B, D and F, 
respectively. 
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Hypoxia significantly affects cell metabolism. Under aerobic conditions, pyruvate, the product of 
glycolysis, is oxidised to CO2 and H2O, through mitochondrial oxidative phosphorylation. However, 
when O2 concentration in tissues is insufficient, pyruvate is reduced to lactate instead, by lactate 
dehydrogenase (LDH) in the cytosol317. This change in metabolism is known to be regulated by 
HIF-180,83. To assess the effect of Co2+-containing BG on SaOs2 metabolism, an LDH activity 
assay was performed (Fig. 4.11 A) and the results were normalised to total DNA content (Fig. 4.11 
B). At days 4 and 7, LDH activity was clearly enhanced by the Co2+-containing BGs, which 
suggests the primary energy source of SaOs2 cells changes as they are exposed to hypoxia-
mimicking ions. Exposure of the cells to the NonCB4Co BG-conditioned media, however, 
significantly decreases LDH activity. This decrease is evident from day 4 onwards, but is simply 
due to Co2+ toxicity and not to metabolism alterations. As Fig. 4.11 B clearly demonstrates, if LDH 
activity is normalised to total DNA content, the decrease with NonCB4Co BG-conditioned media is 
no longer observed. Increased LDH A levels under hypoxia have been previously reported188. A 
proteomic analysis of human leukemic cells (U937 cells) subjected to 2% O2 for 24 h showed a 
two-fold increase in the expression of LDH A protein188. The same study, however, showed 
decreased LDH B levels under exposure to 50 µM of CoCl2, which suggests that Co
2+ ions do not 
mimic hypoxia effect on cell metabolism. The LDH activity assay performed in our study does not 
permit a distinction between the two LDH isoforms. In addition, the cell lines used in the two 
studies are different. For these reasons the two studies are not comparable. The study presented 
here, however, strongly suggests Co2+ BGs mimic the hypoxia effect on SaOs2 metabolism and 
enhance reduction of the glycolysis product, pyruvate, to lactate, by lactate dehydrogenase. The 
effect might not be as large as one would expect since O2 supply was not decreased in our study, 
as the experiments were performed under normoxic conditions. Under exposure to hypoxia-
mimicking BGs, SaOs2 cells could possibly be using both the oxidative phosphorylation and the 
lactate dehydrogenase pathways as energy sources. 
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Fig. 4.11 Effect of hypoxia-mimicking BG on SaOs2 cell metabolism: LDH activity assay. LDH assay was 
performed on the lysates of SaOs2 cells treated with BG-conditioned media (1.5 mg/mL) for 2, 4 and 7 days. 
(A) Absolute LDH values; (B) LDH normalised to total DNA assay. (*) indicates the difference between the 
marked bar and the control (cells cultured with standard cell-culture media, with no BG) for the same time 
period is statistically significant. (¥) indicates that the difference between the marked bar and the sample 
treated with the dissolution products of 0Co BG for the same time period is statistically significant (p<0.05). 
4.3.3.2 Activation of the hypoxia pathway 
To understand the effects of Co2+-containing BG on the hypoxia pathway and subsequent 
response, HIF-1α activity and VEGF expression (a potent angiogenic factor, known to be up-
regulated in hypoxic conditions through the hypoxia pathway) were evaluated by ELISA. 
HIF-1α activity was evaluated using a commercially available immunoassay. The 1.5 to four-fold 
enhancement in HIF-1α activity with exposure to the hypoxia-mimicking BG was evident and 
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shown to be concentration dependent (Fig. 4.12). Even the BG with the lowest Co2+ content 
(NonCB 0.5Co BG) was able to increase HIF-1α stabilisation. The effect observed appears to be 
only due to Co2+ ions, since SaOs2 cells treated with 0Co BG-conditioned media present HIF-1α 
activity levels similar to the control (no BG). Moreover, HIF-1α activity enhancement can be 
correlated to Co2+ concentration in the media. Similar Co2+ concentrations in the media cause a 
similar effect, independent of the Co2+ source (CoCl2 or Co
2+ BG), which suggests the other BG 
ions do not have any effect on HIF-1α stabilisation and activity. Co2+ concentration also explains 
the higher HIF-1α activity of SaOs2 cells treated with 200 µM CoCl2 when compared to the 
NonCB4Co BG-conditioned media, as Co2+ concentration is around 14 ppm and 9 ppm, 
respectively (Table 4.2). 
 
Fig. 4.12 Effect of hypoxia-mimicking BG on SaOs2 hypoxia pathway: HIF-1α activity. HIF-1α activity was 
determined using an immunoassay after SaOs2 cells were treated with BG-conditioned media for 8 h. (*) 
indicates the difference between the marked bar and the control (cells cultured with standard cell culture 
media, with no BG) for the same time period is statistically significant. (¥) indicates that the difference 
between the marked bar and the sample treated with the dissolution products of 0Co BG for the same time 
period is statistically significant (p<0.05). 
VEGF expression was measured using a commercially available VEGF immunoassay and the 
absolute results demonstrated that VEGF production was increased in the presence of Co2+-
containing BG after 2, 4 and 7 days in culture (Fig. 4.13 A). Furthermore, a concentration-
dependent increase in the expression of this angiogenic factor is observed if results are normalised 
to DNA concentration, illustrative of cell number (Fig. 4.13 B). The enhancement observed in 
VEGF levels in the presence of Co2+ BG-conditioned media is particularly significant after days 2 
and 4. The increase observed in VEGF is within the range of values noted in the literature. 
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Activation of HIF-1α in osteoblasts (SaOs2 and U2OS – another human osteosarcoma cell line) 
has been previously shown using CoCl2 at 25 to 125 μM and VEGF up-regulation was evaluated 
using real time-PCR and an increase of 1.2 to four-fold in VEGF mRNA levels was observed167. 
Since VEGF is an angiogenic factor that is known to be overexpressed under hypoxic conditions, 
via HIF-1α1,130, the results mentioned suggest that the BG dissolution products activate the hypoxia 
response. Moreover, enhancement of VEGF expression under exposure to CoCl2 has been shown 
to occur via the HIF-1α pathway167. 
After the 7 day culture period, total VEGF expression decreased if cells were treated with the 
NonCB4Co BG, which may reflect the decreased cell numbers. Continuously adding Co2+ may 
cause its accumulation within the cells, which will then inhibit proliferation and induce cell death. It 
may then be possible for the cells incubated with the NonCB4Co BG dissolution products to 
maintain VEGF expression if Co2+ addition to the cell-culture media is reduced after 3-4 days. In 
this case cell death could possibly be avoided and VEGF expression levels could be maintained. 
Normalised VEGF expression decreases with time in culture. This effect is most probably due to 
cell confluency being reached, which affects cell function. 
Contrary to what Day et al. have shown318 258-260,262, in our experiments BG alone was shown to 
have no effect on VEGF expression (Fig. 4.13). The 45S5 Bioglass® has been to shown to 
stimulate VEGF and bFGF production at both mRNA and protein levels318 as well as suggested to 
promote angiogenesis in vivo319. However, we did not observe any effect on VEGF levels after 
treatment with the 0Co BG-conditioned media. No significant differences between these samples 
and the control were detected at any time period analysed (Fig. 4.13). This lack of effect may be 
due to the slightly different compositions of the 45S5 Bioglass® and the 0Co BG. It can also be 
because, in our experiments, only BG-conditioned media was used instead of BG monoliths, and 
both topography and surface properties are known to alter cell behaviour. Moreover, in Day’s 
studies only fibroblasts and endothelial cells were used, hence their conclusions should not be 
translated to osteoblast cells. 
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Fig. 4.13 Effect of hypoxia-mimicking BG on SaOs2 hypoxia response: VEGF expression. VEGF 
concentration was determined using a VEGF immunoassay after SaOs2 cells were treated with BG-
conditioned media for 2, 4 and 7 days (A). VEGF concentration was then normalised to DNA concentration 
and the normalized results are represented in (B). (*) indicates the difference between the marked bar and 
the control (cells cultured with standard cell culture media, with no BG) for the same time period is 
statistically significant. (¥) indicates that the difference between the marked bar and the sample treated with 
the dissolution products of 0Co BG for the same time period is statistically significant (p<0.05). 
Zn2+ has been previously reported to decrease HIF-1 activity due to suppression of translocation of 
either HIF-1α to the nucleus320. In astrocytes, nuclear migration of hypoxia-sensing transcription 
factors HIF-1α was inhibited by exposure to 0.5 µM of ZnSO4 under hypoxic conditions
320. In 
addition, the use of a zinc-specific chelator enhanced HIF-1α activity and the expression of its 
target genes in a neuroblastoma and a hepatocyte cell lines179. Although a new spliced variant of 
HIF-1α that is induced by zinc has been identified321, that requires significantly higher 
concentrations (500 µM) to the Zn2+ concentration in the BG-conditioned media used in our study 
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(0.33 ppm, equivalent to 5 µM). Our results then were in agreement with these observations since 
a decrease in HIF-1α activity and VEGF levels after treatment with Zn2+-containing BG-conditioned 
media was observed when compared to the other 2% Co2+ BGs (Fig. 4.12 and Fig. 4.13). No effect 
of Mg2+ ions on HIF-1α activity has been previously reported but an increase in VEGF A165 (one of 
the VEGF isoforms) expression in the presence of Mg2+ has been observed322. The Mg2+-
containing BG we have produced, however, did not show any significant effect in HIF-1α activity or 
VEGF expression. This result might be due to the Mg2+ concentration range, which may be 
insufficient to activate a cellular response.  
As mentioned in a previous section, some studies have reported differences between hypoxia- and 
Co2+-induced effects. A decrease in the expression of heme oxygenase-1 in endothelial cells 
caused by hypoxia was shown, whereas Co2+ induced an increase323. A comparative study on the 
gene expression in hypoxia and Co2+-exposed embryonic mouse fibroblasts was also performed 
and the authors found out that only a minor number of the regulated genes after hypoxia and Co2+-
exposure overlapped324. In addition, proteomic analysis of U937 cells exposed to either 2% O2 or 
50 μM CoCl2 showed protein expression is also different under the two sets of conditions
188. 
Moreover, the addition of a ROS scavenger was shown to block the CoCl2-induced hypoxia 
response, but not the hypoxia-induced response167. These discrepancies led Wenger et al. to the 
conclusion that Co2+ interacts with different steps along the oxygen-signalling pathway or that it 
affects additional pathways that cross-talk with the oxygen pathway325. More recently, another 
group showed both hypoxia and Co2+ can promote HIF-1α accumulation in endothelial cells 
(HDMEC), but Co2+ did not stimulate the angiogenic response in vitro, whereas hypoxia did181. 
Some authors, however, have shown increased angiogenesis after CoCl2 treatment. An increase in 
the number of new blood vessels has been observed with the addition of CoCl2 in both rat bladder 
in vivo and rat prostate tumour cells in vitro268,296. Moreover, a study performed in our group has 
shown formation of tubule-like structures using the dissolution products of the NonCB1Co BG to 
culture endothelial cells. The dissolution products of the NonCB2Co BG and the 100 μM CoCl2 
solution did not show the same effect, besides showing higher VEGF production. This difference 
suggests that the hypoxia response is extremely sensitive to Co2+ concentration. 
The results discussed above show evidence that Co2+-containing BG increased HIF-1α activity and 
expression of VEGF. As Co2+ has been shown to induce VEGF expression through the hypoxia 
pathway it is now established the Co2+ BGs produced are capable of activating the hypoxia 
pathway and subsequent cellular responses. It is also clear there is a need to define the ideal 
temporal and relevant concentration ranges for the application of the hypoxia-mimicking BG, so 
that the amount of Co2+ is sufficient to activate the hypoxia response without inducing cell death. 
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4.4 CONCLUSION 
The present chapter describes the initial cell studies performed with the hypoxia-mimicking BG 
developed. These studies are intended to assess the effect of CoCl2 and Co
2+-containing BGs on 
cell viability and the hypoxia pathway in SaOs2 cells. The SaOs2 cell line was chosen since it is an 
osteoblastic cell line commonly used in our laboratory that has been previously been shown to up-
regulate VEGF expression, through HIF-1α stabilisation, under hypoxic conditions and with 
CoCl2
167. 
Firstly, different CoCl2 concentrations were tested to assess the effect of Co
2+ concentration on cell 
viability as well as its effect on the hypoxia pathway of the osteoblastic cell line. In agreement with 
the literature, high CoCl2 concentrations (200 µM) were shown to be toxic. More importantly, the 
hypoxia pathway was shown to be activated by CoCl2 in a concentration-dependent manner. 
Higher CoCl2 concentrations induced higher HIF-1α activity levels and enhanced VEGF 
expression. However, our study suggests that, in order to maintain cell viability while activating the 
hypoxia pathway, CoCl2 should be used within the 50 – 100 µM concentration range for SaOs2 
cells. 
Secondly, BG-conditioned media containing increasing BG concentrations were tested to define an 
optimum BG concentration to use in the subsequent studies. BGs containing 0% and 2% Co2+ 
(0Co and NonCB2Co, respectively) were chosen for this initial study. The highest BG 
concentration tested (9 mg/mL) was shown to be toxic at time periods as short as 24 h, even in the 
absence of Co2+. As expected, the presence of Co2+ in the BG was shown to increase BG toxicity. 
BG-conditioned media prepared using 3 mg/mL of 2% Co2+ BG still decreased SaOs2 cell viability. 
Therefore, a concentration of 1.5 mg of BG per mL of media was chosen as optimum in the later 
studies, as this concentration was able to maintain cell viability within a seven day period as well 
as suggested to release enough Co2+ to activate the hypoxia pathway in SaOs2 cells. 
Finally, the biological activity of the BGs produced and characterised in Chapter 3 was assessed. 
Controlled release of ions within a biologically active concentration range was proven to be 
essential to maintain cell viability. BG-conditioned media with the highest Co2+ content 
(NonCB4Co) was shown to be toxic as early as 2 days in culture. Lactate dehydrogenase activity 
was also shown to be enhanced in the presence of hypoxia-mimicking BGs, which suggests that 
Co2+ ions enhance anaerobic metabolism in SaOs2 cells. Enhancement of HIF-1α activity and 
VEGF expression clearly demonstrated the activation of the hypoxia pathway and the posterior 
cellular responses by the Co2+-containing BG. Moreover, the activation of the hypoxia response by 
Co2+-containing BGs was shown to be concentration-dependent. In the conditions studied here, the 
NonCB2Co BG seems to be the best, since activation of the HIF-1 pathway and subsequent 
cellular responses was achieved using its BG-conditioned media and SaOs2 cell viability was 
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maintained. BGs with higher Co2+ content (NonCB4Co BG) caused cell death and BGs with lower 
Co2+ content (NonCB0.5Co and NonCB1Co BGs) showed only a residual enhancement of HIF-1 
activity. More importantly, the results presented here strongly suggest the potential of these 
hypoxia-mimicking materials in tissue engineering applications. 
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5.1 INTRODUCTION 
The clinical use of mesenchymal stromal cells (MSCs) for regenerative applications has been 
under heated discussion in the last decade326-328. Mesenchymal stromal cells were initially isolated 
from the bone marrow, selected by adherence to plastic329-331. These cells were then shown to be 
able to differentiate into a variety of mesenchymal lineages in vitro, including osteogenic, 
chondrogenic and adipogenic332-337. Since then, multipotent cells have been isolated from many 
different tissues, such as peripheral blood, fat, umbilical cord tissue and blood, amniotic fluid, 
placenta, dental pulps, synovial membrane, skeletal muscle, kidney, pancreas, brain and liver 
(reviewed in 326,327). Although the biological equivalence of these cell populations has still to be 
proven, they all share the ability to differentiate into various lineages in vitro while maintaining their 
genetic stability and a high proliferative capacity. In vitro, MSCs have been shown to differentiate 
into multiple cell types, including tissues that embryologically derive from the three different germ 
layers; ectoderm, mesoderm and endoderm. Some examples of cell types that have been derived 
from MSC cells are endothelial cells, cardiomyocytes, hepatocytes and neural cells326,327,334. This 
chapter, however, will focus on bone marrow-derived MSCs. From now on MSCs refers to bone-
derived mesenchymal stromal cells. 
There is great variability within what are considered to be MSCs, even within the same population 
(reviewed in 326,327,338). Their molecular and cellular definition has been particularly controversial. 
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For clinical purposes, however, a precise molecular definition of MSCs is essential. For this 
reason, the International Society for Cellular Therapy has recently announced the criteria that 
should define the bone marrow-derived mesenchymal stromal cells339. Therefore, in order to be 
used in the clinic, these cells should express a panel of cell-surface markers, including CD73, 
CD90 and CD105, and lack endothelial or haematopoietic cell markers, such as CD45, CD34, 
CD14, CD19 and HLA-DR, in addition to adhering to plastic and presenting multilineage 
differentiation potential339.  
The use of MSCs to promote tissue regeneration has been extensively studied (reviewed in 326-
328,340). Over time, extensive characterisation of these cells has shown that they present 
characteristics that suggest MSCs are a “natural in vivo system for tissue repair”327 and hinting at 
their great potential for use in regenerative therapies. Several lines of research have provided 
evidence that supports MSCs’ plasticity and their ability to differentiate into multiple cell types 
(reviewed in 326-328). Moreover, MSCs have been shown to be recruited to sites of injury (reviewed 
in 327), both naturally in the body as well as after systemic administration. Another of the most 
remarkable aspects of MSCs is their immunomodulatory activity. These cells have been shown to 
inhibit T-cell recognition, as well as B-cell proliferation, dendritic-cell differentiation and natural 
killer cells’ cytolytic potential, through inhibition of Tumour Necrosis Factor-α (TNF-α) and 
Interferon-γ (INF-γ) production (reviewed in 326-328). MSCs express intermediate levels of MHC 
class I proteins and no MHC class II proteins, which makes them non-immunogenic cells (reviewed 
in 326-328). Their immunomodulatory ability is critically important as it facilitates the transplantation 
process and negates the need for immunosuppressive medication. However, it is important to 
remember that most knowledge of MSCs is based on in vitro studies and little is known about 
these cells in vivo. 
MSCs were initially used for regenerative purposes due to their differentiation potential. These 
progenitor cells were loaded in scaffolds that were then implanted into the body either immediately 
after adhesion or, a few weeks later, after in vitro differentiation (reviewed in 327,328,340). Successful 
bone and cartilage defect repair, as well as skin-wound healing, have been achieved (reviewed in 
327). In addition, scaffold-free approaches have also been tested. MSCs have been implanted 
locally into bone and cartilage defects, as well as into skin wounds and ischemic hearts, and they 
successfully repaired those tissues in humans341-344. Functional gain was also observed in rat 
brains after direct implantation of hMSCs327,345 and injured meniscus, tendonitis and spinal-cord 
interruption have also been successfully treated with MSC implantation (reviewed in328). Systemic 
administration of MSCs has also been shown to be extremely promising. Glucose levels were 
lowered in diabetic mice and repair of damaged kidneys and brain was facilitated by systemically 
injecting MSCs (reviewed in 327). Furthermore, various studies suggest that MSC systemic 
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implantation shows great potential for the treatment of osteogenesis imperfecta in paediatric 
patients, as well as for myocardial infarction, haematological malignancies and Crohn’s and graft-
versus-host diseases (reviewed 326,327). Interestingly, homing to the site of injury was observed, 
although in very low number in some cases. Recently, however, it has been reported that the 
therapeutic efficacy of MSCs does not directly correlate with the efficiency of their engraftment346. 
This fact suggests that the ability of these multipotent cells to repair injuries does not rely on their 
differentiation potential into appropriate cell phenotypes. Instead, the regenerative potential of 
MSCs could be attributed to their ability to secrete specific proteins and factors that actively modify 
the tissue environment. The production by MSCs of various factors that influence several biological 
processes essential for regeneration, such as angiogenesis347, neurogenesis and inflammation 
(reviewed in 327,328), has been extensively described since. MSCs were shown to inhibit fibrosis and 
apoptosis, as well as stimulate mitosis of tissue-intrinsic progenitor cells, in all cases through 
secretion of specific effector proteins (reviewed in 328). Therefore, MSCs are now known to exhibit 
autocrine and paracrine activity, known as “trophic activity”, as defined by Caplan328. This is 
thought to be their greatest contribution in tissue regeneration. 
The number of MSCs in the bone marrow is, however, extremely low and it significantly decreases 
with aging328. A newborn has 1 MSC per 10,000 marrow cells approximately; while a teenager and 
a 50 year old have 1/100,000 and 1/400,000, respectively, and an 80 year old has on average 
1/2,000,000 MSCs per marrow cells328. The use of these cells for regenerative purposes thus 
requires ex vivo expansion. Nonetheless, the maintenance of MSC self-renewal and therapeutic 
potential, as well as their multipotency, throughout the ex vivo expansion is essential. 
Molecular oxygen has been shown to be a regulator of stem-cell behaviour79,348. At the common 
pO2 value in vitro (21%), MSCs were shown to have a limited growth potential; they stop 
proliferating after a few passages, due to cellular senescence165. The physiological pO2 value in 
bone marrow has been shown to vary between 1 and 7%. Marrow sinuses are well-oxygenated 
regions, while the endosteal region is the more hypoxic349. In the case of the haematopoietic cells, 
the most primitive progenitors are in the most hypoxic region of the bone marrow, and expansion 
and differentiation increase towards the higher pO2 values
350,351. For this reason, the effect of pO2 
on ex vivo expansion of MSCs has been extensively studied and characterised. As MSCs were 
expanded under hypoxia (1-3 % pO2), their life-span was extended and senescence avoided
165,352. 
In addition, a low pO2 value has been shown to maintain MSCs in an undifferentiated state
165,352-354 
as well as increase population homogeneity355. Interestingly, hypoxia demonstrably stimulates 
angiogenic properties of MSCs. Migration of these multipotent cells in vitro, as well as tropism to 
sites of injury in vivo, has been described169,356,357. In addition, matrix metalloproteinase (MMP) 
activity and tubule-formation ability were enhanced as MSCs were cultured in vitro at pO2 values of 
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lower than 3%168,169,358,359. Hypoxia has been shown to enhance activity of the hypoxia-sensing 
transcription factor, HIF-1α, in MSCs185,309,353,357,359,360 and HIF-1α activity  induces expression of 
pro-angiogenic factors such as VEGF, HGF and bFGF168,169,184,185,352,358-361. All the processes 
described above are induced by hypoxia via protein secretion, through a paracrine effect. In most 
cases, HIF-1α has been shown to be an essential factor and a sequential contributor. 
In this chapter, the effect of hypoxia-mimicking bioactive glasses (BGs) on human mesenchymal 
stromal cells will be discussed. Human MSCs (hMSCs) were treated with the Co2+-containing BG-
conditioned media and cell viability and proliferation, as well as activation of the hypoxia pathway 
and subsequent responses, were assessed.  
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5.2  MATERIALS AND METHODS 
5.2.1 Cell culture 
Human mesenchymal stromal cells (hMSCs) were purchased from Cambrex Corporation. These 
cells were then expanded in low glucose Dulbecco’s Modified Eagle Medium (DMEM, GIBCO®) 
with 10% (v/v) foetal bovine serum (FBS, GIBCO®) and 50 U/ml penicillin and 50 μg/ml 
streptomycin (GIBCO®). Initial culture was performed in 75-cm2 flasks at 37 ºC in a humidified 
atmosphere of 95% air with 5% CO2 and the cells were supplied with fresh medium every 2-3 
days. At 90% confluence, cells were detached using trypsin-EDTA (GIBCO®), and cell count was 
determined with a haemocytometer. Cells were resuspended to the appropriate concentration for 
seeding in complete medium. 
For the experiments described in this chapter, only cells in passage 5-8 were used. Human MSC 
cells were seeded in tissue-culture-treated well plates and treated for different time periods with 
BG-conditioned media (DMEM, GIBCO®). CoCl2-containing media was used as a positive control. 
Cell-culture medium was replaced every 2-3 days (Fig. 5.1). 
 
Fig. 5.1 Schematic representation of the procedure followed in this study. Dissolution products of the 
different BGs in cell-culture media (DMEM, GIBCO
®
) were prepared. The BG-conditioned media were then 
used to treat hMSC cells and after different incubation periods, samples were collected to assess cell 
viability and activation of the hypoxia response.  
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5.2.2 Preparation of BG-conditioned media 
BG-conditioned media were prepared as described in the previous chapter. BG particles (<38 µm) 
were incubated in DMEM (GIBCO®) at a concentration of 1.5 mg/mL, with continuous rolling, for 4 
h at 37 °C, prior to filtration (0.2-µm pore filters). To stabilise pH, conditioned media were 
incubated (37oC, 5% CO2) in a vented flask for 2 h prior to use. Only the BGs from the non-charge-
balanced (NonCB) series indicated in Table 5.1 were used for this study. The concentration of the 
ions released from the BG to the conditioned media was determined by ICP-OES (Table. 5.1). 
Table 5.1. Concentration of the different ions (Si, Ca, Na, P, Co) in BG-conditioned DMEM (in ppm) 
determined by ICP-OES. The Co concentrations presented in the shadowed column were converted to µM. 
The values presented here are the average ± standard deviation of all batches used for the experiments 
presented in this chapter. 
 Si Ca Na P Co Co (µM) 
DMEM 0.0 ± 0.2 81.3 ± 6.6 2920 ± 420 39.1 ± 3.0 0.03 ± 0.05 0.51 ± 0.85 
0Co 73.7 ± 13.0 95.7 ± 27.2 3047 ± 508 15.1 ± 7.0 0.02 ± 0.03 0.33 ± 0.51 
NonCB0.5Co 69.3 ± 6.6 103.5 ± 14.7 2916 ± 413 19.2 ± 7.6 2.18 ± 0.40 36.97 ± 6.78 
NonCB1Co 76.8 ± 12.9 106.1 ± 17.1 2996 ± 487 16.0 ± 7.6 5.35 ± 0.89 90.74 ± 15.09 
NonCB2Co 76.9 ± 18.1 110.3 ± 18.3 2993 ± 489 16.8 ± 9.7 10.55 ± 2.06 178.93 ± 34.94 
NonCB4Co 80.6 ± 17.6 109.8 ± 17.2 2995 ± 523 16.5 ± 7.4 22.97 ± 2.06 389.57 ± 34.94 
CoCl2 100 µM 0.0 ± 0.9 81.5 ± 8.3 2928 ± 475 38.7 ± 4.0 6.61 ± 0.62 112.11 ± 10.52 
5.2.3 AlamarBlue® assay 
The alamarBlue® assay (InvitrogenTM) is commonly used as a cell-viability indicator. It uses the 
natural reducing power of living cells to convert resazurin to the fluorescent molecule resorufin. 
Resazurin, the alamarBlue® active ingredient, is blue and nonfluorescent. Once inside the cells, it 
is reduced to resorufin, which produces red fluorescence. Viable cells continuously convert 
resazurin into resorufin, so it is possible to use fluorescence as a quantitative indicator of cell 
viability. The amount of fluorescence produced is proportional to the number of living cells. The 
alamarBlue® assay was performed as indicated by the manufacturer. Briefly, hMSCs were seeded 
in 96-well plates (5*103 cells/cm2) and treated with BG-conditioned media. At specific time points 
(1, 2, 4 and 7 days), cell-culture media were removed from the well plates and the wells were 
washed with 100 µL of PBS. 150 µL of 10% (v/v) alamarBlue® in DMEM with no phenol red 
(GIBCO®) was added per well (including one with no cells to be used as blank) and the well plates 
were incubated for 2 h at 37 ºC. 100 µL of the reaction product was then transferred to a black 96-
well plate and fluorescence was measured at an excitation wavelength of 540 nm and an emission 
wavelength of 585 nm using a microplate reader (SpectraMax M5, Molecular Devices). 
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5.2.4 MTT assay 
MTT assay was performed as described in the previous chapter. Briefly, hMSCs were seeded in 
96-well plates at a seeding density of 5*103 cells/cm2 and treated with the BG-conditioned DMEM. 
MTT salt solution (Thiazolyl Blue Tetrazolium bromide, M2128, Sigma®) (5 mg/mL) was added to 
cell culture 4 h prior to the end of the experiment. After removal of cell-culture media, 200 µL of 
DMSO was added to solubilise the formazan crystals. Absorbance was measured using a 
microplate reader (SpectraMax M5, Molecular Devices) at a wavelength of 570 nm with a 
reference wavelength of 620 nm.  
5.2.5 BrdU assay 
The measurement of BrdU (5-bromo-2’-deoxyuridine) incorporation in newly synthesised DNA 
precisely evaluates cell proliferation. The cell proliferation ELISA (Roche) used in this study allows 
accurate quantification of BrdU incorporation. The assay was performed according to the 
manufacturer’s instructions. Briefly, hMSCs were seeded in 96-well plates (5*103 cells/cm2). After 
adhesion, cells were starved with 1% (v/v) FBS media for 24 h, to synchronise them on the same 
phase of the cell cycle. The hMSC cells were then cultured in the presence of the BG-conditioned 
DMEM. At specific time periods (1, 2, 3 and 4 days), 20 μL of BrdU-labelling solution was added 
per well and the cells were incubated for 24 h. During the labelling period, BrdU is incorporated in 
place of thymidine into the DNA of proliferating cells. After 24 h, the cell-culture medium was 
removed and the cells were fixed. The anti-BrdU antibody was then added to the wells and the 
immune complexes detected by the subsequent substrate reaction. The reaction was quantified by 
measuring absorbance at 450 nm with a reference wavelength of 690 nm in a microplate reader 
(SpectraMax M5, Molecular Devices). 
5.2.6 LDH assay 
The colorimetric LDH assay (CytoTox 96® Non-Radioactive Cytotoxicity Assay, Promega) was 
performed as described in the previous chapter, to assess the effect of Co2+ BG on hMSCs 
metabolism. In brief, hMSCs were seeded in 96-well plates at a seeding density of 5*104 cells/cm2. 
These cells were then treated with BG-conditioned media for 2, 4 and 7 days before adherent cells 
were lysed. 50 µL of reconstituted substrate mix was added to 50 µL of the cell lysates and 
incubated for 30 min. The reaction was stopped with 50 µL of stop solution and absorbance read at 
490 nm using a microplate reader (SpectraMax M5, Molecular Devices).  
5.2.7 HIF-1α activity assay  
The TransAMTM HIF-1 assay kit (Active Motif®) was used to assess HIF-1α activity as described in 
the previous chapter. Human MSCs were seeded (5x104 cells/cm2) in 25-cm2 flasks and were 
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cultured until they were approximately 90% confluent. Cells were then incubated for 8 h in BG-
conditioned media and the assay was performed according to the manufacturer’s instructions. 
Briefly, 8 µg of nuclear extracts was prepared and added to a 96-well plate pre-coated with HRE 
(hypoxia responsive elements) specific oligonucleotides. A primary antibody specific for the bound 
and active form of the transcription factor was then added, followed by incubation with secondary 
antibody conjugated to horseradish peroxidase and a substrate solution. Absorbance was 
measured using a microplate reader (SpectraMax M5, Molecular Devices) at a wavelength of 450 
nm and a reference wavelength of 655 nm. 
5.2.8 Analysis of VEGF expression 
A VEGF A165 ELISA kit (Quantikine: Human VEGF immunoassay, R&D Systems
®) was performed 
as described in the previous chapter to assess VEGF A165 production by ELISA. In short, cell 
culture supernatant samples or standards together with assay diluent were added to the provided 
96-well plate (pre-coated with a monoclonal antibody specific for VEGF A165). VEGF A165 present 
was bound by the immobilised antibody. An enzyme-linked polyclonal antibody specific to VEGF 
was then added to the wells and a substrate solution was added to the wells. Colour developed in 
proportion to the amount of VEGF A165 bound in the initial step and its development was then 
stopped using the Stop solution provided by the kit. The colour intensity was measured in a 
microplate reader (SpectraMax M5, Molecular Devices) at 450 nm with a reference wavelength of 
540 nm. 
5.2.9 Assessment of collagen production 
The SircolTM assay was used to monitor the effect of Co2+ BG on collagen production by hMSC 
cells. This is a dye-binding method that allows quantification of acid and pepsin-soluble collagens 
in in vitro cell culture. The Sircol dye binds to the [Gly-x-y]n helical structure found in collagen and 
the intensity of colour of the reaction product is proportional to the amount of collagen in the 
sample analysed. The assay was performed according to the manufacturer instructions. In brief, 
cell-culture supernatants were collected and collagen was concentrated and precipitated according 
to manufacturer’s instructions. Collagen dye was added to the concentrated collagen solution and 
incubated for 30 min. During this period the collagen-dye complex formed and precipitated out of 
the unbound dye. The precipitate was then washed and an alkaline reagent was added to dissolve 
it. Absorbance was measured in a microplate reader (SpectraMax M5, Molecular Devices) at a 
wavelength of 555 nm. Total collagen was calculated using a standard curve prepared with 0-50 
µg of collagen. 
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5.2.10 Statistical analysis 
All experimental data shown are expressed as mean±SD and were obtained from experiments 
performed at least twice and in quadruplicate. All data analysis was performed in Excel. Statistical 
analysis was by one-way analysis of variance (ANOVA) using multiple comparisons (Bonferroni 
test) and p values of less than 0.05 were considered significant. Statistical analysis was performed 
using SPSS.  
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5.3  RESULTS AND DISCUSSION 
O2 availability has been shown to be essential for the regulation of embryonic development and 
stem-cell biology (reviewed in 79). Its role in controlling other progenitor cells function is also 
extremely important 362. Hypoxia has been shown to direct mesenchymal stromal cell behaviour in 
various different cellular processes. Low pO2 values significantly affect MSC metabolism, 
proliferation and life-span ex vivo (reviewed in 362). In addition, the pO2 value also controls MSC 
differentiation (reviewed in 362). The effect of Co2+ ions on MSCs has not been extensively studied. 
Although Co2+ has been shown to activate the hypoxia pathway184,185, its effect on the biology of 
MSCs requires further assessment. In this chapter the effect of the hypoxia-mimicking BG on MSC 
proliferation, metabolism and activation of the hypoxia pathway will be discussed. 
5.3.1 Determining the effect of the hypoxia-mimicking BG on hMSC viability and 
proliferation 
The effect of hypoxia on MSC proliferation is rather controversial in the literature. Similarly, the 
effect of hypoxia-mimicking ion, Co2+, has not been clearly defined. Some BG compositions, 
however, have been shown to enhance osteoblast proliferation271,363. For this reason, it is hard to 
predict how the Co2+-containing BGs will affect MSC growth. AlamarBlue® and MTT assays were 
used to assess MSC viability and proliferation with exposure to the hypoxia-mimicking BGs 
described in the previous chapters (Fig. 5.2 and Fig. 5.3, respectively). Both assays measure 
enzymatic activity; alamarBlue® assay assesses the cytoplasmic reduction potential of 
metabolically active cells and MTT measures the mitochondrial activity of the cells. The 
alamarBlue® results (Fig. 5.2) showed no significant difference in cell viability of the MSCs treated 
with the BG-conditioned and control media up to day 4. At day 7, however, the presence of Co2+ 
ions on the BG significantly increased cell number in a concentration-dependent manner. The BG 
with the highest Co2+ concentration, however, cancelled the hypoxia-mimicking BG effect. Cell 
metabolic activity was very similar to the control when MSCs were exposed to the NonCB4Co BG-
conditioned media. The CoCl2 control showed a similar effect to the NonCB1Co and NonCB2Co 
BGs, which could be explained by the Co2+ concentrations in the conditioned media being very 
similar in these three different conditions. 
At early time points, the MTT results (Fig. 5.3) showed a similar trend to the AlamarBlue® results. 
At days 1 and 2, MTT signal was significantly enhanced when hMSCs were exposed to the 
dissolution products of the hypoxia-mimicking BGs. At later time-points, however, the increase of 
cell viability by Co2+-containing BG was no longer observed. In fact, in some cases, cell viability 
decreased in comparison to the control. After 7 days in culture, cell activity significantly increased 
when hMSCs were exposed to the 0Co BG-conditioned media while, when hMSCs were treated 
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with the Co2+-containing BGs, cell number remained similar to that of the control. The NonCB4Co 
BG significantly arrested cell viability from day 1; cell activity was decreased to half of the control at 
day 1 and it did not increase up to day 7. Toxicity has been previously observed with high Co2+ 
concentrations and is most probably due to the formation of reactive oxygen species (ROS)205. As 
for the alamarBlue® results, the hMSCs treated with the CoCl2 control showed a similar behaviour 
to the NonCB1Co and NonCB2Co BGs treated cells. The similar Co2+ concentrations in the three 
different conditioned media explain this fact.  
Although the two assays present slightly different trends, some unambiguous conclusions can be 
drawn. The highest Co2+ concentration BG (NonCB4Co) is undoubtedly toxic. To maintain cell 
viability under exposure to the hypoxia-mimicking BGs, Co2+ levels should be precisely controlled. 
On the other hand, the 0Co BG was never shown to decrease cell viability or proliferation, which 
indicates that BG with no Co2+ does not have a negative effect on the growth of hMSCs. The 
differences in data obtained with the two assays can be explained by the fact that the assays 
assess different processes in the cell. While the alamarBlue® assay measures the reduction 
potential of the cells, the MTT assay evaluates the activity of mitochondrial enzymes. Hypoxia and 
hypoxia-mimicking ions can affect these processes in different ways, which would then explain the 
differences observed in the results. 
 
Fig. 5.2 Effect of hypoxia-mimicking BGs on hMSC viability: alamarBlue
®
 assay. The alamarBlue
®
 assay was 
performed after hMSCs were treated with BG-conditioned media (1.5 mg/ml) for 1, 2, 4 and 7 days. (*) 
indicates the difference between the marked bar and the control (cells cultured with standard cell-culture 
media, with no BG) for the same time period is statistically significant. (¥) indicates that the difference 
between the marked bar and the sample treated with the dissolution products of 0Co BG for the same time 
period is statistically significant (p<0.05). 
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Fig. 5.3 Effect of hypoxia-mimicking BGs on hMSC viability: MTT assay. The MTT assay was performed 
after hMSCs were treated with BG-conditioned media (1.5mg/ml) for 1, 2, 4 and 7 days. (*) indicates the 
difference between the marked bar and the control (cells cultured with standard cell-culture media, with no 
BG) for the same time period is statistically significant. (¥) indicates that the difference between the marked 
bar and the sample treated with the dissolution products of 0Co BG for the same time period is statistically 
significant (p<0.05). 
The incorporation of 5-bromo-2’-deoxyuridine (BrdU) into newly synthesised DNA allows precise 
assessment of the effect of the hypoxia-mimicking BGs on cell proliferation. The synthetic 
nucleoside is incorporated into the DNA of replicating cells during DNA synthesis and its 
quantification permits accurate determination of proliferation rates. A commercially available BrdU 
quantification kit was used to study how hMSC proliferation is affected by exposure to Co2+-
containing BG and the results are presented in Fig. 5.4. A similar trend to that described above 
was observed at all time points assessed. BG alone (0Co BG) significantly enhanced the hMSC 
proliferation. The presence of Co2+ in the BG, however, seemed to cancel the BG effect in a 
concentration-dependent manner. The enhancement of the proliferation rate decreased with 
increasing Co2+ addition to the BGs. Once again, the NonCB4Co BG-conditioned media was 
shown to significantly decrease cell proliferation, which corroborates the toxic effect of high Co2+ 
concentrations. Also, cells treated with the CoCl2-conditioned media behaved similarly to those 
treated with the NonCB1Co and NonCB2Co BGs, which can be explained by the similar Co2+ 
concentrations in the conditioned media. 
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Fig. 5.4 Effect of hypoxia-mimicking BGs on hMSC proliferation: BrdU assay. The BrdU assay was 
performed after hMSCs were treated with BG conditioned media (1.5 mg/ml) for 1, 2, 3 and 4 days. (*) 
indicates the difference between the marked bar and the control (cells cultured with standard cell culture 
media, with no BG) of the same time period is statistically significant. (¥) indicates that the difference 
between the marked bar and the sample treated with the dissolution products of 0Co BG of the same time 
period is statistically significant. (p<0.05) 
The literature is controversial about the way in which hypoxia affects hMSC viability and 
proliferation. There are reports of no significant effect of hypoxia on hMSC survival361, but other 
authors show growth arrest after relatively short time periods353 and others even show increased 
proliferation184. This controversy is probably due to heterogeneity in the experimental designs. 
Different hypoxia levels (from 1 - 8% O2) have been used, as have cells from different species, 
different cell-culture media, and different incubation periods and methods to assess MSC viability 
and proliferation. Recent papers, however, tend to agree that hypoxia increases MSCs life-span ex 
vivo 165,352,354. In vitro survival and expansion levels have been shown to increase under hypoxic 
conditions184,357,364. In addition, genes involved in proliferation and cell survival have also been 
shown to be up-regulated under hypoxia359. Low pO2 values decrease in vitro cell death
354 and 
significantly increase colony forming units352. Plus, the number of doublings was also increased 
under hypoxia165,352,354. Jin et al. have recently suggested the enhanced life-span is due to 
decreased senescence, via p16 down-regulation under hypoxia165. Besides, the tissue-repair 
capabilities of MSCs have been enhanced after in vivo implantation, if MSCs were previously 
expanded under low pO2
365. 
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In the bone marrow, O2 pressure is known to vary between 1 and 7% 
349. In vitro, 21% pO2 is a 
hyperoxic environment for MSCs. The high pO2 value could therefore be one of the causes of cell 
death or decreased MSC life-span ex vivo. High pO2 increases ROS production which causes DNA 
damage and consequent cell death205. The expansion of MSCs under pO2 values similar to the 
physiological levels in bone marrow would thus explain the enhanced MSCs proliferation and life-
span under hypoxia. 
Due to the low numbers of MSCs present in the adult body, the enhancement of expansion and 
life-span ex vivo is essential for the use of MSCs in TE or regenerative therapies. Hypoxia seems 
to have an essential role since, in addition to enhancing expansion; it has also been shown to 
increase culture homogeneity355, another vital aspect for successful regenerative applications. The 
most primitive haematopoietic progenitor cells localise within the most hypoxic regions, while 
expansion and proliferation increases towards the higher pO2 regions
350,351. This variability in 
behaviour in regions of the bone marrow with different pO2 values could explain the different 
cellular responses observed in vitro at different pO2 levels. 
There are only a few studies on the effect of the hypoxia-mimicking ion, Co2+, on MSC viability and 
proliferation184,185. In those studies, proliferation was shown to decrease with exposure to 100 μM 
of CoCl2. The authors, however, considered that this result was not due to toxicity but simply to 
growth arrest as expression of p21 and PC3 mRNA (anti-proliferative proteins) is enhanced and 
cyclin D1 is reduced185. Moreover, the effect is probably dependent on the hypoxia levels as MSCs 
at very low pO2 levels (1%) have been shown to accumulate on the G1 phase
353 and, when these 
cells were incubated at higher pO2 levels (8%), proliferation was enhanced. The results presented 
above corroborate these findings. The presence of Co2+ in the BG significantly decreases 
proliferation in a concentration-dependent manner, as the BrdU incorporation assay shows. With 
the exception of the NonCB4Co BG, the reduced proliferation is probably due to growth arrest and 
not to toxicity, as suggested by Pacary et al.185. 
The effect of BG alone (0Co BG) on hMSC proliferation can not be ignored. The 0Co BG-
conditioned media significantly enhanced hMSC proliferation (Fig. 5.4); with proliferation doubling 
on days 3 and 4. These data clearly indicate that one of the ions released from the BG stimulates 
cell growth. Previous studies with similar BG compositions have already shown enhanced 
proliferation of different cell types either using dissolution ions or BG discs or coatings271,363, but 
this effect is not consistent throughout the literature. Some other studies showed no effect of BG 
on proliferation254,263,366. The proliferation enhancement, however, could be attributed to Si4+ ions. 
Increased concentrations of silicon ions (released from a silicate cement) have been shown to 
enhance osteoblast (MG63) proliferation progressively with culture time367.  
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5.3.2 Determining the effect of hypoxia-mimicking BG on the activation of the 
hypoxia pathway 
The HIF-1α pathway is the main regulator of the cells’ response to hypoxia1. This pathway has 
previously been shown to be activated in hMSCs exposed to low pO2 levels
184,185,353,357,359 and to be 
essential for most of the subsequent cellular responses185,309,352. To evaluate the effect of hypoxia-
mimicking BG on the hypoxia pathway and subsequent responses, HIF-1α activity and VEGF 
expression (up-regulated in hypoxic conditions through the hypoxia pathway309,368) were evaluated 
by ELISA. 
HIF-1α activity was significantly enhanced in a concentration-dependent manner when hMSCs 
were incubated with the hypoxia-mimicking BG-conditioned media (Fig. 5.5). The NonCB0.5Co BG 
doubles HIF-1α activity and NonCB2Co BG quadruplicates it when compared to the levels seen in 
the control. The enhancement of HIF-1α activity after exposure of hMSCs to NonCB4Co BG-
conditioned media is lower than when the same cells are treated with NonCB1Co and NonCB2Co 
BG-conditioned media. The reduction of HIF-1α activity is therefore probably due to Co2+ toxicity at 
high concentrations.  
Accumulation of HIF-1α in the cytoplasm, as well as increased expression, has been previously 
reported after hMSCs were exposed to low pO2 levels
184,352,353,359,360. In addition, exposure of 
hMSCs to hypoxia-mimicking ions has also been studied and Co2+ ions have been shown to 
increase HIF-1α levels in a similar manner184,185. The hypoxia-mimicking BGs were able to 
reproduce these results. CoCl2-conditioned media, however, did not cause an effect as strong as 
the BG-conditioned media. Even with a similar Co2+ concentration in the media (Table 5.1), the 
HIF-1α activity was not enhanced to the same extent as for the NonCB1Co and NonCB2Co BGs. 
There was probably a synergistic effect of Co2+ and another BG ion that could explain this 
difference.  
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Fig. 5.5 Effect of hypoxia-mimicking BGs on the hypoxia pathway: HIF-1α activity. The HIF-1α activity was 
determined using an immunoassay after hMSCs were treated with BG-conditioned media (1.5 mg/ml) for 8 h. 
(*) indicates the difference between the marked bar and the control (cells cultured with standard cell-culture 
media, with no BG) for the same time period is statistically significant. (¥) indicates that the difference 
between the marked bar and the sample treated with the dissolution products of 0Co BG for the same time 
period is statistically significant (p<0.05). 
VEGF expression was evaluated after hMSCs were treated with the BG-conditioned media for 2, 4 
and 7 days (Fig. 5.6). At every time point assessed, VEGF expression was significantly enhanced 
when cells were incubated with the hypoxia-mimicking BG-conditioned media. Interestingly, the 
effect observed was concentration-dependent. Although the trend was maintained, VEGF levels 
decreased with time; this was probably due to confluency of the cells which is known to alter 
cellular behaviour. 
VEGF expression was assessed as an example of the activation of the hypoxia responses, as it is 
well established that VEGF is a HIF-1α-regulated gene368, and this data strongly suggests that 
exposure of hMSCs to the hypoxia-mimicking BGs activates the hypoxia pathway and subsequent 
response. In the literature, VEGF up-regulation in hMSCs due to hypoxia exposure has been 
extensively described. The up-regulation of this growth factor has been shown at both mRNA and 
protein levels at various time-periods, under a series of different pO2 values and in various 
species168,184,352,358-360. Although Co2+ ions are not always able to activate all cellular responses to 
hypoxia181, VEGF expression has been shown to be up-regulated by exposure to Co2+ in a similar 
way184,185. These data is in agreement with the literature; the Co2+-containing BGs were able to 
enhance VEGF expression by hMSCs in a concentration-dependent manner. 
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Fig. 5.6 Effect of hypoxia-mimicking BGs on the hypoxia response: VEGF expression. The VEGF 
concentration was determined using a VEGF immunoassay after hMSCs were treated with BG-conditioned 
media (1.5 mg/ml) for 2, 4 and 7 days. (*) indicates the difference between the marked bar and the control 
(cells cultured with standard cell-culture media, with no BG) for the same time period is statistically 
significant. (¥) indicates that the difference between the marked bar and the sample treated with the 
dissolution products of 0Co BG for the same time period is statistically significant (p<0.05). 
More than an indicator of activation of the hypoxia pathway, VEGF is also extremely important in a 
series of processes essential for tissue regeneration. One of the processes where VEGF is known 
to be essential is the formation of new blood vessels, or angiogenesis369. In addition, a study by 
Kanczler et al. showed enhanced bone regeneration after implantation of encapsulated VEGF 
biodegradable poly(DL-lactic acid) scaffolds with MSCs in mouse femur defects for 4 weeks370. 
Bone volume was enhanced and trabecular separation was reduced. In addition, formation of new 
bone matrix, and specifically, expression of Collagen type I were also enhanced in the presence of 
the angiogenic growth factor370. Moreover, a separate study used VEGF-releasing scaffolds coated 
with bioactive glass and significant enhancement of blood vessel density was observed as early as 
2 weeks and, after 12 weeks, the density of mineral bone was also significantly enhanced in the 
VEGF-releasing scaffolds371. 
VEGF is unlikely to be the only growth factor that is up-regulated in hMSCs exposed to the 
hypoxia-mimicking BGs. Expression of many other growth factors known to be up-regulated by 
HIF-1α under hypoxia, including bFGF, HGF, TNF-α, IL-1 and IL-6352,359,362, might also be up-
regulated by the Co2+-containing BGs. However, it is not only the secretion of soluble growth 
factors that is enhanced at low pO2 values. Increased expression of several membrane receptors 
Chapter 5. Assessment of Biological Activity of Hypoxia-Mimicking Bioactive Glasses in Human MSCs 
 
Hypoxia-mimicking bioactive materials for skeletal tissue engineering 
 
134 
involved in MSCs migration and homing to damaged sites, including CXCR4 and CXCR7, has also 
been reported in hypoxic conditions357 and CoCl2 showed a similar effect
357. Several mechanisms 
critical for tissue regeneration, including angiogenesis, migration and immunomodulatory activity, 
could then be enhanced under exposure to Co2+-containing BGs, through the MSCs’ “trophic 
activity” (paracrine activity). 
Moreover, hypoxia has been previously shown to control and direct progenitor cells stemness and 
differentiation, via regulation of expression of key factors such as Oct4 by HIF-1α372. This is also 
the case for MSCs (reviewed in362). Plasticity and differentiation potential of these progenitor cells 
have been shown to be reduced at low pO2 values in most cases
352-354,356,361; only the 
chondrogenic differentiation potential was shown to be enhanced with hypoxia (reviewed in362). 
These findings are probably related to the fact that the most primitive HSCs are found in the most 
hypoxic regions of the bone marrow350,351. The hypoxia-mimicking BGs could then help maintain 
MSCs in an undifferentiated state or keep their stemness, which is essential for ex vivo expansion 
before implanting MSCs for regenerative therapies or promote MSC differentiation into the 
chondrocytic lineage. Bioactive glasses have, however, been shown to stimulate osteogenic 
differentiation250,373. It would be interesting to study the combinatorial effect of the hypoxia-
mimicking BGs on the differentiation potential of hMSCs.  
Finally, pre-conditioning of hMSCs under hypoxia has been shown to enhance hMSCs survival to 
an in vivo hypoxic environment, for example after implantation in cardiac tissue after myocardial 
infarction374,375. The hypoxia-mimicking BGs might then activate several critical cellular processes 
in the hMSCs that may enhance tissue regeneration. 
5.3.3 Determining the effect of the hypoxia-mimicking BG on hMSC metabolism 
Under hypoxia, cells alter their metabolism through activation of the hypoxia pathway. Reduction of 
pyruvate to lactate by lactate dehydrogenase (LDH) becomes their main energy source317. LDH 
expression and activity are then enhanced at low pO2 values
122,188, but reduced in HIF1a-/- cells, 
even under hypoxia103. To assess the effect of the hypoxia-mimicking BGs on hMSCs’ metabolism, 
LDH activity was measured at days 2, 4 and 7 (Fig. 5.7). At every time point evaluated, LDH 
activity (normalised to total DNA) was increased with the presence of the hypoxia-mimicking BGs 
in a concentration-dependent manner; with time, the difference between samples even increased. 
These data clearly indicate that there is a switch in metabolism as hMSCs are exposed to the 
hypoxia-mimicking BG-conditioned media. Once more, the NonCB4Co BG does not follow the 
trend. LDH activity significantly decreased as hMSCs were treated with the dissolution products of 
the BG with the highest Co2+ concentration. The reduction observed is due to Co2+ toxicity, when 
the ion is present at high concentrations. LDH activity of the cells treated with the CoCl2-
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conditioned media was similar to that of cells treated with the NonCB1Co and NonCB2Co BG-
conditioned media, which is explained by the approximate Co2+ concentrations in conditioned 
media (Table 5.1).  
 
Fig. 5.7 Effect of hypoxia-mimicking BGs on hMSC metabolism: LDH assay. The LDH assay was performed 
after hMSC cells were treated with BG-conditioned media (1.5 mg/ml) for 2, 4 and 7 days. (*) indicates the 
difference between the marked bar and the control (cells cultured with standard cell-culture media, with no 
BG) for the same time period is statistically significant. (¥) indicates that the difference between the marked 
bar and the sample treated with the dissolution products of 0Co BG for the same time period is statistically 
significant (p<0.05). 
5.3.4 Determining the effect of hypoxia-mimicking BG on collagen synthesis 
Proper formation of the extracellular matrix (ECM) is critical, not only during development, but also 
for correct regeneration of damaged tissues376-379. ECM has been shown to present essential clues 
for organ formation and to direct cell differentiation, but, in some tissues (e.g., cartilage), it is also 
crucial for cell survival, through specific cell-matrix interactions380. Furthermore, the achievement of 
the necessary mechanical and physical properties during tissue development and regeneration is 
strongly dependent on the correct ECM formation and composition26,381. 
Oxygen regulates ECM production in various tissues and it has been shown to be critical for 
correct ECM formation and renewal during development and in adults79,379,382. Low pO2 values 
have been shown to up-regulate expression of proteoglycans and other ECM proteins in cartilage, 
via SOX9 up-regulation159,383-387. Additionally, in fibroblasts, expression of procollagen X is also 
enhanced under hypoxia376. Hypoxia-induced effects are mainly regulated by the hypoxia pathway, 
by activation of either HIF-1α or HIF-2α379,387. 
As far as collagen production is concerned, hypoxia has been shown to enhance protein 
synthesis376, but in most cases it mainly regulates collagen post-translational modifications376,379. 
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The regulation mechanisms are thought to be tissue-specific. However, the most extensively 
described hypoxia control mechanism is the regulation of the activity of prolyl-4-hydroxylases I and 
II (P4Ha I and P4Ha II), which are enzymes critical for the formation of the collagen triple 
helices379.  
Prolyl hydroxylases are a family of enzymes responsible for the addition of prolyl groups 
(hydroxylation) to proline residues. Enzymes belonging to this family are involved in the 
maintenance of O2 homeostasis, but also in the formation of the collagen triple helices
116,382,388. 
The prolyl hydroxylases involved in the regulation of cellular response to pO2 (HIF-PHDs) are 
PDH1, PHD2 and PHD3116. These proteins are localised either in the cytoplasm, nucleus or 
membrane of the endoplasmic reticulum116. On the other hand, the prolyl hydroxylases involved in 
collagen triple helix formation are prolyl-4-hydroxylases (P4Ha) and are in the lumen of the 
endoplasmic reticulum. P4Ha I and P4Ha II are the enzymes that catalyse the formation of the 4-
hydroxyprolines essential for the collagen triple helices formation379. All prolyl hydroxylases require 
Fe2+, 2-oxoglutarate, ascorbate and O2 as co-factors
114,389. However, these enzymes are substrate-
specific which, in addition to their cellular localisation, guarantees there is no interference from a 
member of the family on the function of another prolyl hydroxylase379. This family of enzymes is 
considered to be a good pharmacological target for collagen-synthesis-associated disorders. The 
efficacy of such approaches has been demonstrated for various applications, both in animal 
models, as well as in clinical trials with prolyl hydroxylase inhibitors (reviewed in388). 
Under hypoxia, HIF-PHDs are inactivated due to low pO2 (one of the enzyme co-factors). HIF-1α 
hydroxylation does not occur and its degradation is prevented. So HIF-1α accumulates in the 
cytoplasm and later activates the hypoxia pathway and subsequent responses1. Collagen-P4Ha, 
however, maintains its activity with minimal pO2 levels, as it has a much lower Km for O2 
390. The α 
subunits of P4Ha I and P4Ha II have, however, been shown to be targets of hypoxia, via HIF-1α, in 
chondrocytes and other cell types379. Hypoxia does not directly regulate P4Ha with pO2, but 
instead enhances its activity via HIF-1α379. HIF-1α enhances expression of P4Ha I and P4Ha 
II379,382. CoCl2 effect has also been studied and the hypoxia-mimicking ion was clearly shown to 
enhance P4Ha I and II mRNA and protein levels as well as their enzymatic activity382. The 
enhancement was demonstrated in a series of different cell types, including smooth muscle, 
juntaglomerular and hepatoma cell lines from mouse, with hypoxia levels of 1% O2 and a CoCl2 
concentration of 100 µM382. In addition, this effect was proven to be HIF-1α dependent, as 
disruption of the HIF-1α gene in mouse embryonic fibroblasts abrogates the effect382.  
To evaluate the effect of hypoxia-mimicking BGs developed, the SircolTM assay was used (Fig. 
5.8). This assay permits quantification of acid and pepsin-soluble collagens in in vitro cell culture, 
but it does not distinguish between different collagens. Collagen production was assessed after 
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hMSCs were exposed to the BG-conditioned media for 5 and 10 days. At both time periods, 
enhancement of the collagen production after treatment with the hypoxia-mimicking material was 
clear. In addition, the enhancement appears to happen in a concentration-dependent way. At day 
5, only the media conditioned with the lower Co2+ concentration BGs showed a significant effect. At 
day 10, however, all BGs showed a significant increase in collagen secretion, including the 0Co 
BG, although the effect of 0Co BG-conditioned media is significantly lower than that of the Co2+-
containing BG-conditioned media. Enhancement of collagen expression by exposure to either BG-
conditioned media or BG particles has been previously reported249,253,254. In these studies, 
osteoblasts increased production of Collagen I when treated with 45S5 Bioglass®-conditioned 
media249,254 in the absence of osteogenic factors/media. Jones et al. showed a similar effect in the 
presence of a phosphate-free bioactive glass253. In all cases, the enhancement of collagen 
production is closely associated with further differentiation into the osteogenic lineage and ECM 
production. The enhancement of collagen production by 0Co BG might be due to the presence of 
Si4+ ions, as exposure of hMSCs and MG-63 cells to various concentrations of orthosilicic acid (0-
50 μM) has been shown to enhance Collagen type I synthesis391. CoCl2-conditioned media did not 
significantly increase collagen secretion in comparison to the control. The effect observed when 
hMSCs were treated with the hypoxia-mimicking BGs could therefore be due to a synergistic effect 
of Co2+ and other BG ions. Our data is thus in agreement with the literature; hypoxia-mimicking 
BGs significantly enhanced collagen synthesis. Although the mechanism was not assessed here, 
literature suggests that the enhancement occurs via HIF-1α activation. Under hypoxia, HIF-1α 
increases P4Has I and II mRNA and protein levels, as well as their activity, which is essential for 
the formation of the collagen triple helices379,382. 
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Fig. 5.8 Effect of hypoxia-mimicking BGs on collagen production: SIRCOL
®
 Collagen assay. Collagen 
concentration per well was determined using a colourimetric assay after hMSCs were treated with BG-
conditioned media (1.5 mg/ml) for 5 and 10 days. (*) indicates the difference between the marked bar and 
the control (cells cultured with standard cell-culture media, with no BG) for the same time period is 
statistically significant. (¥) indicates that the difference between the marked bar and the sample treated with 
the dissolution products of 0Co BG for the same time period is statistically significant (p<0.05).  
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5.4  CONCLUSION 
Human mesenchymal stromal cells (hMSCs) are adult progenitor cells that have shown great 
potential for use in tissue regeneration therapies328. They exhibit great plasticity as well as 
immunomodulatory properties328. Oxygen is one of the main regulators of hMSC biology362. Low 
pO2 values have been shown to enhance hMSC life-span ex vivo, alter the cells metabolism, 
control their differentiation potential, and a variety of other processes that are beyond the scope of 
this chapter. Not all but most of these processes have been shown to be regulated by the hypoxia 
pathway352. 
In this chapter, the effect of hypoxia-mimicking BGs on hMSCs was evaluated. The activation of 
the hypoxia pathway and subsequent responses by the Co2+-containing BGs was clearly 
demonstrated. Both HIF-1 activity and VEGF expression were enhanced under exposure to the 
hypoxia-mimicking BG-conditioned media in a concentration-dependent manner. These findings 
are exciting as various cellular processes essential for natural tissue repair and regeneration can 
then be subsequently activated by the Co2+-containing BGs. 
As expected, the viability of hMSCs was significantly decreased by high Co2+ concentrations in the 
BG (4 molar% Co2+, NonCB4CO BG). Lower Co2+ concentrations (≤2 molar%), however, did not 
produce a toxic effect. Nevertheless, hMSC proliferation was significantly decreased by the 
hypoxia-mimicking BGs (even the low Co2+ concentration BGs) in a concentration-dependent 
manner. Since cell death was not observed with the lower Co2+ concentration BGs, this effect is 
suggested not to be due to Co2+ toxicity, but instead to the cells entering a resting state. Such an 
effect has been previously reported in the literature185.  
ECM formation is critical in the regulation of hMSC behaviour and fate377. In addition, it has been 
previously shown to be regulated by pO2 and the hypoxia-mimicking ion, Co
2+ 382. For these 
reasons, the effect of Co2+-containing BGs on hMSC collagen production was also evaluated. 
Although the type of collagen was not specified, data presented here clearly showed that collagen 
production is increased by the BGs produced.  
Although activation of the hypoxia pathway by the Co2+-containing BGs was clearly demonstrated, 
further studies should be performed to better comprehend how these BGs affect hMSC behaviour; 
their effect on ex vivo life-span, as well as the mechanism behind reduction of hMSCs proliferation 
should be assessed. In addition, the study of hMSC gene expression under exposure to these BGs 
would be of great interest, as it could indicate the main cellular processes affected by the glasses. 
Finally, together with the information referred to previously, the effect of Co2+-containing BGs on 
hMSCs differentiation potential would give hints on how the BGs could be applied in a clinical 
setting. 
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Nonetheless, the results presented in this chapter suggest the hypoxia-mimicking BGs we have 
developed are of great potential for use in tissue regeneration therapies. Their ability to activate 
the HIF-1 pathway and subsequent responses, as VEGF expression, on hMSCs suggests the 
Co2+-containing BGs might be able to promote cellular processes involved in tissue regeneration 
as is the case of angiogenesis. However, this study indicates that, to maintain hMSCs viability 
while activating the HIF-1 pathway and responses, the NonCB1Co and NonCB2Co BGs are 
probably more adequate. The next chapter (Chapter 6) describes the effect of these BGs on 
angiogenesis directly on endothelial cells, but also through activation of the HIF-1 pathway in 
hMSCs.  
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6.1 INTRODUCTION 
Blood vessels play an essential role in the body; they are responsible for transporting O2 and 
nutrients to all tissues, as well as removing CO2 and the waste products of metabolism. 
Engineered tissues are no exception; formation of blood vessels is required for metabolically active 
tissues to grow beyond the O2 diffusion limit
36,392. Therefore, the ability to induce blood vessel 
growth within TE scaffolds would be of benefit to the regeneration of many clinically important 
tissues.  
The process of blood vessel formation is extremely complex and not fully understood yet. Different 
cell types, including endothelial (ECs) and periendothelial cells, are involved and known to be 
essential for correct blood vessel formation and maturation369,377,393. The process is tightly 
regulated by a cocktail of factors precisely orchestrated in a spatial and temporal fashion378. The 
mechanism and molecular regulation of blood vessel formation has been extensively 
reviewed369,377,378,393-395. Here, the main steps and players involved in the formation of a functional 
vascular network will be summarized but our attention will focus on those aspects relevant to the 
present work.  
In the embryo, the formation of blood vessels starts with a process called vasculogenesis. During 
this process, angioblasts, the endothelial cells precursors (EPCs), differentiate towards either 
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blood or endothelial cell precursors via haematopoietic or vasculogenic processes, respectively. 
The selection between these two lineages is dependent on vascular endothelial growth factor 
(VEGF) concentration and the expression of VEGF receptor 2 (VEGFR2) on the surface of the 
cells. The cells expressing the VEGFR2 follow vasculogenesis and give rise to EPCs while those 
lacking the receptor undergo haematopoiesis. The primary vascular plexus formed at the end of 
the vasculogenesis process is still disorganized and immature. At this stage, new capillaries are 
formed through a process called angiogenesis. It consists of the formation of new capillaries by 
two distinct mechanisms involving sprouting or splitting of the pre-existing vessels, known as 
sprouting and non-sprouting angiogenesis respectively. Sprouting angiogenesis occurs usually in 
the embryo, in tissues that are initially less vascularised, such as the brain. There is an initial 
proteolytic degradation of the extracellular matrix (ECM) around the pre-existing vessels, followed 
by chemotatic migration and proliferation of ECs that will later mature and form the capillaries. 
Non-sprouting angiogenesis occurs essentially in highly vascularised tissues, for example the 
lungs, and in this case, proliferation of ECs occurs inside the vessels leading to splitting of the pre-
existing vessel by the formation of transcapillary pillars. Independently of the angiogenesis 
mechanism followed, remodelling and maturation of the vascular system is required in order to 
achieve a mature and functional hierarchically organised vascular system. During the maturation 
process, also called pruning, excess ECs are lost and other ECs reassemble into new vessels or 
dedifferentiate. Their fate is controlled by the combined expression of various positive and negative 
signals, which are transduced by their respective receptors. High levels of receptors, including 
VEGF receptors 1 and 2 (VEGFR1 and VEGFR2) and tyrosine kinase with immunoglobulin-like 
and EGF-like domains 1 and 2 (TIE-1 and TIE-2), are expressed on the membrane of the ECs, 
while their ligands are secreted in the surrounding tissues. Finally, the vascular system is 
remodelled and differentiated in order to define vessel specialization. At this point, and for the first 
time in the process, forces generated by circulation are involved in the regulation and shaping of 
the vascular system formation (reviewed in 369).  
In adults, the vascular system is usually quiescent and angiogenesis occurs only in the placenta 
during pregnancy or in the cycling ovaries396. Formation of new blood vessels, however, occurs in 
response to specific stimuli, which could be injuries, physiological disorders or increased metabolic 
activity396. Defective angiogenesis is known to be involved in over 70 disorders, many of them 
affecting a large percentage of the population, including cancer and ischemic heart diseases 
(reviewed in 396,397). In these cases, the balance between the pro- and anti-angiogenic stimuli is lost 
and one of them becomes excessive. Examples of pathological disorders where excessive 
angiogenesis is involved are malignant and inflammatory disorders, as is the case of cancer and 
autoimmune diseases. But extreme blood vessel formation also occurs in other diseases as 
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diabetes, asthma and Alzheimer’s disease, where abnormal deposition of ECM impairs O2 delivery 
to the tissue, inducing new blood vessel formation396-398. The opposite situation happens in the 
case of ischemic heart diseases or preeclampsia, where angiogenesis is insufficient and transport 
of O2 and nutrients is not enough to maintain tissue viability
396-398. In order to understand these 
disorders and expand the available treatment options, the process of blood vessel formation in 
adulthood has been extensively studied under both health and disease. A large body of work exists 
in the area of pro- and anti-angiogenic therapies2,399, and the pro-angiogeneic therapies will be 
discussed later in this section.  
Although they are quiescent during adulthood, ECs maintain the ability to divide rapidly in 
response to physiological stimuli. The main stimulus able to activate the angiogenesis process is 
hypoxia2,399. Hypoxia activates the HIF-1α pathway, which regulates the expression of all main 
angiogenesis regulator genes, including VEGF, stromal derived factor 1 (SDF1), angiopoietin 2 
(Ang 2), placental growth factor (PGF), platelet-derived growth factor B (PDGFB) and stem cell 
factor (SCF), but also genes involved in matrix metabolism such as matrix metalloproteinases 
(MMPs) and collagen prolyl hydroxylases, in the hypoxic tissue2,399. In addition, the HIF-1α 
pathway also controls the expression of their receptors in ECs and periendothelial cells and their 
precursors2,399. The interaction between the receptors and their ligands then activates the cells and 
initiates the angiogenic process. Importantly, the response to hypoxia is cell type specific2,91,102,400. 
The secreted pro-angiogenic proteins also act as homing signals; they are able to recruit pro-
angiogenic cells from distant places in the body to the angiogenic site399. The recruited cells 
express the receptors for these cytokines in their cellular membrane309. In addition, several 
processes essential for angiogenesis have also been shown to be activated by hypoxia in vitro2, as 
is the case for cell migration103,104,126, tubule formation401-403 and ECs proliferation404,405.  
The indispensible role of the HIF-1α pathway on developmental angiogenesis has been 
emphasized by inactivating studies that showed that although mouse embryos lacking HIF-1α 
expression initiate vasculogenesis properly, the vascular plexus degenerates before maturation 
and the phenotype is lethal at midgestation2,399. Nevertheless, in adults, HIF-1α has also been 
shown to accumulate in most diseased/damaged tissues, including ischemic tissues, tumours and 
inflamed sites2,396,397  and promote angiogenesis and vascular remodelling396-398.  
As discussed in Chapter 2, vascularisation is still a major obstacle to the engineering of thicker, 
metabolically demanding organs. Growth or regeneration of tissues thicker than the O2 diffusion 
limit (100-200 μm) requires the presence of a functional vascular network that delivers O2 and 
nutrients to the cells36,392. Various possible solutions have been suggested by different authors but 
the pre-vascularization of the constructs used prior to implantation is likely to be one of the most 
promising strategies.  With this purpose, several approaches have been tested. The following are 
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the main approaches tested with the aim of stimulating the formation of mature vessel networks 
(reviewed in 2,36,377). The delivery of either single or a cocktail of angiogenic molecules either in the 
form of protein or as gene therapy has been tested377. Initially, people mainly focused on the 
delivery of VEGF, as this growth factor is the main angiogenic cytokine. Different delivery methods 
were tested, but the vessels formed in vitro and in vivo were leaky and immature and degenerated 
very quickly after implantation406,407. The delivery of other pro-angiogenic factors, as PDGF, bFGF 
and Ang1, combined with VEGF was also tested and the vessels formed were in general more 
mature and resistant to leakage406,408,409. However, it is extremely difficult to define the minimum 
number of pro-angiogenic factors necessary to promote angiogenesis, and furthermore the 
delivery of these proteins in a correct spatial and temporal way is technically challenging. 
Therefore, the ability to initiate a global angiogenic response without having to select and optimise 
the delivery of an array of individual biomolecules could have significant advantages.  
With this in mind, several groups have attempted to activate angiogenesis-regulating transcription 
factors2,377,399. Several authors centred their attention on HIF-1α using a variety of different 
strategies. Inhibition of HIF-1α degradation was achieved using either specific HIF-hydroxylases 
inhibitor molecules410 or a macrophage-derived peptide (PR39)411. Other authors used gene 
therapy; William et al. tested the effect of over-expression of peptides specific for the VHL-binding 
prolyl-hydroxylation sites in human HIF-1α412 and Vincent et al. and Shyu et al. fused the N-
terminal DNA-binding domain of HIF-1α to the transactivation domain of the herpes simplex virus 
VP16413,414. Finally, Elson et al. deleted the central oxygen-dependent domain on the HIF-1α gene 
and the transgenic mice constitutively expressing HIF-1α in the epidermis were shown to increase 
formation of dermal capillaries, as well as VEGF expression. Interestingly, oedema, inflammation 
and vascular leakage were not induced415. 
Finally, direct seeding of both cellular components of vessel walls, ECs and perivascular cells, on 
the constructs has also been tested (reviewed in 36). Interestingly, co-implantation of ECs and 
perivascular cell precursors was shown to lead to long-lasting and stable microvessels in vivo and 
the vessels remained functional for over a year after implantation416. This is thought to be 
associated with production of tissue inhibitor of metalloproteinase-2 and -3 (TIMP-2 and -3) by 
pericytes and ECs in a co-culture system. These proteins are then able to stabilise vessels by 
inhibiting matrix breakdown417. Since then, many other co-culture systems and different 
perivascular cell sources were tested, with promising results in many cases. In order to use the 
pre-vascularised constructs for tissue regeneration, a third cell type can be added to the co-culture 
system that is specific for the target tissue. One study, by Levenberg et al., achieved enhanced 
endothelial cell survival and blood perfusion after pre-vascularization of skeletal muscle constructs 
co-cultured with myoblasts, ECs, and embryonic fibroblasts as a source of perivascular cells78. 
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More recently, Tsigkou et al. designed a similarly elegant approach to promote bone 
regeneration77. MSCs were initially differentiated into osteoblasts in a poly(lactic-co-glycolic acid) 
(PLGA) porous scaffold to which a gel containing ECs and undifferentiated MSCs was later added. 
Osteoblastic differentiation was observed, as well as microvessel formation. After implantation, 
anastomoses occurred and the vascular network was found functional and leak resistant after 8 
weeks77.  
These studies are a cause for optimism, but there are still many challenges that need to be 
addressed if scaffold prevascularisation is to become a reality. One of them is the availability of 
cells. Firstly, it is not easy to obtain large number of cells. But most importantly, it is necessary to 
define what cell sources can be used for each specific application. ECs phenotypes vary 
significantly depending on the vessel type and organ, and this specificity is thought to play a crucial 
role on local physiology. Therefore, it is still not known whether different cell sources can be used 
in any tissue.  
The work described in this chapter draws upon the two themes that have just just discussed: 
namely the activation of the angiogenic response via the HIF-1 pathway and co-culture of ECs with 
other cell types to promote vascularisation. Co2+-containing BGs were used to activate the 
hypoxia-pathway (as described in the previous chapters), in a co-culture system of ECs with 
hMSCs. Initially, the direct effect of the hypoxia-mimicking BGs on ECs viability and HIF-1 pathway 
will be discussed. Secondly, the effect of the hypoxia-mimicking BGs on the ECs and hMSCs co-
culture system will be assessed. The potential of these BGs to stimulate ECs migration and 
angiogenesis in vitro, either directly or through hMSCs paracrine interactions, will be evaluated.  
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6.2  MATERIALS AND METHODS 
6.2.1 Cell culture 
Two sources of endothelial cells (ECs) were used for this study: primary human umbilical vein 
endothelial cells (HUVEC) and human microvascular endothelial cell line (HMEC-1, from ATCC). 
Primary HUVEC cells were a kind gift of Dr Patrick Au, Steele Lab, MGH, Boston, MA77. For the 
tubule formation assay, DsRed-transduced HUVECs were used. The protocols for preparation of 
the DsRed retrovirus and transfection can be found in Appendix 1. Both cell types were expanded 
in endothelial cell growth medium (EGM-2, from Lonza). This medium was used throughout the 
study, except when stated otherwise. Initial culture was performed in 75-cm2 flasks at 37 ºC in a 
humidified atmosphere of 95 % air with 5 % CO2 and supplied with fresh medium every 2-3 days. 
At 90 % confluence, cells were detached using trypsin-EDTA (GIBCO®), and cell count was 
determined in a haemocytometer. Cells were ressuspended to the appropriate concentration for 
seeding in complete medium. Tissue culture plastic flasks or plates were always coated with 0.1% 
gelatine for 15 min before seeding cells. 
In this chapter hMSCs were also used in some experiments. These cells were purchased from 
Cambrex Corporation and the cell culture protocols were as detailed in the previous chapter.  
For the different cell behavioural and viability assays, both endothelial cells types were seeded in 
well plates at a density of 5x104 cells/cm2 (except when stated otherwise) and treated for different 
time periods with BG-conditioned media, either EGM-2 or DMEM. CoCl2-containing media was 
used as positive control. Cell culture medium was replaced every 2-3 days (Fig. 6.1).  
6.2.2 Preparation of BG-conditioned media 
BG-conditioned media was prepared as described in Chapter 4. BG (<38 µm particles) was 
incubated in the desired media (EGM-2, from Lonza or DMEM, from GIBCO®), in a roller, for 4 h at 
37 °C, prior to filtration (0.2 µm pore filters). BG-conditioned media was generated by the 
incubation of 1.5 mg of BG per ml media. Conditioned media was incubated (37 oC, 5% CO2) in a 
vented flask for 2 h prior to use to stabilise pH. Only the glasses from the non-charge balanced 
(NonCB) series indicated on Table 6.1 were used for this study. ICP-OES was used to determine 
the concentration of the different ions released from the BG to the conditioned media (Table 6.1). 
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Fig. 6.1 Schematic representation of the procedure followed on the studies performed to assess BG 
biological activity. BG conditioned media (EGM-2 and DMEM) was prepared. It was then used to treat both 
types of endothelial cell types (HUVEC and HMEC-1) and after specific time periods, samples were collected 
to assess cell viability and activation of the hypoxia response, as well as the effect of the hypoxia-mimicking 
BGs on angiogenesis.   
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Table 6.1 Concentration of the different ions (Si, Ca, Na, P, Co) in BG-conditioned DMEM and EGM-2 (in 
ppm) determined by ICP-OES. The Co concentrations presented in the shadowed column were converted to 
µM. The values presented here are the average ± standard deviation of all batches used for the experiments 
presented in this chapter. 
Conditioned media Si Ca Na P Co Co (µM) 
D
M
E
M
 
Control (no BG) 0.0 ± 0.2 81.3 ± 6.6 2920 ± 420 39.1 ± 3.0 0.03 ± 0.05 0.51 ± 0.85 
0Co 73.7 ± 13.0 95.7 ± 27.2 3047 ± 508 15.1 ± 7.0 0.02 ± 0.03 0.33 ± 0.51 
NonCB0.5Co 69.3 ± 6.6 103.5 ± 14.7 2916 ± 413 19.2 ± 7.6 2.18 ± 0.40 36.97 ± 6.78 
NonCB1Co 76.8 ± 12.9 106.1 ± 17.1 2996 ± 487 16.0 ± 7.6 5.35 ± 0.89 90.74 ± 15.09 
NonCB2Co 76.9 ± 18.1 110.3 ± 18.3 2993 ± 489 16.8 ± 9.7 10.55 ± 2.06 178.93 ± 34.94 
NonCB4Co 80.6 ± 17.6 109.8 ± 17.2 2995 ± 523 16.5 ± 7.4 22.97 ± 2.06 389.57 ± 34.94 
CoCl2 100µM 0.0 ± 0.9 81.5 ± 8.3 2928 ± 475 38.7 ± 4.0 6.61 ± 0.62 112.11 ± 10.52 
4
E
G
M
-2
 
Control (no BG) 0.2 ± 0.2 68.1 ± 5.9 2197 ± 108 25.3 ± 5.0 0.02 ± 0.03 0.34 ± 0.51 
0Co 60.4 ± 19.6 105.5 ± 12.9 2304 ± 143 11.9 ± 5.7 0.01 ± 0.02 0.17 ± 0.34 
NonCB0.5Co 61.7 ± 18.8 104.0 ± 4.5 2253 ± 88 9.8 ± 2.6 1.34 ± 0.27 22.73 ± 4.78 
NonCB1Co 65.3 ± 17.8 101.3 ± 14.5 2333 ± 177 11.5 ± 2.9 2.77 ± 0.84 46.98 ± 14.25 
NonCB2Co 66.2 ± 17.3 98.2 ± 14.4 2283 ± 123 14.3 ± 6.5 5.45 ± 1.90 92.43 ± 32.20 
NonCB4Co 74.3 ± 12.7 95.1 ± 3.1 2193 ± 63 13.8 ± 1.9 13.12 ± 1.51 222.52 ± 25.61 
CoCl2 100µM 0.1 ± 0.1 71.1 ± 6.2 2222 ± 113 24.8 ± 5.4 7.12 ± 0.51 120.76 ± 8.65 
CoCl2 200µM 0.2 ± 0.0 65.9 ± 3.6 2318 ± 64 19.9 ± 10.2 12.23 ± 1.32 207.42 ± 22.39 
6.2.3 MTT assay 
MTT assays were performed as reported in Chapter 4. Briefly, MTT salt solution (5 mg/ml) was 
added to cell culture 4 h prior to the end of the experiment. After removal of cell culture media, 200 
µl of DMSO was added. Absorption was measured using a microplate reader (SpectraMax M5, 
Molecular Devices) at a wavelength of 570 nm with a reference wavelength of 620 nm.  
6.2.4 AlamarBlue® assay 
The alamarBlue® assay was used to assess endothelial cells viability. The assay was performed as 
indicated by the manufacturer and described in Chapter 5. Briefly, endothelial cells were seeded in 
96-well plates (1x104 cells/cm2). At 1, 2, 4 and 7 days, cell culture media was removed from the 
well plates and the wells were washed with 100 µl of PBS. 150 µl of 10% alamarBlue® in DMEM 
with no phenol red (GIBCO®) was added to each well and the well plates were incubated at 37 ºC 
for 2 h. 100 µl of the reaction product was then transferred to an opaque black 96-well plate and 
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fluorescence was measured at an excitation wavelength of 540 nm and an emission wavelength of 
585 nm using a microplate reader (SpectraMax M5, Molecular Devices). 
6.2.5 HIF-1α activity assay  
The TransAMTM HIF-1 assay kit (Active Motif) was used to assess the effect of Co2+-containing BG 
on HIF-1α activity. The assay was performed according to the manufacturer’s instructions and as 
described on Chapter 4. Briefly, the two sources of endothelial cells (HUVEC and HMEC-1) were 
seeded (5x104 cells/cm2) in 25-cm2 flasks and then cultured until they reached approximately 90% 
confluency. Cells were then incubated for 8 and 24 h with BG-conditioned media before 8 µg of 
nuclear extracts were prepared. Nuclear extracts were added to a 96-well plate pre-coated with 
HIF-1α specific oligonucleotides. A primary antibody specific for an epitope on the bound and 
active form of the transcription factor was added followed by subsequent incubation with 
secondary antibody conjugated to horseradish peroxidase and a substrate solution. Absorption 
was measured using a microplate reader (SpectraMax M5, Molecular Devices) at a wavelength of 
380 nm and a reference wavelength of 655 nm. 
6.2.6 Analysis of VEGF expression 
VEGF A165 production was evaluated by ELISA (Quantikine: Human VEGF immunoassay, R&D 
Systems®). Cell culture supernatant samples or standards together with assay diluent were added 
to the provided 96-well plate (pre-coated with a monoclonal antibody specific for VEGF A165). Any 
VEGF A165 present was bound by the immobilized antibody. An enzyme-linked polyclonal antibody 
specific for VEGF A165 was added to the wells before a substrate solution was added. Colour 
developed in proportion to the amount of VEGF A165 bound in the initial step and its intensity was 
then measured in a microplate reader (SpectraMax M5, Molecular Devices) at 450 nm with a 
reference wavelength of 540 nm.  
6.2.7 Migration assay  
The effect of hypoxia-mimicking BG on ECs chemotaxis (directed migration) was evaluated using a 
cell migration assay kit (QCMTM Chemotaxis 96-Well Cell Migration Assay, from Chemicon® 
International). The kit is based on the Boyden Chamber assay and uses microporous membrane 
inserts of 8 µm pores. Cells are placed on the top of the inserts and the chemoattractive agent on 
the bottom well. Migration towards the chemoattractant is then quantified using the fluorescent 
CyQuant GR nucleic acids dye (Fig. 6.2). The assay was performed accordingly to the 
manufacturers’ instructions. BG-conditioned DMEM (Series A), and BG-conditioned DMEM 
previously pre-conditioned in culture with hMSCs for 48 h (Series B), were used as 
chemoattractants. In both series the following conditions were tested: Control (no BG), 0Co BG, 
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NonCB1Co BG, NonCB2Co BG and 100 µM CoCl2. As a positive control complete EGM-2 media 
was used. ECs (both HUVEC and HMEC-1 cells) were cultured in T175 flasks until they reached 
80 % confluency. Prior to the assay, cells were starved for 24 h with serum-free EGM-2. ECs were 
then harvested and ressuspended in serum-free DMEM containing 5 % bovine serum albumin 
(BSA). On the bottom tray, 150 µl of serum-free media containing the BG-conditioned media 
described above (Series A and B, as well as blank and positive control) was added to each well. 
The microporous membrane tray (migration chambers) was then placed on top of the bottom tray 
before 7.5x104 cells in 100 µl was added per migration chamber. The plate was then covered and 
incubated for 8 h at 37 ºC. After discarding the cells and media on the top side of the migration 
chamber by discarding the remaining cell suspension, the migration chamber was placed in a new 
tray containing 150 µl of pre-warmed cell detachment solution. The plate was incubated for 30 min 
at 37 ºC. To dislodge cells completely from underneath the migration chamber, the plate was 
gently tilted back and forth several times. Meanwhile, CyQuant GR Dye solution was diluted in 4X 
lysis buffer (1:75) and, after the 30 min incubation, 50 µl of the CyQuant GR dye/lysis buffer 
solution was added to each well of the bottom tray. The plate was again incubated, for 15 min at 
room temperature, before 150 µl of the mixture was transferred to a black well plate and 
fluorescence was read at emission and excitation wavelengths of 480 and 520 nm, respectively, in 
a microplate reader (SpectraMax M5, Molecular Devices). 
 
Fig. 6.2 Schematic representation of the migration assay. ECs were seeded on a microporous membrane (8 
μm pores) and incubated for 8h with the BG-conditioned or hMSCs-pre-conditioned media on the bottom 
chamber. Migration towards the chemoattractant was quantified using a DNA dye. 
6.2.8 Tubule-forming assay   
A tubule-forming assay was used to assess the effect on the hypoxia-mimicking BGs on the 
angiogenic response of endothelial cells in vitro, making use of DsRed-transfected HUVEC cells 
(DsRed-HUVECs). 3D collagen gels (rat tail collagen type I, BD Biosciences) containing DsRed-
HUVECs at a concentration of 1x106 cells per ml of gel were prepared before the gels were treated 
with BG-conditioned media. Collagen gels were prepared by mixing in a 50 ml centrifuge tube 1.5 
mg/ml of collagen, 25 µL/ml of  25 mM HEPES buffer (GIBCO®) and cell culture media (either 
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EGM-2 or DMEM) to adjust the volume. NaOH (0.1 M) was added to adjust the pH to 7.4. DsRed-
HUVEC cells were then added to the gel solution at a concentration of 1x106 cells/ml gel. 500 µl of 
the gel suspension was placed per 24-well and the plates were then incubated at 37 ºC for 1h to 
allow gelation of the collagen suspension. All well-plates were pre-heated to 37 °C for 30 min 
before adding the gel solution to achieve uniform gelation. BG-conditioned media was added (500 
µl/well) to the gels 45 min after. Media was replaced every 2 days. Tubule-forming ability was 
assessed using fluorescence microscopy. Photos were taken of each condition (performed in 
triplicates) at days 1, 2, 4 and 7 in a Olympus microscope at 40X magnification. These 
experiments were performed using both EGM-2 and DMEM media. In addition, three different 
approaches (summarized in Fig. D3) were tested. Approach A: DsRed-HUVECs were dispersed in 
the collagen gel before gelation at a concentration of 1x106 cells/ml of gel and the BG-conditioned 
media was then added to gels after gelation (Fig. 6.3 A). Approach B: DsRed-HUVECs with 
hMSCs in a 4:1 ratio were dispersed in the collagen gel before gelation at a concentration of 1x106 
cells/ml of gel and the BG-conditioned media was then added to gels after gelation (Fig. 6.3 B). 
Approach C: hMSCs were seeded at a concentration of 5x104 cells/cm2 on 24-well plates. After 
adhesion, BG-conditioned media was added to the wells and incubated with the hMSCs. 48 h later, 
BG-conditoned media was removed and a collagen gel containing 1x106 cells/ml (DsRed-
HUVECs) was added on top of the hMSCs and after gelation standard DME was added to the gels 
(Fig. 6.3 C).  
 
Fig. 6.3 Three different approaches used in the in vitro angiogenesis assay (tubule-forming assay). Approach 
A: HUVECs were dispersed throughout the 3D collagen gel and BG-conditioned media was added after 
gelation. Approach B: HUVECs with hMSCs in a ratio of 4:1 were dispersed throughout the 3D collagen gel 
and BG-conditioned media was added after gelation. Approach C: hMSCs were seeded on the bottom of the 
wells and BG-conditioned media was added after adhesion. 48 h after the media was removed and the 
collagen gel containing HUVECs only was added on top. Standard cell-culture media was added to the gels 
after gelation.  
6.2.9 Statistical analysis 
All experimental data shown are expressed as mean±SD and were obtained from experiments 
performed at least twice in quadruplicates. All data analysis was performed in Excel. Statistical 
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analysis was by one-way analysis of variance (ANOVA) using multiple comparisons (Bonferroni 
test) and p-values less than 0.05 were considered significant. Statistical analysis was performed 
using SPSS.  
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6.3 RESULTS AND DISCUSSION 
Tissue engineering and regenerative medicine are areas of research where the formation of a 
functional, mature vascular network remains a challenge. As discussed earlier in this chapter, 
angiogenesis is an extremely complex process, precisely regulated by various different cell types 
and a large number of factors. For this reason, attempting to stimulate new blood vessel formation 
by delivering single or a cocktail of pro-angiogenic factors is technically challenging and may not 
deliver optimal results. There are difficulties inherent both in deciding which are the correct factors 
to use, and in delivering them in an effective temporal and spatial manner. There may be greater 
potential in activating a pro-angiogenic intracellular pathway, such as the HIF-1α pathway. In this 
chapter the effect of the hypoxia-mimicking BGs on EC viability and hypoxic response will be 
discussed. First, BG-conditioned media (EGM-2) was used to culture both endothelial cell types 
(HUVECs and HMEC-1) and alamarBlue® and MTT assays were performed at several time points 
to assess ECs viability and proliferation. Next, as the EGM-2 medium contains high concentrations 
of various growth factors that could later interfere with or hide the BG effect, culture of ECs in a 
growth factor-free medium was evaluated. BG-conditioned DMEM was used to culture both types 
of ECs and the alamarBlue® assay was used to compare the effect of the media (EGM-2 and 
DMEM) on EC viability and proliferation. Then, the ability of the hypoxia-mimicking BGs to activate 
the HIF-1 pathway in ECs was evaluated measuring HIF-1 DNA-binding activity. Finally, the ability 
of the hypoxia-mimicking BGs to stimulate the EC angiogenic potential, either directly or through 
hMSC paracrine interactions, was assessed. A migration assay was performed to evaluate EC 
migration towards BG-conditioned media and BG-conditioned media pre-conditioned with hMSCs 
for 48 h. Then, HUVECs were encapsulated in 3D collagen gels either alone or with hMSCs and 
their in vitro tubule-forming ability was evaluated in the presence of BG-conditioned media. 
6.3.1 Determining the effect of the hypoxia-mimicking BG on EC viability 
The effect of hypoxia on EC viability and proliferation is controversial404,405. Some authors have 
reported enhanced EC proliferation404, but others show EC division slows down but does not arrest 
under hypoxia405. Similarly, exposure to Co2+ ions has shown contrary effects418,419. It was then 
difficult to predict what the effect of Co2+-containing BGs exposure on EC viability and proliferation 
would be. AlamarBlue® and MTT assays were performed after both HUVECs and HMEC-1 were 
exposed to BG-conditioned EGM-2 for 1, 2, 4 and 7 days (Fig. 6.4 and Fig. 6.5, respectively). The 
two cell lines responded in slightly different ways to the BGs. HUVECs stopped growing after 
confluency was reached, between days 2 and 4, as it clearly seen on Fig. 6.4 A and Fig. 6.5 A and 
cell death was observed. HMEC-1, however, although they reached confluency at approximately 
the same time, kept on proliferating and both the alamarBlue® and MTT signals kept increasing 
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after day 2. HMEC-1 signals were generally stronger on both assays, but their higher resistance 
and proliferation rate was probably due to them being an immortalized cell line and HUVECs being 
primary cells. In addition, HMEC-1 can grow in layers, while HUVECs seem to be more sensitive to 
confluency.  
Both cell types were significantly affected by the Co2+-containing BGs. A decrease in the viability of 
HUVECs cultured in BG-conditioned media was observed as early as day 2 in the alamarBlue® 
assay (Fig. 6.4 A). The reduction in viability appeared to be due to the presence of Co2+ ions, as it 
occurred in a concentration-dependent way. At days 4 and 7, however, cell viability was decreased 
in all BG-conditioned media, independently of the presence of the hypoxia-mimicking ion. This 
suggests that, at later time points, the BG dissolution products, and not the Co2+ ions alone, were 
responsible for HUVEC viability decrease. The MTT assay showed no significant effect of the 
hypoxia-mimicking BGs on HUVEC viability, except for the NonCB4Co BG (Fig. 6.5 A). After day 2, 
however, HUVECs viability decreased but in a similar way in all conditions tested. It seemed to be 
a confluency-induced effect. The CoCl2-treated cells here showed a slightly different behaviour. 
Although at later time periods, they were not significantly different from the standard EGM-2 
control, at days 1 and 2, their MTT signal was significantly decreased. 
Generally, both assays showed HMEC-1 were less susceptible to the hypoxia-mimicking BGs 
toxicity. The alamarBlue® assay showed that, until day 4, only the BG with highest Co2+ 
concentration (NonCB4Co) reduced HMEC-1 viability (Fig. 6.4 B). At days 4 and 7, however, the 
alamarBlue® signal was decreased with Co2+-containing BGs in a concentration-dependent fashion 
and the 0Co BG appeared to be able to maintain cell viability unaffected. The effect of the CoCl2 
control was similar to the NonCB1Co and NonCB2Co BG-conditioned media, which suggests it 
was a Co2+ concentration-driven effect, since the concentration of the hypoxia-mimicking ion on 
these three media was similar (Table 6.1). The MTT assay also showed a significant reduction of 
HMEC-1 viability with Co2+ concentration from day 4 onwards (Fig. 6.5 B). Plus, at day 7, only the 
0Co BG-conditioned EGM-2 was able to maintain viability compared to the control. However, more 
interestingly, was the effect observed at days 1 and 2, as HMEC-1 were exposed to the 0Co, 
NonCB0.5Co, NonCB1Co and NonCB2Co BGs-conditioned media. Proliferation was increased 
and, as the effect was independent of the Co2+ concentration in the BG, it was probably caused by 
the other BG dissolution ions. The enhanced proliferation could be caused by Si4+ ions, as 
previously discussed on Chapter 5 367. The CoCl2 control significantly reduced HMEC-1 viability 
and proliferation rate. The reduction was clear from day 1 onwards. 
A reduction in alamarBlue® and MTT signals does not necessarily indicate decreased cell viability; 
a similar effect would be observed if the cells entered a resting state. Hypoxia has been shown to 
cause proliferation arrest in hMSCs353, as has been discussed in the previous chapter. However, in 
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this case, cell death was observed throughout the study in all Co2+- treated groups, strongly 
suggesting that exposure to the Co2+ BG-conditioned media caused EC cell death within 4-7 days 
in a concentration-dependent manner. The differences observed between the data from the two 
assays are probably due to the fact that different cellular processes are being assessed. 
The literature is controversial with regards to the effect of hypoxia and Co2+ on EC viability and 
proliferation. Both enhancement and reduction of EC proliferation under hypoxia have been 
reported404,405 and exposure to Co2+ has also shown contradictory effects. The differences are 
probably due to the severity of hypoxia and the Co2+ concentration used. Various studies have 
demonstrated that ECs viability decreases in a concentration-dependent way with exposure to 
CoCl2
418. Although, in general, CoCl2 concentrations up to 100 μM have been shown to maintain 
cell viability418,420, exposure to higher CoCl2 concentrations significantly reduces cell number and 
enhances apoptosis418,421. A gene array has demonstrated the existence of a balance between 
expression of survival and pro-apoptotic genes at early times of exposure to CoCl2
421. The CoCl2 
toxicity mechanism is not totally understood. However, it is known that exposure to high CoCl2 
levels leads to apoptosis418,420,421. A study by Peters et al. suggested apoptosis is triggered by 
impaired integrins signalling, that leads to damaged cytoskeleton and then apoptosis420. 
In our study, reduction of viability of both cell types was clear and shown to be Co2+ concentration-
dependent. After longer exposure times, however, even low Co2+ concentration seemed to 
significantly affect these cells. This could be a synergistic effect of Co2+ ions and glass particles. 
Although only BG-conditioned media was used for this study and it was filtered prior to use, 
smaller particles (< 20 μm) could still be present in the conditioned media. Internalization of BG, as 
well as Co2+-containing, nano-scale particles has been previously described263,422, with EC viability 
significantly reduced after exposure to the Co2+ nano-scale particles, even at lower Co2+ 
concentrations422. 
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Fig. 6.4 Effect of hypoxia-mimicking BG on EC viability: alamarBlue® assay: alamarBlue® assay was 
performed in both HMEC-1 (A) and HUVEC (B) cells after these endothelial cells were treated with BG 
conditioned EGM-2 media for 1, 2, 4 and 7 days. A solution of 100 μM CoCl2 in EGM-2 was used as positive 
control. (*) indicates the difference between the marked bar and the control (cells cultured with standard cell 
culture media, with no BG) of the same time period is statistically significant. (¥) indicates that the difference 
between the marked bar and the sample treated with the dissolution products of 0Co BG of the same time 
period is statistically significant. (p<0.05) 
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Fig. 6.5 Effect of hypoxia-mimicking BG on EC proliferation: MTT assay. MTT assay was performed after 
HMEC-1 (A) and HUVECs (B) were treated with BG conditioned EGM-2 media for 1, 2, 3 and 4 days. A 
solution of 100 μM CoCl2 in EGM-2 was used as positive control. (*) indicates the difference between the 
marked bar and the control (cells cultured with standard cell culture media, with no BG) of the same time 
period is statistically significant. (¥) indicates that the difference between the marked bar and the sample 
treated with the dissolution products of 0Co BG of the same time period is statistically significant. (p<0.05) 
6.3.2 Effect of cell culture media on EC viability and proliferation 
The EGM-2 media used to culture ECs contains various growth factors that strongly promote EC 
proliferation and pro-angiogenic behaviour in vitro. Therefore, there was the concerned that the 
effects of the hypoxia-mimicking BG on the in vitro angiogenic ability of ECs (presented later in this 
chapter) could be masked by the presence of all the growth factors in the media. To investigate the 
possibility of performing the in vitro angiogenesis study using growth factor-free media (DMEM), 
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cell viability in both DMEM and EGM-2 was compared for the two EC types. The alamarBlue® 
assay was performed after both EC types were exposed to BG-conditioned EGM-2 and DMEM for 
2, 4 and 7 days (Fig. 6.6). The experiment was performed in parallel for the two different cell 
culture media with identical initial seeding densities. 
As expected, proliferation of both EC types was significantly reduced in DMEM compared to EGM-
2 (Fig. 6.6). HMEC-1 were still able to proliferate, although at a slower rate (Fig. 6.6 D). HUVECs, 
however, did not survive in DMEM (Fig. 6.6 B). The growth factors provided in the EGM-2 media 
appeared to be essential to maintain HUVEC viability. This difference in sensitivity to the absence 
of growth factors (in DMEM) is again probably due to the fact that HUVECs are primary cells and 
HMEC-1 are an immortalized cell line. The 0Co BG-conditioned DMEM significantly reduced 
HMEC-1 viability compared to the control (Fig. 6.6 D), which suggests BG dissolution ions are toxic 
in DMEM. Interestingly, the presence of Co2+ ions at low concentration in the BGs (NonCB0.5Co 
and NonCB1Co BGs) rescued HMEC-1 viability to a level similar to the control. This could be 
caused by activation of survival mechanisms, via activation of the hypoxia pathway. From this 
experiment it became clear that the EGM-2 medium with all the growth factors can significantly 
affect EC behaviour and probably hide any smaller effect that the BGs might have. Similarly, EC 
viability was clearly decreased in DMEM. It is then necessary to be extremely careful when 
analysing the data presented next and both the EGM-2 stimulatory effect and reduced cell viability 
in DMEM should be kept in mind.  
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6.3.3 Determining the effect of hypoxia-mimicking BGs on activation of the hypoxia 
pathway 
Activation of the hypoxia pathway is one of the main pro-angiogenic stimuli during both 
development and regeneration2,369,377,397. Activation of HIF-1α under hypoxia was first described by 
Jiang et al. in HeLa cells99. HIF-1 DNA-binding activity was shown to increase as cells were 
exposed to lower O2 concentrations
99. Since then, HIF-1α activation by hypoxia has been 
described in many other cell types, including ECs423. The hypoxia-mimicking ion, Co2+, has also 
been clearly shown to reproduce the cellular response181-183. At a concentration of 100 μM, CoCl2 
has been shown to enhance HIF-1α levels at both mRNA and protein levels181, as well as HIF-1 
DNA-binding activity182 in ECs.  
In order to assess whether the hypoxia-mimicking BG are able to elicit this response in ECs, HIF-
1α activity was quantified using the TransAM™ HIF-1 immunoassay after both HUVECs and 
HMEC-1 were exposed to BG-conditioned EGM-2 for 8 and 24 h (Fig. 6.7). On HUVECs, HIF-1α 
activity was enhanced only when cells were exposed to the NonCB4Co BG- or 100 μM CoCl2-
conditioned media, which are the conditions previously shown to be toxic as early as 2 days after 
exposure (Fig. 6.7 A). Activation of the hypoxia pathway by the BGs with lower Co2+ content, 
however, was not observed at the time points assessed. Nevertheless, the possibility of 
enhancement of HIF-1α activity with the NonCB1Co and NonCB2Co BGs at an earlier time-point 
should be considered. Transcription factors are only active during specific time intervals that can 
be very brief; this is also the case of HIF-1α181. Therefore, HIF-1α activity could be negligible at 8 h 
after exposure to the NonCB0.5Co, NonCB1Co and NonCB2Co BGs, even if at 2 or 4 h it had 
been significantly enhanced. At both time points assessed, however, the response observed was 
similar (Fig. 6.7 A). HMEC-1 showed a clear concentration-dependent response to the hypoxia-
mimicking BGs (Fig. 6.7 B). At both 8 and 24 h, HIF-1α activity significantly increased with 
exposure to the Co2+-containing BG-conditioned media. A reduction of HIF-1α activity was 
observed from 8 to 24 h of exposure, especially on the cells treated with the NonCB4Co BG-
conditioned media (Fig. 6.7 A). This decrease is probably not due to a Co2+ toxic effect, but to a 
hypoxia pathway auto-regulatory mechanism. As discussed above, often transcription factors act in 
short intervals, which are just enough to activate the desired cellular responses without causing 
any damage. Auto-regulatory mechanisms are then activated to control the transcription factors’ 
activity. 
The data presented in this chapter therefore suggests that the hypoxia-mimicking BG were able to 
activate HIF-1α activity. Both the NonCB4Co BG- and 100 μM CoCl2-conditioned media and all 
BG- and the 100 μM CoCl2-conditioned media enhanced HIF-1α activity in HUVECs and HMEC-1, 
respectively. The lack of response on HUVECs exposed to the lower Co2+-content BGs can be due 
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to either low concentration of the hypoxia-mimicking ion in the conditioned media (Table 6.1) or to 
the time interval in which HIF-1α activity was assessed. The difference in response by the two 
types of ECs used in this study is due to the different sensitivity of the cells to Co2+ ion. 
Although Co2+-containing BGs enhanced HIF-1α activity, the subsequent activation of a pro-
angiogenic response is not guaranteed. Some authors claim that although Co2+ ions can activate 
the HIF-1α pathway and even VEGF expression on ECs, the pro-angiogenic activity is not 
activated by Co2+ in the same way as it is by hypoxia181. Peters et al. showed that hypoxia and 
Co2+ (100-700 μM) enhanced HIF-1α and VEGF expression on human dermal microvascular 
endothelial cells (HDMECs) in a similar way, but the in vitro tubule-forming ability of these cells 
was enhanced with exposure to hypoxia and not with exposure to CoCl2
181. On the other hand, Liu 
et al. has shown enhanced ECs migration and tubule-forming ability after exposure of HUVECs to 
100 μM CoCl2
183. Therefore the effect of the Co2+-containing BGs on the angiogenic ability of ECs 
was further assessed with an in vitro tubule forming assay. 
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Fig. 6.7 Effect of hypoxia-mimicking BG on HIF-1α activity: HIF-1α assay. HIF-1α activity assay was 
performed after both sources of endothelial cells, (A) HMEC-1 and (B) HUVECs, were incubated with BG 
conditioned media (EGM-2) for 8 h and 24 h. (*) indicates the difference between the marked bar and the 
control (cells cultured with standard cell culture media, with no BG) of the same time period is statistically 
significant. (¥) indicates that the difference between the marked bar and the sample treated with the 
dissolution products of 0Co BG of the same time period is statistically significant. (p<0.05) 
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6.3.4  Determining the effect of hypoxia-mimicking BGs on in vitro angiogenesis 
Pre-vascularisation is one of the most promising approaches to vascularising engineered organs or 
tissues. ECs can spontaneously form microcapillary-like structures in vitro in the presence of 
specific growth factors424 and, if implanted, regular ECs were also shown to form blood vessels in 
vivo36. However, the networks formed are not stable and do not last for long periods of time either 
in vitro or in vivo (reviewed in 36,377). Vessels regress mainly due to EC death36. Over-expression of 
anti-apoptotic genes (Bcl2) or telomerase reverse transcriptase has been shown to enhance ECs 
survival, as well as to promote the formation of perfused blood vessels425,426. Although promising, 
permanent genetic manipulations carry risks including that of insertion into oncogenes leading, 
potentially, to cancer. 
During embryonic development, recruitment of mural cells is essential for nascent vessel 
stabilization377. Perivascular cells are extremely important not only because they provide the 
structural integrity for the new vessels and lay down the ECM, but also because they secrete 
various growth factors that regulate ECs fate and behaviour377. Communication between these two 
cell types is essential for the formation of a mature vascular network377. Co-implantation of ECs 
with mesenchymal precursor cells also resulted in the formation of stable and long-lasting vessels 
in vivo, and they were shown to remain functional for over a year416. Since then, co-culture or co-
implantation of ECs with an additional cell type that can be used as mural/perivascular cells has 
been shown to lead to the formation of leakage resistant and mature vessels36.  
Different cell types, including embryonic fibroblasts78, mesenchymal precursor cells416 and smooth 
muscle cells377, have been used as sources of mural/perivascular cells (Fig. 6.8). Human 
mesenchymal stromal cells are also a good candidate77. These cells have been shown to promote 
blood vessel formation and remodelling both in vitro and in vivo through a paracrine effect2,427. 
They secrete angiogenic, arteriogenic and vasculogenic growth factors2,427. Media pre-conditioned 
with hMSCs for 2 days has been shown to inhibit hypoxia-induced apoptosis in ECs, as well as 
enhance their tubule-forming ability in vitro2. 
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Fig. 6.8 Pre- and post-natal sources of endothelial and mural cells (adapted from 
377
).  
Exposure of hMSCs to hypoxia significantly enhances production of angiogenic growth 
factors2,393,428 and so their paracrine effect on ECs as well168,347. hMSC-pre-conditioned media 
prepared at low pO2 not only significantly enhances proliferation, migration and tubule-forming 
ability of ECs2,427, but also their own migration and tubule-forming ability429. In vivo, transplantation 
of MSCs cultured under hypoxia into murine ischemic limbs led to a significant increase in blood 
vessel density378. 
In the previous chapter, activation of the hypoxia pathway, as well as enhancement of VEGF 
secretion, in hMSCs by exposure to the Co2+-containing BGs was clearly demonstrated. So, 
although exposure to the hypoxia-mimicking BGs reduced EC viability and did not always activate 
the hypoxia pathway, it was hypothesised that co-culture of BG-induced activated hMSCs with ECs 
might enhance the ECs angiogenic potential. In this section, the effect of Co2+-containing BGs on 
the angiogenic potential of the ECs with hMSCs co-culture system will be discussed, beginning 
with an analysis of the effect of the glasses on EC migration. 
6.3.4.1 Effect of Co2+-containing BGs on EC migration 
Migration of both EPCs and ECs is critical for the formation of new blood vessels during either 
vasculogenesis or angiogenesis369. Their migration is chemotactic and one of the main directing 
factors is VEGF369,378. EPCs and ECs are known to express VEGF receptors 1 and 2 (VEGFR1 
and VEGFR2)309,378, which regulate migration towards cells or tissues producing VEGF A 165
309,378.  
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EC migration is often regulated by hypoxia399. Low pO2 activates the HIF-1α pathway, which then 
activates not only the expression of cytokine receptors on ECs309 but also the secretion of 
chemoattractant cytokines by the chemoattractive cells or tissues399. Similarly, CoCl2 has been 
shown to activate VEGF expression as in hypoxic tissues. We hypothesised that the Co2+-
containing BGs could stimulate migration, perhaps by enhancing expression of VEGF receptors in 
ECs. To test this hypothesis, a Boyden chamber-based assay was performed and migration of 
ECs (HUVECs and HMEC-1) towards BG-conditioned DMEM was assessed (Fig. 6.9). 
As BG-conditioned DMEM (DMEM) was used as chemoattractant, 0Co BG-conditioned media 
significantly reduced HUVEC migration (Fig. 6.9 A). Co2+ addition to the BG, however, rescued the 
migration levels to values similar to the control. The presence of BG dissolution ions or the slight 
change of the pH in the media due to BG dissolution could be the cause for decreased HUVECs 
migration. The presence of Co2+ ions could then contradict the BG effect by activation of the 
hypoxia pathway. Although the enhanced HIF-1α activity was not observed in HUVECs after 
exposure to low Co2+ concentration BGs for 8 h, it is possible that HIF-1α activity had peaked at an 
earlier time point, as discussed earlier in this chapter. Or else, the enhancement of the chemotatic 
activity could be regulated by a HIF-1-independent mechanism. In the case of HMEC-1, although 
the Co2+ BG-conditioned media enhanced HIF-1α activity, it had no effect on cell migration (Fig. 
6.9 B). 
In the previous chapter, the hypoxia-mimicking BGs were clearly shown to activate the hypoxia 
pathway in hMSCs (Fig. 5.5), as well as enhance VEGF expression, in a concentration-dependent 
fashion (Fig. 5.6). Although VEGF was the only growth factor assessed, it is probably not the only 
one that is over-expressed by hMSCs when exposed to the BGs. The expression of a cocktail of 
other pro-angiogenic factors, naturally over-expressed in the body in response to hypoxia, may 
also be enhanced. To assess the effect on EC migration of hMSC-secreted paracrine factors, 
secreted in response to the BG, the following experiment was designed. hMSCs were incubated 
with BG-conditioned media and, after 48 h, the media was collected and used as chemoattractant 
on the Boyden chamber-based assay (pc DMEM). VEGF concentration in the media, which 
reflects the variation in activation of the hypoxia response, was assessed after the pre-conditioning 
period (Table 6.2). As expected, VEGF concentration increased in a concentration-dependent way 
with exposure to the Co2+ BGs. The VEGF concentration in the 0Co BG-conditioned media, 
however, was significantly lower than in the control (as seen in Chapter 5). 
Surprisingly, HUVEC migration towards pc DMEM negatively correlated with VEGF concentration 
(Fig. 6.9 A). HUVEC migration was significantly higher with 0Co BG-conditioned media, which had 
the lowest VEGF concentration. The other conditions were similar between them. This effect is not 
completely understood. It may be due to a concentration-dependent effect, which decreases 
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migration when VEGF concentration rises above a specific level. HMEC-1 migration, however, was 
significantly enhanced in the BG-conditioned media, independently of the presence of Co2+ in the 
BG or VEGF concentration on the pc DMEM (Fig. 6.9 B). An immunoassay performed on ECs 
exposed to BG-conditioned EGM-2 showed a drastic decrease in VEGF in the supernatant 
compared to the control even after 4 h of exposure (data not shown). Interestingly, the reduction in 
free VEGF in the media occurred with all the BGs and was independent of Co2+ presence. This 
data suggests BG-conditioned media stimulates expression of a VEGF receptor in ECs or simply 
binding and uptake of the receptor-ligand complex. Only this would explain such a drastic and fast 
decrease in VEGF levels in the media. Thus, the presence of the BG-conditioned media might be 
responsible for the enhanced expression of the VEGF receptors and subsequent enhanced 
migration. 
In summary, a clear effect of the hypoxia-mimicking BG on EC migration directly or through 
activation of the hypoxia pathway on hMSCs was not observed. This could be due to variation of 
pro-angiogenic factors other than VEGF or their receptors in the presence of the BGs. Although 
VEGF is one of the most relevant pro-angiogenic factors and critical for ECs migration, it is not the 
only factor involved. Various other growth factors, including PDGF, play important roles as well378. 
As only VEGF concentration was assessed, variation of other relevant proteins can not be 
predicted, which could maybe explain the behaviour observed. 
Table 6.2 VEGF concentration in the media used as chemoattractant on the migration assay: BG-
conditioned DMEM, EGM-2 and pc DMEM. EGM-2 was used as a positive control. pc DMEM is BG-
conditioned DMEM pre-incubated with hMSCs for 48 h. Prior to use in the migration assay, the media was 
collected and filtered. VEGF concentration on the media was determined using a VEGF immunoassay; each 
sample was assessed in triplicate. The values presented in here are mean ± standard deviation. 
Media [VEGF] (pg/ml) 
BGs-conditioned DMEM 0.0 ± 0.0 
EGM-2 1000.0 ± 50.8 
p
c
 D
M
E
M
 
Control 1077.4 ± 48.1 
0Co BG 789.6 ± 18.3 
NonCB1Co BG 1250.7 ± 31.5 
NonCB2Co BG 1406.5 ± 11.4 
100 μM CoCl2 1498.0 ± 34.8 
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Fig. 6.9 Effect of hypoxia-mimicking BG on EC migration. ECs migration was assessed using a Boyden 
chamber-based assay. ECs from both sources ((A) HUVECs and (B) HMEC-1) were seeded on the 
microporous membrane. BG-conditioned DMEM (DMEM) or BG-conditioned DMEM pre-conditioned with 
hMSCs for 48 h (pc DMEM) were placed in the bottom chamber and migration towards the different 
conditions during a period of 8 h was quantified using a DNA dye. EGM-2 media was used as positive 
control. (*) indicates the difference between the marked bar and the control (cultured with standard cell 
culture media, without any BG) of the same condition is statistically significant. (¥) indicates that the 
difference between the marked bar and the sample treated with the dissolution products of BG without cobalt 
of the condition is statistically significant. (p<0.05) 
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6.3.4.2 Determining the effect of Co2+-containing BGs on tubule formation by ECs 
Evaluation of different conditions and paracrine effect of hMSCs 
The tubule-forming assay is commonly used to assess angiogenic ability in vitro. Before testing the 
effect of the hypoxia-mimicking BGs on EC tubule-forming ability, a series of different experimental 
conditions was assessed. As discussed earlier in this chapter, the cell culture media used can 
strongly affect EC viability and proliferation rates, as well as control their phenotype and behaviour. 
The EGM-2 media is a media that contains several growth factors, including VEGF, hFGF-B, many 
of them know to stimulate not only ECs proliferation, but also pro-angiogenic properties369,378. As 
mentioned earlier, if Co2+-containing BGs have a relatively small influence on EC angiogenic 
potential, then variations induced by the BGs could be negligible if the experiments were 
performed in EGM-2. In addition, as discussed earlier in this section, ECs alone do not generate 
resistant, long-lasting blood vessels377. A source of perivascular cells is critical to stabilise the new 
formed tubules36,377.  
An initial study was then prepared to compare the effect of EGM-2 and DMEM on the tubule-
forming ability of HUVECs, and, simultaneously, assess the effect of a co-culture system of 
HUVECs with hMSCs, the hMSCs as a perivascular cells source. 3D collagen gels were prepared 
in either EGM-2 or DMEM. DsRed-transduced HUVECs were dispersed on the gels either alone or 
with hMSCs (at a ratio of 4:1). In DMEM, an extra condition was tested; hMSCs were seeded on 
the bottom of the well and, after adhesion, the DsRed-HUVECs-containing collagen gel was added 
on top. The tubule-forming ability was assessed using fluorescence microscopy; only the HUVECs 
are visible (Fig. 6.10). 
Clear differences were observed between the two cell-culture media tested. As HUVECs were 
seeded alone, tubule formation was observed in EGM-2 (at day 4 - Fig. 6.10 C), but not in DMEM 
(Fig. 6.10 I-L). In fact, HUVEC viability was shown earlier in this chapter to be significantly reduced 
in DMEM (Fig. 6.6 B). The difference observed was then somehow expected, since, contrary to 
DMEM, EGM-2 contains a cocktail of growth factors, known to stimulate pro-angiogenic behaviour. 
Due to the presence of all the growth factors, the effect of hypoxia-mimicking BGs could then be 
masked in EGM-2. 
Addition of hMSCs to the culture system induced major changes in the HUVEC tubule-forming 
ability, independently of the media used. In EGM-2, tubule morphology was significantly altered. 
When ECs were seeded in a single-culture system, they seemed to aggregate with time and 
connections between those aggregates were observed. However, the structures formed did not 
resemble tubules, as the ones formed when hMSCs were added to the culture system. In addition, 
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at day 7, signs of degeneration of the tubules were observed in the single-culture system (Fig. 6.10 
D), while in the co-culture system the networks formed were stable and robust (Fig. 6.10 H). 
In DMEM, the single-culture system resulted in cell death and tubule formation was never 
observed (Fig. 6.10 I-L). Interestingly, addition of hMSCs to the culture resulted in tubule formation 
at day 4 (Fig. 6.10 O). The same happened when hMSCs were seeded in a bottom layer and were 
not in direct contact with the HUVECs (Fig. 6.10 S). These data strongly suggests that hMSCs not 
only stabilise the tubules by differentiating into smooth muscle cells (SMCs) but, more importantly, 
they induce tubule formation by secreting pro-angiogenic growth factors. 
Similar phenomena have been previously described in the literature. Initial studies have shown that 
injection of MSCs would significantly enhance collateral blood perfusion in damaged tissues430. 
This was initially thought to be caused by incorporation of MSCs in the new vessels formed or 
remodelled, as MSCs have been shown to be able to differentiate into both ECs and SMCs431-434. 
However, the extent of incorporation (of MSCs in the vessels) varies significantly between the 
different studies435-437, which suggests a different mechanism is likely to then be responsible for the 
enhancement observed. Since then, various studies have been performed that demonstrated that 
MSCs secrete a cocktail of pro- and anti-angiogenic growth factors, including Ang-1, FGF-1 and 
FGF-2, HGF, VEGF and many others168. Interestingly, an in vitro study showed that MSC-
conditioned media (instead of MSCs in a co-culture system) significantly reduced EC hypoxia-
induced apoptosis and cell death and their tubule-forming ability was also enhanced347. The effect 
was suggested to be caused by a combination of factors, as addition of antibodies anti-IL-6 and 
anti-VEGF did not attenuate the response347. Activation of the ECs’ response is thought to happen 
via activation of the PI3K-Akt pathway, as addition of a PI3K pathway inhibitor abrogated the ECs’ 
response347. A different study using a similar approach reported enhancement of EC proliferation 
and migration when cultured with MSC-conditioned media168. Plus, in vivo, in a mouse ischemic 
limb model, injection of MSC-conditioned media significantly enhanced flow perfusion and 
ambulatory function and reduced calf atrophy347. The ability of hMSCs to promote blood vessel 
formation and remodelling seems to be mainly due to a paracrine effect, via production of pro- and 
anti-angiogenic growth factors. In our study, the hMSC-related paracrine effect was also clear; the 
tubules formed were not result of hMSCs differentiating into ECs or SMCs. The networks seem to 
be formed only by HUVECs, the fluorescent cells. In addition, the hMSCs paracrine effect was not 
dependent on direct contact between the hMSCs and ECs, since a similar result was obtained 
when hMSCs were cultured on the bottom of the well (Approach C – Fig. 6.10 S). 
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Determining the effect of hypoxia-mimicking BGs on EC angiogenic ability 
Exposure of MSCs to hypoxia has been shown to enhance secretion of pro-angiogenic growth 
factors as VEGF168,169,185,347,352,358-361. In addition, the use of MSCs-conditioned media prepared 
under low pO2 has been shown to significantly enhance the angiogenic potential of ECs both in 
vitro and in vivo168,347. Therefore, exposure of hMSCs to the hypoxia-mimicking BGs could then 
also enhance EC angiogenic potential, since activation of the hypoxia pathway and response in 
hMSCs was achieved (Chapter 5). 
Taking note of the variation caused by the use of different media and addition of hMSCs to the 
culture system, the study continued to assess the effect of the hypoxia-mimicking BGs on the in 
vitro angiogenic ability of HUVECs. 3D collagen gels were prepared and HUVECs were added in a 
single-culture or co-cultured system with hMSCs. BG-conditioned media (EGM-2 or DMEM) was 
added after gelation and the evolution of the culture was followed by up to one week. In this 
section, the results will be discussed separately for the two cell culture media used. 
Determining the effect of hypoxia-mimicking BGs on EC angiogenic ability in EGM-2 
The effect of the BGs-conditioned EGM-2 will be discussed based on the 7 day data point (Fig. 
6.11). EGM-2 media was shown in the previous section to promote tubule formation by HUVECs 
(Fig. 6.10 C-D). However, contrary to what we had hypothesised, addition of BG dissolution ions 
reduced HUVECs tubule-forming ability (Fig. 6.11 A-E). The length and number of tubules formed 
when the gels were incubated with BG-conditioned EGM-2 were significantly reduced (Fig. 6.11 A-
D). The presence of Co2+ ions in the BG did not have any effect; HUVECs tubule-forming ability 
was similar between all BG-conditioned media (Fig. 6.11 B-D). The viability study discussed earlier 
in this chapter showed a significant decrease on HUVEC cell viability when exposed to BG-
conditioned EGM-2 (Fig. 6.4 A and Fig. 6.5 A). The disruption of tubule formation when the gels 
were incubated with BG-conditioned media is then probably caused by reduction of HUVEC 
viability. Addition of hMSCs to the culture system, however, seemed to rescue the HUVEC tubule-
forming ability in the presence of BG-conditioned EGM-2 (Fig. 6.11 F-J). Tubule formation 
occurred to a similar extent on the control, 0Co BG and NonCB1Co BG conditions (Fig. 6.11 F-H). 
The tubules formed had similar morphology and length, as well as similar density. hMSCs are most 
probably producing growth factors that promote HUVECs survival. In the presence of the hypoxia-
mimicking BGs, hMSCs were shown to activate the hypoxia pathway and significantly enhance 
VEGF production (Fig. 5.5 and Fig. 5.6). A 1.5 to 2 fold increase in VEGF production was observed 
with NonCB1Co BG-conditioned media (Fig. 5.6). Moreover, VEGF was probably not the only 
protein enhanced by exposure to Co2+ BGs. Expression of a series of other pro-angiogenic and 
survival factors, including bFGF, PDGF and PGF, must also have been enhanced, as it has been 
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shown to be increased by exposure to CoCl2 
184. This cocktail of factors produced by hMSCs, 
previously shown to be critical for both EC survival and stimulation of angiogenesis79,358, must then 
be the responsible for the maintenance of the HUVEC viability and tubule-forming ability under 
exposure to BG-conditioned EGM-2. This is in agreement with data reported by Hung et al., that 
showed MSCs-conditioned media prepared under hypoxia protects ECs from hypoxia-induced 
apoptosis347. When the gels were treated with the BG- and CoCl2-conditioned media with higher 
Co2+ content, however, hMSCs were not able to preserve the HUVEC tubule-forming ability 
anymore (Fig. 6.11 I-J). In these conditions the Co2+ toxic effects probably prevailed. 
 
Chapter 6. Evaluation of Effect of Hypoxia-Mimicking BGs on Endothelial Cells and in vitro Angiogenisis 
 
Hypoxia-mimicking bioactive materials for skeletal tissue engineering 
 
173 
 
Fig. 6.11 Effect of hypoxia-mimicking BG-conditioned media on in vitro angiogenesis: tubule-forming assay. 
The tubule-forming ability of HUVECs exposed to the different hypoxia-mimicking BG-conditioned EGM-2 
was assessed after 7 days in 3D collagen gels both in the absence (HUVECs - approach A) and presence 
of hMSCs (HUVECs + hMSCs – approach B). See Fig. 6.3 for schematic representation.  
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Determining the effect of hypoxia-mimicking BGs on EC angiogenic ability in DMEM 
The results obtained when gels were prepared and incubated with BG-conditioned DMEM are 
illustrated in Fig. 6.12. To better demonstrate the effect of the Co2+-containing BGs in DMEM, the 4 
day exposure time was chosen. As discussed in the previous section, in a single-culture system in 
DMEM tubule formation did not occur and exposure to the Co2+-containing BG- or CoCl2-
conditioned DMEM did not enhance the HUVEC tubule-forming ability (Fig. 6.12 A-E). Addition of 
hMSCs to the culture system stimulated the HUVEC in vitro angiogenic ability in a paracrine 
manner (Fig. 6.12 O). Exposure to Co2+-containing BGs, however, and contrary to our hypothesis, 
cancelled the effect of the hMSCs and inhibited tubule formation (Fig. 6.12 H-I). Tubule formation 
was also inhibited by exposure to CoCl2-conditioned DMEM (Fig. 6.12 J), which suggests this was 
a Co2+-induced toxicity effect. HUVEC tubule-forming ability was maintained in 0Co BG-
conditioned DMEM (Fig. 6.12 G). In order to avoid Co2+-induced toxicity, a third approach was 
tested (Approach C). Human MSCs were seeded on the bottom of the well plates and BG-
conditioned DMEM was added after adhesion. The cells were incubated for 48 h with the BG-
conditioned media to activate the hypoxia pathway and stimulate growth factor production. Before 
adding the collagen gel with the HUVECs to the wells, the media was removed and thus, most of 
the toxicity-inducing agent (Co2+ ions). The hypoxia pathway should be kept active, even after 
removal of the stimulus. In this experimental condition, HUVEC tubule-forming ability was 
maintained when gels were incubated with the 0Co and NonCB1Co BG-conditioned media (Fig. 
6.12 L-M). When higher Co2+ concentrations were used, however, the Co2+ toxic effect was not 
avoided. Tubule formation was not observed and that was probably due to the presence of a 
residual amount of Co2+ ions in culture. 
Chapter 6. Evaluation of Effect of Hypoxia-Mimicking BGs on Endothelial Cells and in vitro Angiogenisis 
 
Hypoxia-mimicking bioactive materials for skeletal tissue engineering 
 
175 
 
Fig. 6.12 Effect of hypoxia-mimicking BG-conditioned media on in vitro angiogenesis: tubule-forming assay. 
The tubule-forming ability of HUVECs exposed to the different hypoxia-mimicking BG-conditioned DMEM 
was assessed after 4 days in 3D collagen gels both in the absence (HUVECs - approach A) and presence 
of hMSCs (HUVECs + hMSCs – approach B and HUVECs + pc hMSCs – approach C). See Fig. 6.3 for 
schematic representation. 
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The effect of Co2+ ions on ECs is rather controversial in the literature. Some authors discuss the 
fact that, although Co2+ ions can enhance HIF-1α activity and VEGF production on ECs, their 
tubule-forming ability in vitro is not enhanced by Co2+ 181. Others, however, have shown enhanced 
tubule formation after exposure to CoCl2 
183. Contrary to what we had hypothesised, the hypoxia-
mimicking BGs tested here were not able to enhance the angiogenic potential of ECs either alone 
or through the activation of the hypoxia pathway in hMSCs. The toxic effect of Co2+ seemed to 
prevail, although in the presence of Co2+-pre-activated hMSCs toxicity was significantly reduced. 
In vivo studies, however, are a cause of optimism. Administration of CoCl2 solutions in rats has 
been shown to reduce the number of apoptotic cells and enhance proliferation of ECs in 
tubulointestinal injuries190. In addition, enhanced angiogenesis and bladder growth were also 
observed after administration of a CoCl2 solution in rats, through activation of the hypoxia 
pathway189. In vivo, Co2+ ion toxicity is probably reduced due to body fluid flow, which will 
significantly reduce ion concentrations and local pH changes.  
Bioactive glasses have been reported to promote angiogenesis both in vitro and in vivo (reviewed 
in 391). Enhanced expression of the pro-angiogenic cytokine VEGF by ECs or fibroblasts has been 
reported in the presence of BG or their dissolution ions258,259,310,438-440, as well as enhanced EC 
proliferation and tubule-forming ability258,259,438. In addition, in vivo studies using BG particles 
incorporated in collagen or polymer scaffolds have shown enhanced vascularization259,310,438-441. In 
our study, however, the 0Co BG did not increase the angiogenic potential of ECs or any of the 
other cell types assessed. Enhancement of VEGF by 0Co BG was not observed in any of the cell 
types tested, including SaOs2 and hMSCs (Chapters 4 and 5). Plus, in vitro tubule-forming ability 
of ECs was also not enhanced by exposure to the 0CO BG either in the presence or absence of 
hMSCs. The difference between the studies could be due to the use of slightly different BG 
compositions or simply to the fact that different cell types were used. In addition, the results from in 
vitro and in vivo experiments can not be directly compared. Those studies, however, justify the 
enhancement of angiogenic potential with the increased expression of VEGF. As the enhancement 
of VEGF expression is significantly higher when cells are exposed to the hypoxia-mimicking BGs, 
the use of these BGs in vivo might show greater potential. 
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6.4  CONCLUSION 
The formation of blood vessels is currently one of the most critical challenges of regenerative 
medicine. In the body, the angiogenic process is regulated by a cocktail of pro- and anti-angiogenic 
factors orchestrated in a precise spatial and temporal way369,377,378 and one of its main stimuli is 
hypoxia2,399. Hence, in this chapter the effect of the hypoxia-mimicking BGs on ECs viability and in 
vitro angiogenic ability was discussed. 
Although the sensitivity of different cell types was different, viability of HUVECs and HMEC-1 was 
significantly reduced by Co2+-containing BGs in a concentration-dependent manner. After 7 days of 
exposure to the BGs, only the 0Co BG was able to maintain cell viability and the use of a cell 
culture media with no growth factors added enhanced the toxic effect. Activation of the hypoxia 
pathway was demonstrated in both cell lines tested. In HUVECs, however, only the BGs with high 
Co2+ content, also shown to be toxic at very early time points, showed increased HIF-1 activity 
after 8 and 24 h of exposure. 
Enhancement of the HIF-1 DNA-binding activity does not necessarily assure activation of an 
angiogenic response. Therefore, the effect of the hypoxia-mimicking BGs on the in vitro chemotatic 
and tubule-forming abilities of ECs was assessed. Migration of ECs was not enhanced by either 
BG-conditioned media or hMSC-pre-conditioned BG-conditioned media. The in vitro tubule-forming 
ability of HUVECs was significantly reduced; exposure to BG disrupted network formation in both 
media tested, EGM-2 and DMEM, and, addition of Co2+ to the BG had even more severe effects. 
Addition of hMSCs to the culture system clearly enhanced the angiogenic potential of the ECs. 
Migration was increased towards hMSC-conditioned media and tubule formation occurred even 
when DMEM was used. The paracrine effect of hMSCs was clearly observed. However, activation 
of the hypoxia pathway in hMSCs by the BGs was not enough to suppress the Co2+-induced 
toxicity on ECs. The Co2+-containing BGs not only did not enhance in vitro angiogenesis, as they 
even reduced it when Co2+ ions were present.  
However, these results can not be simply translated to an in vivo situation. In vivo, Co2+ toxicity 
would probably be reduced, which would increase the angiogenic potential of the hypoxia-
mimicking BGs. In vivo studies performed with BGs with no Co2+ ions or with CoCl2 solutions 
suggest there is great potential for the Co2+-containing BGs.  
In this chapter, the paracrine effect of hMSCs on ECs tubule-forming ability was shown. In 
addition, the ability of the Co2+-containing BGs to activate the HIF-1 pathway and subsequent 
responses, as enhancement of the expression of the pro-angiogenic factor VEGF, on hMSCs was 
also demonstrated in the previous chapter. The implantation of hMSCs and ECs together would 
then probably be the best approach to promote angiogenesis using the hypoxia-mimicking BGs. 
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The NonCB1Co and NonCB2Co BGs are the most promising Co2+-containing BGs, since these 
compositions were shown to significantly enhance HIF-1 activity and activate the subsequent 
cellular responses while maintaining cell viability. The assessment of the effect of these two 
hypoxia-mimicking BGs on the angiogenic potential of a construct containing MSCs and ECs in 
vivo would be of great interest. 
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7.1 INTRODUCTION 
In the present chapter, the incorporation of the hypoxia-mimicking BGs into 3D scaffolds is 
described. As collagen is one of the main extracellular matrix (ECM) components, various collagen 
scaffolds have been extensively studied for TE applications. Low antigenicity, the fact that collagen 
promotes cell attachment and proliferation and the ease with which the mechanical and structural 
properties, as well as degradation rates, can be tuned are some of the advantages the collagen 
scaffolds present. 
Highly porous collagen-glycosaminoglycan (CG) freeze-dried scaffolds were chosen as the Co2+ 
BG delivery system. These constructs are already in use for skin TE applications and various 
studies have assessed their effect on conjunctiva and peripheral nerve regeneration442-445. In 
addition, various studies have shown that CG scaffolds support differentiation of progenitor cells 
through both the osteogenic and chondrogenic lineages446-451. 
The structural and mechanical properties of CG scaffolds, as well as their composition, can easily 
be tailored to specific applications. Depending on the tissue of interest, the macromolecules used 
(collagen and glycosaminoglycans) can be varied. If the scaffolds are intended for bone TE, 
collagen type I should be used446,447. If, however, the scaffolds are intended for cartilage TE, 
collagen type II scaffolds have been shown to improve chondrogenic differentiation446,448-451.  
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The pore size is also extremely important. Optimal pore size, which permits maximal cell migration 
and adhesion as well as matrix deposition, has been shown to vary with different cell types452,453. 
Also, pores > 300 µm have been shown to be essential to permit vascularisation452,454-456. 
Fabrication of scaffolds with a wide range of pore sizes has been reported in the literature457,458. 
Variations in the fabrication process can be used to tailor the pore size on CG scaffolds. Pore size 
has been demonstrated to increase with increasing freezing temperature457 as well as with 
decreasing glycosaminoglycans (GAG) content447. 
The mechanical properties of these constructs can also be easily tailored. Collagen and GAG 
concentrations, as well as different cross-linking methods, have been shown to alter both 
compressive and tensile modulus of the scaffolds as well as their permeability. CG scaffold 
degradation has also been extensively studied459,460 and shown to be non-toxic and adjustable 
using different cross-linking methods. Additionally, CG scaffolds are produced using simple 
fabrication and sterilisation methods. 
We hypothesised that collagen freeze-dried scaffolds may be a very attractive Co2+ BG delivery 
system. The incorporation of Co2+-containing BGs in CG scaffolds should still allow release of 
hypoxia-mimicking ions (Co2+), and in addition an extra level of control over Co2+ ions release is 
achievable (BG concentration in the scaffolds). The activation of the hypoxia response by Co2+ is 
probably maintained and Co2+ BG toxicity avoided. Moreover, their mechanical properties are 
potentially easily tailorable for specific applications, as in the case of cartilage TE. In this chapter, 
the incorporation of hypoxia-mimicking BG in collagen freeze-dried scaffolds will be discussed, as 
well as the response of hMSCs seeded in the scaffolds.  
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7.2 MATERIALS AND METHODS 
7.2.1 Scaffold fabrication 
Collagen scaffolds were fabricated using a lyophilisation (freeze-drying) method457. Briefly, 1 wt% 
collagen suspension was produced by blending fibrillar collagen (Integra, Plainsboro NJ, USA) with 
a 0.5 M aqueous acetic acid solution. 20 mL collagen suspension was then degassed prior to the 
addition of 0.5 mL of bioactive glass (BG) suspended in distilled water at a concentration of 0.14 
g/mL. 10 mL of 0.5 M acetic acid solution was added to the blending suspension, followed by 
another 0.5 mL of the BG suspension. Finally, another 10 mL of 0.5 M acetic acid solution was 
added to yield a final collagen concentration of 0.5 wt%. 1 mL of the collagen-BG suspension was 
pipetted into each well of a 24-well plate and placed in a -20 °C freezer until frozen. The 24-well 
plate was then placed in the chamber of the freeze-dryer (Advantage EL, Vir-Tis Co., Gardiner, 
NY, USA) and the collagen-BG suspension was lyophilised for 24 h at a final freezing temperature 
of -40 °C. After freeze-drying the scaffolds were cross-linked using a dehydrothermal treatment 
(DHT) at 105 °C under a vacuum of 50 mTorr for 24 h. (The scaffolds used in this study were 
prepared by Sonia Partap at the Royal College of Surgeons, in Dublin, Ireland) 
7.2.2 Scaffold preparation for SEM 
Coll-BG scaffolds were sputter-coated with gold at 30 mA for 4 min under vacuum for scanning 
electron microscopy (SEM). Silver paint was also applied to improve the samples’ conductivity and 
they were then viewed using a Jeol JLV5610LV SEM (Carl Zeiss STM Lta.) operated at 15 kV. 
7.2.3 Ion dissolution from the Coll-BG scaffolds in Tris buffer and DMEM 
For the dissolution study in Tris buffer, two scaffolds of each type were placed in a 50-mL 
centrifuge tube together with 40 mL of Tris buffer and incubated rolling at room temperature. At 
specific time points, 3 mL samples were collected and subjected to ICP-OES. For the dissolution 
study in DMEM, the Coll-BG scaffolds were placed in 24-well plates (1 scaffold per well) and 500 
μL of DMEM were added per well. Media was replaced at days 1, 2, 3, 5 and 7 for fresh DMEM. 
The media removed was filtered (0.2 μm filter) and stored at 4 °C. After 7 days, the media 
collected at the different time points was subjected to ICP-OES to determine the concentration of 
the different ions released from the Coll-BG scaffolds. In both studies the ions assessed were Si, 
Ca, Na, P, and Co.  
7.2.4 Cell culture 
Human mesenchymal stromal cells (hMSCs) were purchased from Cambrex as in Chapter 5. The 
cells were expanded in Dulbeccos’ modified eagle medium (DMEM, from GIBCO®) with 10% (v/v) 
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FBS (GIBCO®) and 1% (v/v) penicillin-streptomycin (GIBCO®). Initial culture was performed in 75-
cm2 flasks at 37 °C in a humidified atmosphere of 95% air with 5% CO2 and supplied with fresh 
medium every 2-3 days. At 90% confluence, cells were detached using trypsin-EDTA (GIBCO®), 
and cell count was determined in a haemocytometer. Cells were resuspended to the appropriate 
concentration for seeding in complete medium. 
Various seeding methods were tested to achieve a homogeneous distribution of cells throughout 
the scaffolds. For every method used the scaffolds were pre-conditioned with DMEM for different 
periods of time.  
Method A - vacuum: 20 mL of a cell suspension (106 cells/mL) together with the scaffolds was 
placed inside a 50-mL capped syringe. The plunger of the syringe was retracted to create a 
vacuum inside the syringe and promote perfusion of the scaffolds with the cell suspension. The 
scaffolds were then removed from the suspension and placed in 24-well plates. 500 µL of DMEM 
were added per well and the plates were placed at 37 °C in a humidified atmosphere of 95% air 
with 5% CO2.  
Method B - dropwise: scaffolds were placed in a 24-well plate and a 50-µL drop of cell suspension 
(14x106 cells/mL) was placed on top of each scaffold. Scaffolds were incubated at 37 °C and 1 h 
after, they were turned up-side-down. Another 50-µL drop of cell suspension (14x106 cells/mL) was 
placed on the other side of the scaffolds and they were again incubated at 37 °C for 1 h. Finally, 
500 µL of DMEM were added per well and the plates were placed at 37 °C in a humidified 
atmosphere of 95% air with 5% CO2.  
Method C - rotator: a suspension of cells (106 cells/mL) was placed inside the rotator as well as the 
scaffolds (Fig. 7.1). The rotator was then placed at 37 °C rotating at 170 rpm. After 2 h, the 
scaffolds were removed from the rotator and placed in 24-well plates, 500 µL of DMEM were 
added per well and the plates were placed at 37 °C in a humidified atmosphere of 95% air with 5% 
CO2. 
 
 
Fig. 7.1 Rotator used to seed hMSCs 
on Coll-BG scaffolds. The scaffolds 
were immobilised on the central axes of 
the rotator and the cell suspension was 
added to the flask. A magnet on the 
bottom of the flask allowed control of 
the rotation speed. 
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7.2.5 Histological staining 
Histological staining was used to assess the infiltration of cells through the scaffolds. The Coll-BG 
scaffolds were seeded using the methods described above and incubated at 37 °C in a humidified 
atmosphere of 95% air with 5% CO2. After 24 h in culture, the constructs were washed twice in 
PBS and fixed with 10% (v/v) formalin over night. The scaffolds were then embedded in paraffin 
wax and sectioned (4-10 μm sections). Two sections of each were stained with haematoxylin and 
eosin (H&E). 
7.2.6 alamarBlue® assay 
The alamarBlue® assay was used to assess cell viability of the hMSCs seeded on the Coll-BG 
scaffolds. The assay was performed as indicated by the manufacturer and described in Chapter 5. 
Briefly, hMSCs were seeded on the Coll-BG scaffolds (2x104 cells/cm2, which corresponds to 
1.6x104 cells/scaffold). At specific time points (1, 2, 4, 7 and 14 days), cell-culture medium was 
removed and the scaffolds were washed with 500 µL of PBS. The scaffolds were then transferred 
to a new well plate and 500 µL of 10% (v/v) alamarBlue® in DMEM with no phenol red (GIBCO®) 
was added per scaffold, and the scaffolds were incubated at 37 °C for 2 h. 100 µL of the reaction 
product was then transferred to a black 96-well plate in duplicates and fluorescence was measured 
at an excitation wavelength of 540 nm and an emission wavelength of 585 nm using a microplate 
reader (SpectraMax M5, Molecular Devices). The scaffolds were finally washed with 500 µL of 
PBS, placed on the initial well plate, 500 µL of fresh DMEM was added per well and the scaffolds 
were incubated at 37 °C in a humidified atmosphere of 95% air with 5% CO2 until the next time 
point. 
7.2.7 Actin and DAPI staining 
After 1 and 7 days in culture, Coll-BG scaffolds seeded with hMSCs were washed with PBS twice 
and fixed with 4% (v/v) paraformaldehyde (Sigma®) in deionised H2O for 15 min at room 
temperature. The scaffolds were washed again three times with PBS and stained with Alexa Fluor 
568 actin antibody (Sigma®, 1:40 in 1% (w/v) BSA) for 20 min at room temperature. A 1% (w/v) 
BSA solution was used to wash the scaffolds three times before they were stained with DAPI 
(Sigma®, 1:50000 in 1% (w/v) BSA) for 5 min at room temperature. The scaffolds were then 
washed with PBS, before they were viewed using a confocal epifluorescence microscope (Zeiss 
LSM-510 inverted confocal microscope, Carl Zeiss STM Lta.).   
7.2.8 Analysis of VEGF expression 
The cell-culture medium collected from the scaffolds at the different time periods (days 1, 2, 4, 7 
and 14) was used to assess VEGF production by ELISA (Quantikine: Human VEGF immunoassay, 
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R&D Systems®). In short, cell-culture supernatant samples or standards together with assay 
diluent were added to the provided 96-well plate (pre-coated with a monoclonal antibody specific 
for VEGF). Any VEGF present was bound by the immobilised antibody. After washing away any 
unbound substances, an enzyme-linked polyclonal antibody specific for VEGF was added to the 
wells. Following a washing step to remove any unbound antibody-enzyme reagent, a substrate 
solution was added to the wells and colour developed in proportion to the amount of VEGF bound 
in the initial step. The colour development was then stopped and the intensity of the colour was 
measured in a microplate reader (SpectraMax M5, Molecular Devices) at 450 nm with a reference 
wavelength of 540 nm.  
7.2.9 Statistical analysis 
All experimental data shown are expressed as mean±SD and were obtained from experiments 
performed in quadruplicates. All data analysis was performed in MS Excel. Statistical analysis was 
by one-way analysis of variance (ANOVA) using multiple comparisons (Bonferroni test) and p-
values less than 0.05 were considered significant. Statistical analysis was performed using SPSS® 
(IBM®).  
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7.3 RESULTS AND DISCUSSION 
The previous chapters describe the synthesis, characterisation and biological effects of the 
hypoxia-mimicking BGs. In this chapter the possibility of incorporating the BGs into scaffolds that 
would facilitate the in vivo implantation of the glasses in a 3D scaffold format as well as the 
assessment of their effect on hMSCs viability and activation of the hypoxia pathway is discussed. 
7.3.1 Collagen scaffolds: incorporation of BG during fabrication 
Initially the incorporation of BG into the collagen scaffolds presented some problems. Collagen 
requires a very acidic pH (approximately 3.2) to be kept in solution. Dissolution of BG, however, 
even in acetic acid causes a drastic pH increase that triggers collagen precipitation within a few 
seconds of BG addition. Various different methods were tested to avoid collagen precipitation. BG 
was pre-incubated in PBS or acetic acid for 24 h to avoid the initial burst of ions release. The 
controlled freezing rate shown to create a more homogeneous pore structure was replaced by 
immediate freezing at -40 °C. The processing of the collagen slurry was shortened, passing over 
some steps such as degassing, for example. However, most of the methods tested were not 
successful, the collagen would still precipitate and, when it didn’t, BG particle distribution on the 
scaffolds was extremely heterogeneous (Table 7.1). 
In collaboration with Prof. Fergal O’Brien’s group (Royal College of Surgeons, Dublin, Ireland), a 
new method to incorporate the Co2+ BG into the collagen scaffolds during the fabrication process 
was developed. The effect of a series of variables was evaluated including BG-particle size and 
concentration. The initial studies reported on Table 7.1 were performed during the time I spent in 
Prof. Fergal O’Brien’s laboratory. The optimization of the process, however, was continued by a 
post-doc in his group. However, as the method was developed in Prof. O’Brien’s group it will not be 
discussed in detail here.  
The scaffolds fabricated were then analysed in our lab. SEM was performed to assess the 
presence of BG in the scaffolds and their effect on scaffold morphology (Fig. 7.2). The presence of 
the BG particles on the scaffolds is clear. Especially at higher magnification, the BG particles are 
clearly observed and appear to be homogeneously distributed on the smooth collagen surfaces, 
both on the surfaces and on the centre of the scaffolds (Fig. 7.2 F and H, respectively). In general, 
the BG particles are smaller than 5 µm. The scaffold structure does not seem to be significantly 
affected by BG addition. A more extensive structural analysis of the scaffolds and the effect of BG 
addition was not performed in our lab. However, Prof. O’Brien’s group showed that BG addition 
slightly decreases scaffold porosity (although maintaining high degrees of porosity, > 97%). In 
addition, BG incorporation significantly enhances the scaffolds’ mechanical properties.  
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The compressive moduli of the composites were significantly improved by the addition of bioactive 
glass. It was observed that the moduli increased with increasing BG concentration (Fig. 7.3). The 
results suggested that the BG particles reinforced the scaffold, and as more particles were added 
the stiffer the scaffold became. However, at a certain particle size (100 µm) and higher 
concentrations (70 mg per scaffold (1ml)) the particles may have prevented scaffold formation by 
not allowing collagen network formation to occur fully resulting in a reduction in compressive 
modulus. This effect was observed for all of the collagen only scaffold variants (Fig. 7.3 A) and for 
the positive collagen-glycosaminoglycan (Col-GAG) control (Fig. 7.3 B) where lower moduli were 
observed. In these cases, the optimal BG concentration appeared to be 28 mg per scaffold (1ml) 
(Fig. 7.3 A). In comparison, for the Col-GAG scaffolds the optimal BG concentration was 70 mg per 
scaffold (1ml) (Fig. 7.3 B). The difference in optimal concentrations of BG for the two scaffold 
variants may be attributed to the presence of glycosaminoglycan (GAG). It was hypothesized that 
the Co2+-containing BG particles which have a positive charge, may possibly be interacting with 
GAG (which has a negative charge) causing the formation of a tighter and stronger network 
allowing for the incorporation of more BG thus resulting in a stiffer scaffold461. 
Table 7.1 Different approaches tested to incorporate BGs on the collagen scaffolds, avoiding collagen 
precipitation after addition of BG to the collagen slurry. 
Approaches: Results: 
Preparation of a BG suspension in 0.05 M acetic acid before adding 
the suspension to collagen slurry. Preparation of scaffolds using a 
controlled freezing rate. 
Collagen precipitated within 1 min. 
Addition of BG directly to the collagen slurry. Preparation of scaffolds 
using a controlled freezing rate. 
Collagen precipitated within 30 sec. 
Increasing the acetic acid concentration in the slurry to 0.5 M. 
Preparation of scaffolds using a controlled freezing rate. 
Collagen precipitated within 1 min. 
Pre-incubation of BG in PBS for 2h to 24h before adding it to the slurry. 
Preparation of scaffolds using a controlled freezing rate. 
Collagen precipitated within 1 min. 
Pre-incubation of BG in 0.05 M acetic acid for 2h to 24h before adding 
it to the slurry. Preparation of scaffolds using a controlled freezing rate. 
Collagen precipitated within 1 min. 
Addition of a sodium acetate buffer (pH 3.2) to the collagen slurry 
before adding the BG suspension. Preparation of scaffolds using a 
controlled freezing rate. 
Delayed collagen precipitation, but  did not 
avoid it. 
Flash freezing the collagen slurry at -40 °C immediately after BG 
addition. 
Collagen precipitation was avoided 
/inhibited but BG distribution in the 
scaffolds was very heterogeneous. 
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Fig. 7.2 Incorporation of Co
2+
 BG in collagen scaffolds: SEM pictures of the collagen scaffolds without (A, B, 
C, D) and with BG (E, F, G, H). Figures A, B, E and F show the surface of the scaffolds at both low (100x: 
(A) and (E)) and high (1000x: (B) and (F)) magnifications. Figures C, D, G and H show the centre of the 
scaffolds also at both low (100x: (C) and (G)) and high (1000x: (D) and (H)) magnifications. The BG particles 
are clearly visible throughout the scaffolds.  
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Fig. 7.3 Compressive moduli (kPa) of (A) collagen only and (B) Collagen-glycosaminoglycan (Col-GAG) 
bioactive glass (BG) composites. Negative controls (Neg. Ctrl) are collagen only or CG scaffolds with no 
bioactive glass. Positive controls (Pos. Ctrl) are collagen only or CG scaffolds with cobalt-free bioactive 
glass. BG with two different particle size were added to the scaffolds: <38 μm (38) and <100μm (100). The 
high concentration (H) refers to scaffolds having 70 mg BG per scaffold, medium concentration (M) refers to 
scaffolds having 28 mg BG per scaffold and the low concentration (L) refers to scaffolds having 14 mg BG 
per scaffold (n=3). (p<0.001) (Data collected by S. Partap in the laboratory of Prof. O’Brien, Dublin, Ireland). 
During scaffold fabrication, BG was suspended in acetic acid, which causes BG dissolution at a 
quicker rate than in Tris buffer, deionised H2O or even cell-culture media (data not shown). To 
assess ion release from the Coll-BG scaffolds fabricated, a dissolution study in Tris buffer was 
prepared. Two scaffolds of each type were incubated in 40 mL of Tris buffer for 24 h at room 
temperature. At various time periods, 3 mL of buffer was collected and the ion concentration was 
analysed by ICP-OES (Fig. 7.4). Comparison of the ions released from the control scaffolds from 
the Coll-BG scaffolds clearly proves the presence of BG in the scaffolds. The scaffolds containing 
BG release Si4+ and Ca2+ and the control scaffolds do not (Fig. 7.4 A and B). The NonCB4Co BG 
scaffolds appear to release higher quantities of both Si4+ and Ca2+ than the 0Co BG scaffolds. 
However, the differences are minor. Co2+ release was also confirmed (Fig. 7.4 C). The absolute ion 
concentrations in Tris buffer are not relevant for the cell culture studies presented later in the 
chapter. In the study presented in this chapter, two scaffolds were incubated in 40 mL of Tris 
buffer. In subsequent cell-culture experiments, 500 µL of cell-culture media will be added per 
scaffolds. The dissolution rates will then be very different both because the solution composition 
and the amount of solution per scaffold are not comparable. These data, however, confirm the 
presence of the hypoxia-mimicking BGs in the collagen scaffolds and prove there is still release of 
relevant ions from the composite scaffolds fabricated. The BGs’ ability to release ions at a 
controlled rate is not impaired by the scaffold fabrication process. 
 
Chapter 7. Incorporation of Hypoxia-Mimicking Bioactive Glasses in Collagen Scaffolds 
 
Hypoxia-mimicking bioactive materials for skeletal tissue engineering 
 
189 
 
Fig. 7.4 Dissolution study in Tris buffer: two scaffolds (1 cm diameter) were incubated in 40 mL of Tris buffer 
for 24 h. At specific time points, 3-mL samples were collected and ICP-OES was performed to assess the 
concentration of the different ions in Tris buffer.  
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7.3.2 Collagen-BG scaffolds: Testing seeding methods 
To perform a 3D cell study, a high and homogeneous cell distribution throughout the scaffold is 
essential. Three different seeding methods were tested to achieve such a cell distribution. The 
collagen scaffolds were seeded using vacuum, dropwise and using a rotator. To assess cellular 
distribution inside the scaffolds, the constructs were fixed 24 h after they were seeded with 
hMSCs, embedded in paraffin, sectioned and stained with haematoxylin and eosin (H&E) (Fig. 
7.5). None of the methods tested resulted in homogeneous cell distribution. When scaffolds were 
seeded using the vacuum and dropwise methods (Fig. 7.5 C, D and E, F, respectively), cells were 
only seen on the scaffold surface; no cells were found in the centre of the scaffolds (Fig. E3C-F). 
Comparison of the two seeding methods however, shows the seeding density is considerably 
higher if scaffolds are seeded dropwise. When scaffolds were seeded using the rotator, cells were 
observed in deeper regions of the scaffolds (Fig. 7.5 G-J). The number of cells in the centre of the 
scaffolds, however, is dependent on the time and speed used for the seeding process. It is clear 
that higher speed and longer seeding processes increase the number of cells in the centre of the 
scaffolds (Fig. 7.5 G-J). Although cells reach the centre of the scaffolds when the rotator is used, 
their distribution is very heterogeneous (Fig. 7.5 I-J). Cell aggregates were observed in some 
regions and other regions have no cells. The result achieved was considered insufficiently reliable 
for a 3D study.  
A literature search was performed to find seeding methods which result in a homogeneous cell 
distribution. However, to our knowledge, no other studies have been published showing 
homogeneous cell distribution in freeze-dried collagen scaffolds with a similar pore size. A study 
performed on CG scaffolds with pores > 300 µm achieved homogeneous cell distribution 
throughout the scaffolds458. In this study however, cells only reach the centre of the scaffolds after 
7 days in culture and the pore size of their scaffolds is significantly larger. For this reason, 
assessment of the effect of Coll-BG scaffolds on hMSCs described later in this chapter was 
performed in 2D and cells were seeded using method B – dropwise. 
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Fig. 7.5 Three different seeding methods were tested to achieve homogeneous hMSC distribution on the 
Coll-BG scaffolds. (A) and (B) control scaffold with no cells; (C) and (D) scaffold seeded using vacuum; (E) 
and (F) scaffold seeded dropwise; (G) and (H) scaffold seeded with rotator at 170 rpm for 2 h; (I) and (J) 
scaffold seeded with rotator at 700 rpm for 16 h. After 24 h in culture the scaffolds were fixed, embedded in 
paraffin and sectioned, before staining them with eosin and haematoxylin. The scaffolds are stained in pink 
and cell nuclei in purple.  
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High concentrations of Co2+, as well as Si4+, have previously been shown to be toxic for cells (see 
Chapters 4 and 5). Also, activation of the hypoxia pathway in hMSCs has been proven to require 
Co2+ concentration to be within a specific range. So, before any cell-culture study was performed, 
the release profile of the different BG ions from Coll-BG scaffolds in DMEM was studied. Coll-BG 
scaffolds were placed in tissue-culture plates and 500 µL of DMEM were added per scaffold. At 
days 1, 2, 3, 5 and 7 cell-culture medium was replaced with fresh DMEM and the ion concentration 
in the medium removed was determined by ICP-OES (Fig. 7.6). Si4+ concentration was kept 
constant at approximately 50-70 ppm throughout the period tested (Fig. 7.6 A). Although very 
similar, the amount of Si4+ released from the NonCB4Co scaffolds was higher than from 0Co 
scaffolds, as previously seen on the dissolution study in Tris buffer. This difference should not 
have a significant effect on cell viability and behaviour. Ca2+ release however, significantly 
decreases after day 1 (Fig. 7.6 B). Initial Ca2+ concentration is approximately 400 ppm and at day 2 
it is already lower than 200 ppm. After day 3, the Ca2+ concentration in DMEM incubated with Coll-
BG scaffolds is equivalent to Ca2+ concentration in DMEM. Ca2+ release seems to stop after 2 days 
in DMEM, and Co2+ concentration in DMEM follows a similar trend; the effect, however, is not as 
severe as with Ca2+ (Fig. 7.6 C). Initial Co2+ release is extremely high, approximately 90 ppm. At 
day 2, it decreases to half that of the initial release rate, and continues decreasing at later time 
points. Yet, after 7 days in DMEM, Co2+ release is still significant. After 1 week in cell-culture 
media, the Co2+ concentration achieved is approximately 10 ppm, which is equivalent to the Co2+ 
concentration in the NonCB2Co BG conditioned DMEM used in Chapter 5 (see Table 7.2). As this 
Co2+ concentration was shown in Chapter 5 to be able to activate the hypoxia pathway and 
response in hMSCs and to be non-toxic, it was decided to pre-incubate the Coll-BG scaffolds for 1 
week in DMEM prior to hMSC seeding, replacing cell-culture media three times during this period. 
Pre-incubation of Coll-BG scaffolds for one week is not ideal. During this period, the surface of the 
scaffolds will definitely change, proteins will be adsorbed and the BG dissolution might significantly 
decrease in the subsequent period due to the formation of a hydroxyapatite layer on its surface. If 
a new batch of Coll-BG scaffolds were prepared, BG concentration would be significantly reduced. 
Scaffold optimisation is required. 
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Fig. 7.6 Dissolution study in DMEM. Scaffolds were incubated in DMEM (500 µL of DMEM per scaffold). 
Cell-culture media were replaced with fresh DMEM at days 1, 2, 3, 5 and 7. ICP-OES was performed in the 
media removed to assess the concentration of the different ions released from the Coll-BG scaffolds.  
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Table 7.2 Concentration of the different ions (Si, Ca, Na, P, Co) in BG-conditioned DMEM used in Chapter 5 
(in ppm), determined by ICP-OES. The values presented here are the average ± standard deviation of all 
batches used for the experiments presented in this chapter. Table adapted from Chapter 5 for better 
comprehension. 
 Si Ca Na P Co Co (µM) 
DMEM 0.0 ± 0.2 81.3 ± 6.6 2920 ± 420 39.1 ± 3.0 0.03 ± 0.05 0.51 ± 0.85 
0Co 73.7 ± 13.0 95.7 ± 27.2 3047 ± 508 15.1 ± 7.0 0.02 ± 0.03 0.33 ± 0.51 
NonCB0.5Co 69.3 ± 6.6 103.5 ± 14.7 2916 ± 413 19.2 ± 7.6 2.18 ± 0.40 36.97 ± 6.78 
NonCB1Co 76.8 ± 12.9 106.1 ± 17.1 2996 ± 487 16.0 ± 7.6 5.35 ± 0.89 90.74 ± 15.09 
NonCB2Co 76.9 ± 18.1 110.3 ± 18.3 2993 ± 489 16.8 ± 9.7 10.55 ± 2.06 178.93 ± 34.94 
NonCB4Co 80.6 ± 17.6 109.8 ± 17.2 2995 ± 523 16.5 ± 7.4 22.97 ± 2.06 389.57 ± 34.94 
CoCl2 100 µM 0.0 ± 0.9 81.5 ± 8.3 2928 ± 475 38.7 ± 4.0 6.61 ± 0.62 112.11 ± 10.52 
 
7.3.3 Collagen-BG Scaffolds: Effect on hMSC viability  
To assess the effect of Coll-BG scaffolds on hMSCs viability and activation of the hypoxia 
pathway, a 2D cell-culture study was prepared. Scaffolds containing no BG, as well as 0Co and 
NonCB4Co BGs were pre-conditioned for 7 days in DMEM prior to hMSC seeding. A viability 
assay (alamarBlue®) was performed and VEGF expression was analysed as an indicator of the 
hypoxia pathway activation.  
The alamarBlue® assay shows hMSCs proliferate in the scaffolds up to day 7 (Fig. 7.7). Between 
days 7 and 14, cell number does not significantly increase. The fact that cells stop proliferating 
does not seem to be due to confluency. It might instead be due to the beginning of the 
differentiation process. BG presence in the scaffolds does not seem to significantly affect cell 
viability. Only at day 4, scaffolds containing 0Co BG present a lower signal than the control 
scaffolds. The presence of NonCB4Co BG in the scaffolds, however, seems to significantly rescue 
cells from the 0Co BG negative effect. At both days 2 and 4, the alamarBlue® signal is significantly 
higher for the scaffolds containing NonCB4Co BG when compared to 0Co BG scaffolds. However 
there is no significant difference between the control and NonCB4Co BG scaffolds. Overall, the 
alamarBlue® assay showed BG addition to the collagen scaffolds does not significantly reduce 
hMSCs viability. 
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Fig. 7.7 hMSCs viability on Coll-BG scaffolds: alamarBlue
®
 assay was performed at days 1, 2, 4, 7 and 14 
after hMSCs were seeded on Coll-BG scaffolds. (*) indicates the difference between the marked bar and the 
control (scaffolds with no BG) for the same time period is statistically significant. (¥) indicates that the 
difference between the marked bar and the 0Co BG scaffolds for the same time period is statistically 
significant. (p<0.05) 
Actin and nuclear staining was performed at days 1 and 7 of the cell-culture study to evaluate 
cellular adhesion and distribution on the scaffold surface, as well as cell morphology on the 
different scaffolds fabricated (Fig. 7.8). After 24 h in culture, hMSCs had attached and spread in a 
similar way for scaffolds with and without BG. The presence of BG in the scaffolds was therefore 
shown not to affect cell attachment to the collagen scaffolds. After 7 days in culture, hMSCs 
appear to have spread throughout the surface of the scaffolds. Once more, the presence of BG did 
not seem to affect cell density. This result is in agreement with the alamarBlue® data. As discussed 
above, there were no significant differences found between the different samples at days 1 and 7, 
which indicates similar seeding densities on the different scaffolds and similar proliferation rates 
over time. Cell morphology appears to be unaffected. However, further studies should be 
performed to confirm this conjecture.  
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Fig. 7.8 hMSCs on Coll-BG scaffolds: actin and nuclear staining. After 1 and 7 days in culture, hMSCs were 
stained with Alexa Fluoro 568 antibody (actin – shown in red) and DAPI (nuclear staining – shown in green) 
and imaged using a fluorescence confocal microscope to assess cell distribution and morphology. 
7.3.4 Collagen-BG Scaffolds: Assessment of the activation of the hypoxia pathway 
Co2+-containing BG was shown in previous chapters to activate the hypoxia pathway and 
subsequent response in various cell types (Chapters 4, 5 and 6). However, its effect after 
incorporation in collagen scaffolds should still be confirmed. VEGF expression was evaluated by 
ELISA to evaluate the hypoxia pathway activation as cells are seeded in Coll-BG scaffolds (Fig. 
7.9).  
VEGF expression is kept constant during the first four days in culture (Fig. 7.9 A), which could be 
due to low cell density or increased proliferation. After 7 days, however, it significantly increases in 
all scaffolds. The presence of NonCB4Co BG in the scaffolds does not significantly increase total 
VEGF production when compared to the control scaffolds (Fig. 7.9 A). However, when compared 
to 0Co BG scaffolds, total VEGF is significantly higher at every time-point tested, which confirms 
the role of Co2+ ion in the activation of the hypoxia pathway. At early time-points the differences in 
VEGF expression between the different scaffolds tested are minor. At 14 days however, they 
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significantly increase. Total VEGF in the control scaffolds was significantly higher than in any of the 
BG-containing scaffolds. This result, however, was masked by cell growth on tissue-culture plastic 
(TCP) where the scaffolds were cultured. During the seeding process, cells fell to the bottom of the 
well-plate (TCP) where the scaffolds were placed. However, this did not happen uniformly in all 
scaffolds or to the same extent in different scaffolds. The amount of cells growing on the TCP 
therefore varied between the different samples, which significantly contributed to the total VEGF 
secreted to the media. AlamarBlue® assay was also performed on the TCP where scaffolds were 
incubated (data not shown). A significant increase in signal was observed at day 14 on TCP of the 
control scaffolds. Total VEGF was normalised to total alamarBlue® (both the scaffolds and the 
wells; Fig. 7.9 B). A significant enhancement on VEGF production is observed when hMSCs are 
seeded on the Co2+ BG-containing scaffolds. These data suggest that the ability of Co2+ BG to 
activate the hypoxia pathway is maintained after BG incorporation in collagen scaffolds. At days 2, 
4 and 7, normalised VEGF production is significantly lower. This fact might be due to high 
proliferation rates during this period. VEGF levels are lower during the proliferation period (up to 
day 7) and they increase as the proliferation rate decreases. The significant decrease in Co2+ 
levels available in the cell-culture media after day 4 (Fig. 7.10 C) could also explain the minor 
differences observed during the proliferation period. Co2+ concentration after 4 days decreases to 
lower than 5 ppm. This concentration is similar to the concentration in DMEM conditioned with 
NonCB0.5Co BG, which has also been shown to result in minor effects (see Table 7.2). 
Since VEGF is an angiogenic factor known to be over-expressed under hypoxic conditions, via 
HIF-1α1,130, the results mentioned strongly suggest that the Coll-BG scaffolds activate the hypoxia 
response. However, regulation of VEGF expression may involve many different mechanisms. 
Oxygen tension has a key role in regulating VEGF expression, but other factors including 
oncogenes, hormonal modulators and a number of growth factors have also been shown to 
activate the expression of this angiogenic factor. For example major growth factors such as 
epidermal growth factor, TGF-α and TGF-β, as well as inflammatory cytokines such as IL-6 and IL-
1α, and oncogenic mutations have been shown to increase VEGF expression462,463. Therefore, to 
confirm the activation of hypoxia response, HIF-1α activity must be assessed.  
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Fig. 7.9 Effect of Coll-BG scaffolds on VEGF expression: VEGF expression was assessed using an 
immunoassay after hMSCs were seeded in the Coll-BG scaffolds for 1, 2, 4, 7 and 14 days. (A) Total VEGF; 
(B) VEGF normalised to total alamarBlue
®
 (*) indicates the difference between the marked bar and the 
control scaffolds (scaffolds with no BG) for the same time period is statistically significant. (¥) indicates that 
the difference between the marked bar and the scaffolds containing 0Co BG for the same time period is 
statistically significant. (p<0.05)  
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Fig. 7.10 Ion concentration in DMEM during cell-culture period. During the experiment presented above, 
when cell-culture medium was replaced it was stored and filtered. ICP-OES was performed at the end of the 
study and the concentrations of the different ions released from the Coll-BG scaffolds to the cell-culture 
media were determined.  
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7.4 CONCLUSION 
The present chapter discusses the incorporation of Co2+-containing BGs in collagen freeze-dried 
scaffolds. Such scaffolds were developed to allow the study of the over time ion release from the 
BGs in a 3D model and to facilitate the in vivo application of these hypoxia-mimicking materials. 
Although there were initial difficulties due to large pH variations, a new method to incorporate Co2+-
containing BGs in freeze-dried collagen scaffolds was successfully developed in collaboration with 
the lab of Prof. Fergal O’Brien, in Dublin, Ireland. The BG particles were shown to be 
homogeneously distributed throughout the scaffolds and, in addition, the ion release profiles were 
still adjustable for specific purposes. In fact, a new level of control of ion-release rates was 
achieved. Ions released can be tailored by varying either the Co2+ concentration in the BG or the 
BG concentration in the scaffolds. The amount of BG incorporated in the scaffolds tested requires 
further optimisation. Lower BG concentrations in the scaffolds would be essential to achieve Co2+ 
concentrations within the biologically active concentration range (Chapters 4 and 5). The reduction 
of the BG concentration in the scaffolds would then also reduce significantly the pre-incubation 
period. 
Importantly, the composite scaffolds produced did not seem to decrease viability of human 
mesenchymal stromal cells. The cell proliferation rate was similar in both the control and the BG-
containing scaffolds. More importantly, evaluation of VEGF expression by hMSCs on the Coll-BG 
scaffolds suggested Co2+ BG-containing scaffolds maintain the ability to activate the hypoxia 
pathway and responses. VEGF expression per cell was shown to be enhanced in the Co2+-
containing scaffolds. 
In conclusion, although the preliminary studies described in this chapter suggest the Coll-BG 
scaffolds have potential as hypoxia-mimicking materials for skeletal TE, further optimisation of the 
composite scaffolds is required. A further study should be performed to obtain scaffolds with a Co2+ 
release rate within the biologically active range (30 – 180 µM for hMSCs, from Table 7.2). In 
addition, the development of a seeding method that allows homogeneous distribution of the cells 
throughout the scaffolds is essential. Finally, the activation of the hypoxia pathway should be 
confirmed evaluating the activity of the HIF-1 transcription factor and subsequent cellular 
responses should be assessed. 
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Designing materials that provide suitable cues to direct cellular behaviour and promote tissue 
regeneration is one of the major current tissue engineering challenges nowadays. The 
development of novel materials that activate a natural a “self-healing” response shows great 
potential. 
In damaged tissue, local oxygen pressure often drops, either due to damaged vasculature or 
enhanced metabolic demand, creating a hypoxic environment. Several processes, essential for 
natural tissue development and repair, such as the recruitment of progenitor cells, differentiation 
and angiogenesis, are activated under hypoxic conditions. The hypoxia pathway (HIF-1 pathway) 
is the main intracellular mechanism responsible for sensing these changes in oxygen pressure and 
activating the subsequent organisms’ responses. Activation of these processes, essential for 
natural tissue development and repair, might be critical for several tissue regeneration strategies. 
Therefore, the development of materials that regulate the HIF-1 pathway might be of great 
potential for tissue engineering therapies. In this thesis, the development of such a material was 
discussed. 
In order to activate the HIF-1 pathway under normoxic conditions, a hypoxia-mimicking agent, 
Co2+, was used. A series of other approaches has been used by different authors, but this was 
thought to be an elegant way of inhibiting HIF-1α degradation, avoiding the dangers of gene 
therapy or inactivation of proteosome units. To achieve controlled release of the hypoxia-mimicking 
ion, Co2+ was incorporated in a melt-derived bioactive glass (BG). The novel hypoxia-mimicking 
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material was successfully developed; synthesis and characterisation of the Co2+-containing BGs 
was discussed in Chapter 3. Characterisation of the BG showed that the Co2+ ions were equally 
distributed in both the silicate and phosphate phases of the glass. Moreover, in the silicate phase, 
Co2+ acts both as an intermediate oxide, entering the network, and as a network modifier, 
disrupting it. To understand the role of the hypoxia-mimicking ion in the BG network is extremely 
important as it can significantly alter the BG properties. Addition of Co2+ to the BG significantly 
delayed the ion release and HCA formation rates. For some applications, as is the case of 
cartilage tissue engineering, formation of a HCA layer is undesirable. In order to further delay or 
inhibit HCA formation, Mg2+ and Zn2+ were also added to the Co2+-containing BGs. Most 
importantly, the BGs developed allowed controlled release of Co2+ ions. 
Although the effects will certainly vary between different cell lines, preliminary studies were 
performed on SaOs2 cells (osteosarcoma cells) to determine the effect of both Co2+ and BG 
concentrations on cell viability and the hypoxia pathway. Those studies were described in Chapter 
4. SaOs2 cells were treated with several CoCl2 solutions and BG-conditioned media. The 
concentrations of CoCl2 and BG chosen to be used in the subsequent studies were 100 μM and 
1.5 mg/ml, respectively. The 100 μM CoCl2 solution was shown to activate the HIF-1 pathway, 
while cell viability was maintained. Preparation of BG-conditioned media using 1.5 mg/ml resulted 
in Co2+ concentrations in the medium that were within the biologically active concentration range 
and still avoided toxicity. 
An initial assessment of biological activity of the hypoxia-mimicking BGs developed was also 
performed in SaOs2 cells (Chapter 4). Controlled release of Co2+ ions was shown to be essential 
for the maintenance of cell viability, but most importantly, the BGs were shown to be able to 
activate the HIF-1 pathway. Both HIF-1α activity and VEGF expression were enhanced after 
exposure to BG-conditioned media, in a concentration-dependent manner. In addition, a switch of 
the energy production mechanism was also suggested; LDH activity was enhanced after exposure 
of the SaOs2 cells to the Co2+-containing BG-conditioned media, which indicated enhanced 
glycolytic activity. 
Due to their great plasticity, trophic activity and immunomodulatory properties, MSCs are adult 
progenitor cells that present great potential for use in skeletal tissue regenerative therapies. 
Oxygen is one of the main regulators of hMSC biology362. Moreover, their life-span ex vivo and 
differentiation potential have been shown to be regulated by exposure to low pO2. The hypoxia 
pathway is the intracellular mechanism that controls these processes352. In Chapter 5, the effect of 
the hypoxia-mimicking BGs on hMSC biology was discussed. Human MSC viability was only 
decreased when cells were exposed to the BG-conditioned medium with the highest Co2+ 
concentration; the BGs with lower Co2+ concentrations (≤ 2 molar%) did not have a toxic effect. 
Chapter 8. Conclusions 
 
Hypoxia-mimicking bioactive materials for skeletal tissue engineering 
 
203 
Interestingly, the enhancement of HIF-1α activity and VEGF expression by hMSCs after exposure 
to the Co2+-containing BG-conditioned media occurred in a concentration-dependent manner, 
which clearly demonstrates the ability of the BGs to activate the hypoxia pathway in hMSCs, even 
those with lower Co2+ content. 
Activation of several processes involved in cell survival under low pO2 was suggested. A switch 
from oxidative phosphorylation to glycolysis as the energy production mechanism was indicated by 
the enhancement of LDH activity in a concentration-dependent fashion with exposure to the BGs. 
Additionally, proliferation was significantly reduced. Further, ECM formation also seemed to be 
affected; collagen secretion was significantly enhanced by exposure to the Co2+-containing BGs. 
The enhancement of VEGF expression suggests that other growth factors and membrane 
receptors, which are normally regulated by hypoxia, might also be up-regulated by exposure to the 
hypoxia-mimicking BGs. Some of these proteins, including VEFGR and bFGF, are known to 
promote critical processes for tissue repair, including cell migration/recruitment and blood vessel 
formation, through a paracrine effect. Thus, the hypoxia-mimicking BGs may be able to activate 
such processes.  
Other processes that could be regulated by the hypoxia-mimicking BGs are the maintenance of 
hMSC multipotency and/or differentiation362, as well as ex vivo expansion rates165. As has been 
described, hMSC proliferation was reduced under exposure to the Co2+-containing BGs. However, 
cell death was not observed, which suggests that Co2+ has no toxic effect resulting in cell death. 
The reduced proliferation is probably due cell cycle arrest, as other authors have previously 
reported both under hypoxia and exposure to Co2+ ions185. The reduced proliferation is one of the 
adaptation mechanisms to a low pO2 environment, in order to reduce the energy requirement of 
the cells. However, it could also be associated with maintenance of the hMSC pluriopotency ex 
vivo352, which is critical if the hMSCs are to be later used in regenerative therapies. 
In addition, hypoxia has been shown to enhance MSC ex vivo expansion, although the proliferation 
rates were slightly decreased165. This would be an important achievement since expansion of 
these cells for use in regenerative therapies is essential due to the low numbers present in the 
body. Hence, several cellular responses involved in tissue regeneration might also be activated by 
the BGs.  
Hypoxia promotes blood vessel formation by several different processes. It stimulates migration of 
both endothelial and mural cells to the hypoxic site, but also activates EC proliferation and 
differentiation of both endothelial and mural cell precursors (reviewed in 2). In addition, hypoxia has 
been shown to enhance MSC angiogenic potential, either via differentiation of these progenitor 
cells into endothelial or stem cells or by secretion of pro-angiogenic growth factors2,427,429. In 
Chapter 5, activation of the HIF-1 pathway and secretion of VEGF by exposure of hMSCs to the 
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hypoxia-mimicking BG was demonstrated. Therefore, Chapter 6 focused on the effect of the Co2+-
containing BGs on blood vessel formation. Both the direct effect of the Co2+-containing BGs on 
ECs and the paracrine effect, via activation of the HIF-1 pathway on hMSCs, were assessed. The 
study started with the evaluation of the direct effect of the BGs on ECs. Unexpectedly, ECs viability 
was significantly reduced in the presence of the BG-conditioned media. Besides, activation of the 
hypoxia pathway was not observed, except with the highest Co2+-content BGs, and both in vitro 
migration and tubule-forming abilities were either not affected or reduced under exposure to the 
hypoxia-mimicking BGs.  
Addition of hMSCs to the culture system, however, significantly enhanced the ECs angiogenic 
potential. EC migration was enhanced when hMSC-pre-conditioned media was used as a 
chemoattractant in the in vitro migration assay. Plus, tubule formation occurred even when media 
with no growth factors (DMEM) was used. Clearly, the hMSCs were able to produce the required 
pro-angiogenic factors; their “trophic effect”, as described by Caplan et al.328, was observed. 
However, contrary to what had been hypothesised, pre-conditioning of hMSCs with the hypoxia-
mimicking BGs did not enhance EC angiogenic potential in the co-culture system used. In fact, the 
EC tubule-forming ability was reduced when high levels of Co2+ ions were present in the media. 
The disruption of the EC tubule-forming ability is thought to be associated with Co2+ reduction of 
EC viability. However, as the 0Co BG also disrupted EC tubule formation, other factors apart from 
the Co2+ ions must affect ECs. These factors could be other ions released from the BGs, such as 
Si4+, the presence of submicron BG particles or even the pH variations caused by BG dissolution. 
Finally, the hypoxia-mimicking BGs were successfully incorporated into collagen freeze-dried 
scaffolds, in collaboration with Prof. Fergal O’Brien’s group (Chapter 7). The initial difficulties 
caused by the BG dissolution-associated pH increase were overcome by the flash-freeze method 
developed. Homogeneous distribution of the BG particles throughout the collagen sponges was 
achieved and, most importantly, the BG ability to release the hypoxia-mimicking ion in a controlled 
manner was maintained. Preliminary tests were performed on the scaffolds produced and the 
presence of Co2+-containing BG seemed not to affect hMSC viability and significantly enhance 
VEGF expression. These preliminary data, together with data from Chapter 5, suggest the 
fabrication process of the collagen-BG composite scaffolds developed did not abbrogate the BG 
ability to activate the hypoxia pathway. However, further optimisation of the scaffolds fabrication 
process is essential. It is necessary to achieve a Co2+ release rate within the biologically active 
concentration range, as well as to develop a seeding method that allows homogeneous 3D 
distribution of the cells throughout the scaffolds. If these are not achieved, a new approach to 
implant the hypoxia.mimicking BGs in the body should be studied. The hypoxia-mimicking BGs 
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could be incorporated in a hydrogel for example, which could facilitate both the incorporation of the 
BG in the gels and the cell seeding process. 
The BGs with the highest Co2+ content decreased cell viability of the various cell types assessed 
however, their ability to activate the HIF-1 pathway and enhance VEGF expression, as an example 
of the subsequent cellular responses, indicates that the hypoxia-mimicking BGs developed hold 
great promise for use in regenerative therapies. From the studies reported in this thesis, the 
NonCB1Co and NonCB2Co BGs, containing 1 and 2 molar% Co2+, respectively, are the 
compositions that hold greater promise from all BGs produced. Their ability to enhance the HIF-1 
activity up to four fold, while maintaining cell viability in both immortalised cell lines and primary 
adult stem cells (hMSCs) illustrates their great potential.  
Nevertheless, further studies are required to better comprehend the effect of the Co2+-containing 
BGs on hMSC biology. Their effect on hMSC ex vivo expansion, as well as regulation of 
multipotency and/or differentiation and, especially, the mechanisms involved in the different 
responses should be assessed. In addition, the co-culture system of Co2+ BG-pre-conditioned 
hMSCs with ECs should be further studied. Pre-activation of the HIF-1 pathway on hMSCs might 
significantly enhance the angiogenic potential of the ECs if the Co2+ concentrations in the media 
could be considerably reduced.  
The assessment of the hypoxia-mimicking BG effect in vivo would be particularly interesting, as it 
is well known that results obtained in vitro can not be directly translated to an in vivo situation. 
Besides, several in vivo studies with different bioactive glasses have been reported and toxicity 
was never an issue310-312 and administration of Co2+ solutions in rats has been shown to enhance 
angiogenesis and promote bladder and tubulointestinal regeneration189,190. Co2+ toxicity might then 
be reduced in vivo due to dilution in body fluid, which would reduce its concentration and toxic 
effects. The subcutaneous implantation of a hypoxia-mimicking BG-containing scaffold or hydrogel, 
previously seeded with hMSCs or hMSCs and ECs, in an appropriate animal model (eg. nude 
mice) could clarify the real effect of the Co2+-containing BGs on blood vessel formation, through 
activation of the hypoxia pathway in hMSCs. 
Although there is still no in vivo data, the hypoxia-mimicking BGs described in this thesis show 
great potential for several applications. They could be used ex vivo to control progenitor cell 
expansion and multipotency and/or differentiation. In addition, they could be implanted in the body 
to promote in situ tissue regeneration, via activation of progenitor cell recruitment, proliferation and 
differentiation. Several processes that are critical for normal tissue repair, such as blood vessel 
formation, might be enhanced by exposure to the hypoxia-mimicking BGs. The BGs could be 
implanted directly in the body, in the form of powder or scaffolds. However, they could also be 
easily incorporated into materials with physical and mechanical properties that could be tailored for 
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each specific application, as with the collagen sponges reported on Chapter 7, or other materials 
such as hydrogels. As mentioned previously, further studies are required to better understand and 
control the cellular response to the hypoxia-mimicking BGs. However, it is hoped that this thesis 
has been able to show the great potential of these materials for skeletal tissue engineering. 
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APPENDIX 1 
Ds-Red transduced Human Umbilical Vein Endothelial cells 
HUVECs were isolated according to ethical procedures at the Center for Excellence in Vascular 
Biology in Brigham & Women’s Hospital, Boston, MA. Cells were maintained up to passage 2 in 
EGM-2. 
To visualize the implanted cells in vivo, HUVECs are first transduced with retrovirus to stably 
express Ds-Red. Retrovirus-mediated transduction of HUVECs is highly efficient (over 90% of 
HUVECs expressed Ds-Red after two to three rounds of transduction in a typical experiment).  
Materials 
1. Endothelial growth medium (EGM) (Cambrex) supplemented with bullet kit (Cambrex). 
2. Eagle’s basal medium (BME) (Invitrogen®) with 2 mM l-glutamine supplemented with 10% fetal 
bovine serum. 
3. Dulbecco’s modified Eagle’s medium (DMEM) (Invitrogen®) supplemented with 10% FBS. 
4. Opti-MEM I reduced-serum medium (Invitrogen®). 
5. Phosphate-buffered saline (PBS) (Sigma®). 
6. Solution of 0.05% trypsin-EDTA-4Na in PBS (Invitrogen®). 
7. Solution of 0.2% gelatin (Sigma®). 
8. Solution of polybrene in PBS at 8 µg/ml (Sigma®). 
9. Lipofectamine 2000 (Invitrogen®). 
10. 0.45-mm filters (Whatman®). 
Retrovirus Production 
1. The 293ET packaging cells are cultured in 100-mm tissue-culture dishes with DMEM 10% FBS. 
The packaging cells should be passaged 2 days prior to transfection at 1:4 split. On the day of 
transfection, the 293ET cells should be approximately 80–90% confluent  
***(The density of 293ET cells is a critical parameter. Transfection with lipofectamine with too low a 
cell density will result in a high number of cell death, whereas if cell density is too high, the 293 
cells tend to detach from the cell-culture dish)*** 
2. On the day of transfection, the 293 cells are given fresh media (10 ml DMEM 10% FBS). The 
packaging cells are then transiently transfected with the retrovirus vector encoding Ds-Red, 
gag/pol, and VSVG using Lipofectamine 2000 (Invitrogen®). The plasmids (5µg VSVG, 7µg 
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gag/pol, and 15 µg retroviral vector) are mixed together in 1.5 ml Opti-MEM in a 15-mL centrifuge 
tube.  
In a separate tube, 40 µL lipofectamine 2000 is added to 1.5 mL Opti-MEM, and it is allowed to 
incubate at room temperature for 5 min. After 5 min of incubation, the two tubes of solution are 
mixed together and allowed to further incubate for 20 min at room temperature. The transfection 
mixture is then added dropwise to the dish of packaging cells. To ensure uniform mixing, the dish 
is gently agitated, and it is then placed in a 37 °C incubator overnight  
***( Instead of lipofectamine, other methods of transfection, such as calcium chloride, can also be 
used)*** 
3. After overnight incubation, the 293ET cells are washed gently three times with 10 ml PBS. It is 
important not to pipette directly on the cells, because 293ET cells tend to detach easily. After 
washing with PBS, 10 ml fresh DMEM 10% FBS is added to the dish of cells, which is then placed 
in the incubator for overnight culture. 
***(The packaging cells should be washed three times with PBS carefully to remove any residual 
lipofectamine-containing plasmids. We have had experience where the residual lipofectamine is 
transferred to the HUVECs culture, causing the HUVECs cells to fuse together because of the 
ectopic expression of VSVG on their cell membrane)*** 
4. The next day, the supernatant containing retrovirus is collected. Fresh media is added to the 
dish, and the cells are allowed to incubate overnight.  
5. The supernatant is spun at 1200×rpm for 5 min to remove any cell debris. It is then passed 
through a 0.45-mm filter (Whatman®) and is either used immediately for infection or kept at −80 °C  
***(If the viral supernatant is not used immediately, it can be stored in a −70 °C freezer and used 
within 3 months. The viral supernatant is stored in 5-ml aliquots to minimize the cycle of freeze–
thaw) *** 
6. The supernatant is collected from the packaging cells for three more times 
***(If the virus titer is low, spin infection can potentially enhance the infectivity of the retrovirus. 
Cells are plated in a 6-well plate at subconfluency. Two milliliters viral  supernatant is added to the 
well along with polybrene at 8µg/ml. The plate is then centrifuged for 45 min at room temperature 
at 2000×rpm. After centrifugation, the plate is incubated for 4 h at 37 °C before exchange with 
fresh medium) *** 
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Transduction of HUVECs 
1. HUVECs are maintained on a gelatin-coated flask. To coat the flask, 2 ml 0.2% solution of 
gelatin is added and allowed to cover the bottom surface of the flask for 10–15 min at room 
temperature. The gelatin solution is then removed by aspiration, and the flask is used immediately. 
2. One day prior to transduction, the HUVECs are passaged at 1:3 to 1:4 split. It is important for 
cells to be subconfluent when transduced by retrovirus. 
3. For transduction of HUVECs, supernatant containing Ds-Red retrovirus is first diluted at 1:1 with 
EGM. Polybrene is then added at final concentration of 8 µg/ml to enhance transduction efficiency.  
4. The HUVECs are incubated with the retrovirus supernatant for 4 h in a 37 °C incubator. After 4 
h, the retrovirus supernatant is replaced with fresh EGM, and the cells are allowed to recover 
overnight. The transduction procedure is repeated the next day. The expression of Ds-Red in the 
transduced HUVECs is confirmed with a fluorescence microscope. Usually, over 90% of HUVECs 
express Ds-Red after two to three rounds of transduction. 
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